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 Abstract 
Sepsis remains a common reason for hospital admission and is associated with a 
high mortality especially in the elderly. Neutrophils are one of the primary immune 
cells involved in the elimination of pathogens; however also contribute to the 
pathogenesis of multi-organ failure in sepsis. Previous studies have demonstrated an 
age-related decline in neutrophil migration and phagocytosis suggesting this as a 
mechanism for the poorer outcomes observed from sepsis in the elderly. 
Observational studies suggest that HMG-CoA reductase inhibitors (statins) are 
associated with improved outcomes from sepsis and potentially modulate neutrophil 
function. 
 
This thesis demonstrates that high dose (80mg) simvastatin improved the migration 
of neutrophils in the healthy elderly without affecting other key neutrophil functions, 
such as phagocytosis and reactive oxygen species production (ROS). Studies in 
patients with sepsis, demonstrated that circulating neutrophils displayed features of 
immune-paresis and failed to migrate, but were activated with increased 
phagocytosis and ROS. This was accompanied by reduced neutrophil extracellular 
trap (NET) formation and delayed late apoptosis. The use of in-vitro simvastatin 
failed to modulate migration, whilst ROS and NET production was reduced by 
simvastatin. Simvastatin remains a potential immune-modulating drug for treating 
early infection in the elderly. 
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1.1 The Neutrophil 
Neutrophils are the most abundant polymorphonuclear (PMNs) cells making up 50-
70% of the circulating pool of leucocytes, with peripheral blood counts of 2.5-7.5 
x106/ml in health. Neutrophils are released from the bone marrow as terminally 
differentiated cells and have a short circulating half-life of 6-8 hours. The bone 
marrow generates and releases large numbers of neutrophils, with up to 5 x1010 cells 
being produced daily. Neutrophils are an essential part of the innate immune system 
being one of the primary cells involved in pathogen containment and elimination. 
Once an invading pathogen has been detected neutrophils are rapidly recruited to 
the site of infection where their principal role is to kill and contain the responsible 
organism (1-3). 
1.1.1 Differentiation, maturation and apoptosis 
Neutrophils are produced within the bone marrow and the process of maturation from 
myeloid stem cells takes approximately two weeks and is principally under the 
controls of granulocyte colony stimulating growth factor (G-CSF), which in turn is 
regulated by the release of interleukin (IL-) 17A and IL-23 from regulator T-cells and 
dendritic cells (1, 4-7).  
1.1.1.1 Maturation 
The neutrophils pass through six distinct morphological stages in their maturation 
starting as nuclear dense myeloid stem cells, which differentiate to form 
promyelocytes then to myelocytes and again to metamyeloblasts. These then 
differentiate to immature neutrophils, called bands, and then finally differentiate into 
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mature segmented neutrophils characterised by their multi-lobar nucleus (see figure 
1.1) (1).  
 
During maturation and differentiation the nucleus changes structure and shape to 
become segmented with reductions in the nuclear cytoplasmic ratio (N/C) observed. 
Myeloid cells have a high N/C ratio of 80-85%, band cells 33-40% N/C ratio and 
mature segmented cells a N/C of 33%.  
1.1.1.2. Granule formation 
The proliferation and maturation of neutrophils prepares the cells for their functions 
once circulating. This involves the production of three distinct granule populations, 
azurophillic/primary granules, neutrophil specific/secondary granules and 
tertiary/small granules. The azurophillic granules are produced during early 
maturation as promyelocytes. At this stage myeloperoxidase (MPO), the three serine 
proteases, neutrophil elastase (NE), cathepsin G (CG) and proteinase 3 (PR3) and 
other antimicrobial proteins (defensins, lysozyme and azurocidin) are produced and 
stored within the cell. Neutrophil specific/secondary granules, such as lysozyme, 
lactoferrin, collagenase and various membrane receptors, are produced during the 
myelocytic phase of development. The tertiary granules are produced last when the 
cells are metamyelocytes. The small granules contain gelatinases (matrix 
metalloproteinases - MMP) and Cathepsin B and D (1). This is summarized in table 
1.1 and figure 1.1. 
 
The azurophillic granules fuse with phagosomes and release their granules within 
them to degrade and kill invading organisms. MPO is considered to be the most 
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effective agent that neutrophils have to neutralise invading organisms, whilst the 
defensins, perforins and bacterial permeability- increasing protein (BPI) target the 
membrane permeability of the pathogen.  
 
Secondary granules are released extracellularly to kill pathogens (cytochrome b558), 
prevent pathogen proliferation (lactoferrin) and to initiate the inflammatory process 
(N-formylmethionyl-leucyl-phenylalanine {fMLP} receptors and plasminogen 
activator) by the further recruitment of immune cells.  
 
Mature neutrophils leaving the bone marrow are capable of effective migration, 
phagocytosis and are armed with an arsenal of antimicrobial products to carry out 
their lethal functions. Mature neutrophils are released into the circulation in a resting, 
latent state and under normal conditions have a short half-life of 6-8hours. 
Neutrophils subsequently marginate into peripheral tissue pools where they undergo 
apoptosis and phagocytosis by macrophages.  
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1.1.1.3 Neutrophil Apoptosis 
Apoptosis is controlled and programmed cell death that eliminates cells from the 
circulation to maintain cellular homeostasis and prevent excessive morphogenesis, 
as well as modulating inflammation. Neutrophil apoptosis requires tight regulation to 
prevent the uncontrolled release of cytotoxic granules and unnecessary accumulation 
that can precipitate collateral tissue injury (8). 
 
Neutrophil apoptosis is characterised by cell body shrinkage, notching of the cell 
membrane, vacuolated cytoplasm, mitochondrial depolarization and the 
fragmentation and condensation of deoxyribonucleic acid (DNA). Apoptotic 
neutrophils are biological inactive and show reduced migration, superoxide burst and 
phagocytosis. A balance of pro- and anti-apoptotic signals regulates the fate of 
neutrophils; these are summarised in table 1.2. (8, 9).  
 
Three principal mechanisms of neutrophil apoptosis have been identified, the 
extrinsic death receptor pathway, the intrinsic (mitochondrial) pathway and the 
endoplasmic reticulum (ER) or stress induced pathway (8). 
 
The extrinsic death receptor pathway is triggered by specific ligand and cell surface 
receptor binding resulting in the recruitment of various proteins that forms the death 
inducing signalling complex (DISC). Apoptosis is induced by FAS, Tumour Necrosis 
Factor alpha (TNF-α) and TNF-α –related apoptosis inducing ligand (TRAIL) 
receptors. These bind to their respectively ligands (FAS ligand, TNF-α and TRAIL) to 
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activate Caspase-8 and -3 which are responsible for the fragmentation and 
condensation of the DNA (8, 10-12). 
 
The intrinsic death pathway is mediated via the production of reactive oxygen 
species (ROS), which causes mitochondrial depolarization. This results in the loss of 
cytochrome C inducing apoptotic proteases activating factor-1 (APAF-1) and 
subsequently activates Caspase 9 and -3 (8, 13-15). 
 
ER stress can directly and indirectly lead to apoptosis and is initiated via 
physiological stress, such as hypoxia and acidaemia. Direct activation of apoptosis is 
via the activation of Caspase 12, which lies on the ER membrane and the 
subsequent activation of Caspase 9 and -3. Indirectly ER stress has been shown to 
trigger the release of cytochrome C from neutrophils thereby activating the intrinsic 
apoptotic pathway. 
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Figure 1.2. Pathways of Neutrophil Apoptosis 
 
A schematic diagram showing the extrinsic, intrinsic and endoplasmic reticulum 
induced stress pathways that lead to neutrophil apoptosis. The extrinsic pathway is 
mediated by specific interactions between ligands and their receptors on the cell 
surface. This activates the Caspase pathways that are responsible for the 
condensation of cellular DNA. The intrinsic pathway is mediated via the release of 
reactive oxygen species (ROS) from mitochondria with the resultant loss of 
cytochrome C, which induces Caspase 9 and subsequent cell apoptosis. Hypoxia 
and acidosis induces endoplasmic reticulum stress with the resultant activation of 
Caspase 12 and subsequently Caspase 9 and 3 to induce apoptosis. ER stress also 
induces death via the intrinsic pathway through the release of cytochrome C. 
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Table 1.2. Intracellular and extracellular modulators of neutrophil apoptosis. 
Modulators Mechanisms 
Intracellular modulator 
 
 
Reactive oxygen species DNA damage. Activation of p38, NFKβ, JNK 
and MAPK 
 
Caspases 
 
Activation of Caspase cascade, PKC-δ and 
DNA cleavage 
 
BCL-2 membrane proteins 
 
Regulate mitochondrial membrane 
permeability and control cytochrome c 
release 
 
Survival/Death pathways 
PKB/AKT 
P38 MAPK 
PKC-δ 
 
Activated Bax and NFKβ 
Inhibits Caspase 8 and 3 
Unknown 
Extracellular modulators 
 
 
Anti-apoptotic factors 
Type 1 and II interferons 
LPS 
 
G-CSF and GM-CSF 
TNF-α (low doses) 
 
Activate STAT 3 
Phosphorylation of Akt and up regulation of 
Mcl-1 and A1 
Via up regulation of PI3 kinase/Akt 
Activation of PI3 kinase, CXCL-8 release 
Pro-apoptotic 
Fas Ligand 
 
TRAIL 
Phagocytosis 
TNF-α (high doses) 
 
Increased mitochondrial permeability and 
Caspase activation 
Via TRAIL–R2 and R3 receptors 
ROS production and caspase activation 
ROS production, activation of JNK and MAPK 
  
The intracellular and extracellular modulators of neutrophil apoptosis with 
mechanisms of actions. Adapted from Luo, H.R. et al, 2008 (8). 
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1.1.2. Neutrophil Function in Health 
Neutrophils form the primary cellular response to bacteria, viruses and fungi. 
Neutrophils are required to migrate (chemotax) to sites of infection by transmigrating 
the vascular endothelium. Once at the site of infection they must eliminate and 
contain the infectious source by engulfing them (phagocytosis) and generating ROS. 
Neutrophils also release their DNA into the extracellular space to ensnare and kill 
pathogens in a process termed neutrophil extracellular traps (NETs) formation (16). 
Finally, neutrophils undergo apoptosis and clearance from tissues (see figure 1.3).   
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Figure 1.3. Neutrophil Function in Health. 
 
Neutrophils tether, roll and adhere to the endothelium prior to transmigrating through 
the endothelium (chemotaxis). Once at the site of inflammation, they kill the invading 
pathogens by phagocytosis, extracellular reactive oxygen species (ROS) release and 
by producing neutrophil extracellular traps (NETS). They also produce cytokines, 
which attract other immune cells and modulates the inflammatory response. Once 
the neutrophils have carried out their function they die by apoptosis, a process that 
contributes to the resolution of the inflammation.  
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1.1.2.1. Neutrophil Chemotaxis 
Chemotaxis is defined as the directional migration of leucocytes along a chemical 
gradient and is the term used to describe the process of neutrophil migration into 
tissues from the intravascular space. Neutrophils migrate towards a range of 
chemoattractants such as the bacterial peptide fMLP, complement factor 5a (C5a), 
leukotriene B (product of phospholipid metabolism) and cytokines such as IL-8, 
known as CXCL-8 (17, 18).  
 
Five distinct stages of chemotaxis have been described, tethering, rolling, adhesion, 
crawling and transmigration (19).  Leucocytes resident within tissues release a 
variety of cytokines, histamine and leukotrienes after contact with invading pathogens 
instigating neutrophil chemotaxis. The endothelial cells directly recognise pathogens 
via specific pattern recognition receptors (PRRs) such as the Toll-like receptor  (TLR) 
family, to up regulate adhesion molecules. The adhesion molecule P-selectin is 
rapidly expressed by their release from Wiebal-Palade bodies in response to 
lipopolysaccharide (LPS), TNF-α and IL-1. E-selectin, another key adhesion 
molecule, is synthesised by endothelial cells and expressed with 90-120 minutes 
after endothelial cell activation. These two-adhesion molecules glycosylate to their 
specific ligand expressed by neutrophils, P-selectin glycoprotein ligand 1 (P-SGL1) 
and E-selectin glycoprotein-1 (E-SGL1) to capture (tether) flowing neutrophils to the 
endothelium (19, 20) 
 
Tethering of the neutrophil to the endothelium via P-selectin and P-SGL1 is 
temporary, as the fast flowing neutrophil has to slow down. The neutrophil rolls along 
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the endothelial surface membrane by releasing the rear tether (P-selectin-P-SGL 
bond) and moving it to the leading edge on the cell, where it interacts with another P-
selectin molecule. This repeated sling shooting of the cells is known as rolling and 
causes deceleration of the neutrophil (19-22).  
 
As activated neutrophils roll in this sling shot manner they come into contact with an 
endothelium laden with chemokines, in particular CXCL-8, causing them to adhere to 
the endothelium. These chemokines are positively charged molecules bound to the 
endothelium by negatively charged heparan sulphates that anchor the neutrophil to 
prevent them being detached and create a chemotactic gradient. CXCL-8 signals via 
G-protein coupled receptors (GPCR) on the neutrophils (CXC-R1 and CXC-R2) 
causing conformational changes and increasing the expression of the adhesion 
molecules, lymphocyte function associated-antigen 1 (LFA1 also known as, 
CD11a/CD18) and macrophage antigen 1 (MAC-1: CD11b/CD18). These adhesion 
molecules bind to intracellular adhesion molecules (ICAM-1 and ICAM-2) resulting in 
the firm adhesion of neutrophils to the endothelial surface (19, 23-26). 
 
Adherence of the neutrophils prepares the cell for transmigration. Transmigration 
requires the neutrophil to be adherent to the cell membrane at all times and is 
achieved through the binding of MAC-1 to ICAM-1. These bonds must be present at 
all times and crawling is in part achieved by the release and formation of new bonds. 
Crawling is initiated by the neutrophil forming pseudopods at random. Pseudopods 
that are correctly orientated in the direction of the chemokine gradient form the 
leading edge of the neutrophil. This pseudopod, with an actin-based leading edge 
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pulls the neutrophil forward, whilst a rear uropod (made from an actin/myosin 
structure) helps the rear to contract as the cell moves forwards (17, 19, 20, 27, 28).  
 
The crawling of neutrophils along the endothelium mediated by a chemokine gradient 
allows pseudopods to sense the location of tight junctions between the endothelial 
cells to allow the paracellular (between the cells) migration of cells. The process of 
transmigration is not fully understood, however studies suggest that 
platelet/endothelial adhesion molecule -1 (PECAM-1) and junctional adhesion 
molecules (JAMs) play an essential role in “labelling” tight junctions and 
subsequently interacting with ICAM-1 and LFA-1 to allow neutrophils to pass through 
the endothelium and into the basement membrane (19, 20, 29, 30). 
 
Once the neutrophils have transmigrated they continue to sense a chemokine 
gradient allowing the directional migration of cells through the extracellular 
membrane towards the sites of infection. These gradients are created by end-target 
chemoattractants, such as fMLP and C5a, which override the signals from the 
endothelial chemoattractants (IL-8 and LTA-4) (19, 29, 31).  
 
The mechanism of migration through the extracellular membrane is not clear, as 
experimental studies investigating this in-vitro cannot replicate in-vivo conditions. 
Current opinion suggests that neutrophils seek out gaps between adjacent pericytes 
to aid migration but also release proteases (e.g. MMP-8 and MMP-9), NE and ROS 
to breakdown the laminin and collagen rich membrane to create a pathway through 
the membrane. The deformable structure of neutrophils created by actin mobilisation 
Page | 16 
 
at the leading edge and the actin/myosin “tail” helps to guide the cells through the 
membrane to the tissue either via gap junctions or the destructive lesions created by 
the neutrophils (32-34). 
 
Traditionally, neutrophils have been thought to die at the site of infection, however 
emerging evidence from murine and human models suggest that some are capable 
of reverse transmigrating back into the blood stream from tissues. These cells are 
usually resistant to apoptosis and seem to maintain a phenotype similar to that seen 
in inflamed tissue (a pro-inflammatory phenotype) resulting in continued 
phagocytosis and ROS production within the systemic circulation. It is postulated that 
these cells may disseminate inflammation and infection and lead to distant organ 
damage (35-37). 
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Figure 1.4. Neutrophil Chemotaxis 
 
A schematic diagram of the process of neutrophil migration from the blood across the 
endothelium. Tethering and rolling is mostly selectin-dependent and binds to the 
specific ligands (e.g. P-selectin glycoprotein-1, P-SGL1). Adhesion, crawling and 
transmigration are dependent upon integrin interactions (e.g. Intracellular Adhesion 
Molecule -1, ICAM -1), which bind LFA-1 (lymphocyte function associated antigen-1) 
and MAC-1 (macrophage-1- antigen). The chemokines that line the endothelium 
activate rolling neutrophils and induce conformational changes of neutrophil integrins 
that instigate crawling and transmigration. Crawling neutrophils follow the chemokine 
gradient along the endothelium, which guides them to the preferential sites of 
transmigration. 
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1.1.2.2. Neutrophil phagocytosis 
Phagocytosis is the process that describes the engulfing and elimination of 
pathogens and cell debris by neutrophils and other leucocytes. The mechanistic 
pathways involved in phagocytosis have been collated from experiments using 
macrophages, which unlike neutrophils, are amenable to manipulation allowing close 
analysis of molecular mechanisms (38). Therefore the mechanisms of neutrophil 
phagocytosis remain unclear with assumptions that the pathways involved in 
phagocytosis are similar in both cell types. 
 
Neutrophils, like macrophages, are capable of internalising opsonised and non-
opsonised pathogens. Opsonisation coats pathogen with antibodies (IgG 
predominantly) and complement (C3b and C4b) and attracts phagocytes to them. 
The Fab proportion of the antibody binds to the pathogen, whilst the Fc proportion is 
left exposed for binding to the phagocytes. On neutrophils the Fc receptors are CD32 
(FcγRIIA), CD16 (FcγRIIIb) and the high affinity receptor CD64 (FcγRI). Complement 
is recognised by a variety of receptors on the cell surface including complement 
receptor (CR) -1 and CR-3 and the β-2 integrin, MAC-1 (Cd11b/CD18) (38-40). 
 
The process of subsequent phagocytosis differs depending on the mechanism of 
detection. Bacteria recognised by Fc receptors leads to the rapid generation and 
entrapment by a pseudopod. Complement based detection leads to the sinking of the 
pathogen slowly into the cell (38). 
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Binding to Fc receptors on neutrophils leads to a series of complex cell signalling 
pathways that triggers the engulfment of bacteria. This is initiated by phosphorylation 
of the Fc receptors and immunoreceptor tyrosine-based activating motif (ITAM). This 
provides a binding site for the tyrosine kinase, Syk and is accompanied by the 
activation of phosphatidylinositol-3-kinase (PI3K). PI3K is responsible for the 
conversion of phosphatidylinositol-4, 5-bisphosphate (PIP2) to phosphatidylinositol 
3,4,5-triphosphate (PIP3) at the phagosomal cup. Although PIP2 acts as the substrate 
for PI3K and is utilised heavily in phagocytosis, the levels increase, as it is also acts 
as a substrate for phospholipase C (PLC) that generates diacylglycerol (DAG). This 
in turn activates isoforms of protein kinase C (PKC), which are recruited to the 
phagosome and are vital for the engulfing of pathogens (41-44).  
 
Activation of these proteins and kinases causes accumulation and polymerisation of 
F-actin and membrane remodelling to allow vacuole formation. The family of Rac 
GTPases are involved in the assembly of actin via Fc receptor stimulation, whilst the 
Rho family is involved in complement mediated activation (38, 40). 
 
Once a vacuole has been formed around the particle/pathogen it is transported into 
the cell by a process known as endocytosis and the receptor recycled to the cell 
surface membrane. The internalised vacuole, known as the early endosome, 
contains the ingested species and is mildly acidic (pH 6.5-6.0). Maturation occurs 
due to lysosome delivery making the endosome increasingly acidic and creating a 
hostile environment for the pathogen. This process is mediated by increases in 
cytosolic calcium levels and a variety of protein kinases (38). 
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Figure 1.5. The phagocytosis of pathogens by neutrophils. 
 
1.The bacteria are opsonised by IgG or complement and the neutrophil migrates 
towards it. 2. Bacteria bind to specific Fc receptors and are engulfed into the cell. 3. 
Formation of the phagosome. 4. The fusion of lysosome with the phagosome to form 
the phagolysosome. 5. The pathogens are digested by the release of enzymes from 
the lysosome. 6. Formation of the residual body containing indigestible products. 7. 
These products are then released into the extracellular space. 
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1.1.2.3. Reactive Oxygen Species (ROS) production and Neutrophil 
Degranulation 
The enzyme, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH 
oxidase), found on the inner cell surface membrane and in mitochondria, is 
responsible for the reduction-oxygenation (redox) reactions that occur to form water 
from oxygen to generate ROS. The initial reaction involves the reduction of oxygen 
by NADPH to form a superoxide oxygen anion. This is converted to hydrogen 
peroxide (H2O2) either spontaneously or by superoxide dismutase (SOD). H2O2 is 
then either converted by catalases to the free radical hydroxyl ion (OH-) or interacts 
with the primary granule, MPO, to produce the highly toxic substance hypochlorous 
acid (HOCL). The OH- ion is neutralised to water, whilst HOCL is converted to the 
toxic free radical singlet oxygen. In addition reactive nitrogen oxygen (RNS) are 
produced by inducible nitric oxide synthetase (iNOS) generating the free radical nitric 
oxide (NO) from L-arginine. NO combines with the oxygen superoxide anion to create 
peroxynitrite (ONOO-) another potent free radical (see figure 1.6) (1, 45-52). 
 
Activation of latent circulating neutrophils by bacterial products (fMLP), cytokines 
(CXCL-8/TNF-α) and cell surface receptors (Fc, MAC-1) results in the mobilisation of 
stored vesicles. These granules bind to the phagosome or the cell membrane in a 
process known as exocytosis and release their antimicrobial load directly into the 
phagosome or the extracellular space. This release of enzymes and proteinases 
plays an essential role in intracellular and extracellular pathogen elimination. 
Neutrophil degranulation and exocytosis, like phagocytosis, is regulated via 
intracellular calcium and phospholipid (PIP2 and PI3kinase) signalling (48, 51, 53-58). 
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Figure 1.6 The Formation of Reactive Oxygen Species (ROS) and Reactive 
Nitrogen Species in neutrophils. 
 
An illustration of the pathways leading to the generation of ROS. Oxygen is 
converted by nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) to form 
an oxygen superoxide ion. This is converted by superoxide dismutase (SOD) to 
hydrogen peroxide (H2O2) that is either converted to a hydroxyl ion (+OH) and water 
or interacts with myeloperoxidase (MPO) to produce hypochlorous acid (HOCL) and 
then singlet oxygen. The oxygen superoxide ion also interacts with nitric oxide (NO) 
to produce nitrogen free radicals. 
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1.1.2.4. Neutrophil Extracellular Trap (NETs) formation 
The phagocytosis of invading organisms and the release of lytic enzymes by 
neutrophils has been regarded as the mechanism the innate immune system utilises 
to eliminate bacteria, fungi and viruses. Brinkmann and colleagues described the 
production of extracellular fibres from activated neutrophils, which created a mesh 
like structure and were capable of ensnaring and potentially killing bacteria. These 
are made up of a DNA backbone laden with neutrophil granule products, such as 
MPO, NE, BPI, CG and lactoferrin. This additional anti-microbial mechanism has 
been termed, neutrophil extracellular traps (NETs) with the process leading to their 
production described as NETosis (16, 59, 60). 
 
Three independent pathways for NET formation have so far been described. The first 
pathway is an oxidant dependent pathway that was described in neutrophils activated 
with either live bacteria or phorbol-12- myristate-13-acetate (PMA) resulting in cells 
becoming highly phagocytic, generating ROS via NADPH-oxidase and leading to 
NET formation. The assembly of NETs follows a particular pattern with the initial loss 
of nuclear segregation (eu- and heterochromatin) and the fragmentation of the 
characteristic lobar nucleus. This is followed by the disintegration of the nuclear 
membrane into vesicles and the disappearance of the neutrophil granules. This 
process allows the nuclear chromatin to mix with the cytoplasm and granules. The 
final stage involves rupture of the cell membrane and the extrusion of the NETs. The 
authors demonstrated that the process of NET formation leads to the eventual death 
of the cell but is a distinct form of cell death separate from apoptosis and necrosis – 
termed NETosis (59, 60). 
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The second pathway describes an oxidant independent pathway of rapid NET 
production from activated neutrophils that does not lead to cellular death and allows 
the neutrophils to continue with their other actions. Neutrophils incubated with 
Staphylococcus Aureus  (S.Aureus) were shown to condense their chromatin into 
discrete vesicles and pass through the cytoplasm to acquire granule products. These 
vesicles are exocytosed into the extracellular space where the chromatin is released 
in the form of a NET. Uniquely this process occurred rapidly (within 10minutes) in 
response to direct stimulation by S.Aureus and was not dependent on the formation 
of ROS (61). 
 
The third pathway describes the release of mitochondrial DNA in an oxidant 
dependent manner from neutrophils that were primed with granulocyte macrophage 
colony-stimulating-factor (GM-CSF) and C5a. Neutrophils that release mitochondrial 
DNA in the form of NETs do not induce neutrophil death (NETosis) but instead 
demonstrate prolonged survival, allowing them to continue their anti-microbial 
actions. This pathway remains controversial with several authors suggesting that 
mitochondrial NETs are not released and that the identification of mitochondrial DNA 
is primarily due to cell lysis (62). 
 
Two of the pathways that mediate NET formation are dependent on the production of 
ROS, with pharmacological blockade of NADPH-oxidase (with diphenylene iodonium- 
DPI) inhibiting NET formation. This is corroborated clinically in patients with inherited 
disorders of NADPH-oxidase (chronic granulomatous disease -CGD), whose 
neutrophils are unable to produce NETs upon stimulation. When given gene therapy 
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to replace NADPH-oxidase is provided to these patients NET generation is restored 
(59, 60, 63). 
 
Another key biological process to the generation of NETs is the citrullination of 
histone H2A, H3 and H4 that occurs early in NET formation and forms the backbone 
of its structure. This process is catalysed by the enzyme peptidylarginine deiminase 4 
(PAD4), which is abundant in neutrophils and converts histone arginine to citrulline. 
This is a vital step in the de-condensation of DNA. Inhibition of PAD4 
pharmacologically and in mice deficient in PAD4 has demonstrated the failure of 
neutrophils to generate NETs, suggesting that this enzyme is crucial for their 
formation (64-68). 
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Figure 1.7. Schematic representation of the NETosis pathway.  
 
A diagram showing the classical pathway of NETosis originally described by 
Brinkmann et al, whereby activation by bacteria or cytokines leads to activation of 
neutrophils and the subsequent degradation of the nuclear envelope and 
peptidylarginine deiminase 4 (PAD-4) mediated citrullination. Finally the plasma 
membrane ruptures and the DNA laden with histones and granule products are 
released extracellularly.  
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1.1.2.5. Summary 
In health, neutrophils are efficient at sensing and migrating to sites of infection and 
once homed in on the target can exterminate the invading organism by phagocytosis, 
degranulation and ROS/RNS production. Neutrophils can kill extracellularly by 
releasing ROS/RNS, the exocytosis of granules and the formation of NETs. This 
makes well functioning neutrophils essential to the innate immunity. 
 
However neutrophils are involved in the pathogenesis of inflammation, as each 
neutrophil function can potentially cause collateral tissue damage. For example the 
process of migration creates a temporary breach of the endothelium, the release of 
granules such as MPO and NE and ROS (H2O2 and HOCL) are highly toxic to tissues 
and the endothelium and NETs may cause tissue damage due to the granules that 
adhere to them (3, 69, 70). 
 
Alterations in neutrophil functions and number are associated with poorer outcomes 
from many congenital (CGD) and acquired diseases (rheumatoid arthritis, systemic 
lupus erythematosus - SLE) with both poor and exaggerated function being 
implicated (3, 69). 
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1.2. Immunosenescence 
Ageing is a modern health care challenge with the population living longer and 
consequently placing increasing demands on health and social care. The ageing 
process is associated with a progressive decline in immune function, referred to as 
immunosenescence. The changes that occur to both the adaptive and innate immune 
systems have been proposed to lead to the increased severity of infection, poor 
responses to vaccination, cancer, autoimmune diseases and other chronic disease of 
old age (e.g. atherosclerosis, Alzheimer’s disease and type 2- diabetes) (71-76). 
 
It has been suggested that immunosenescence is an adaptive process that occurs 
over a lifespan. One adaptation is “inflammaging”, where chronic antigen exposure 
results in a persistent state of low level inflammation within the innate immunity. 
Additionally hormonal changes and alterations in neuro-endocrine function are 
thought to play a role in “inflammaging.” Cytokine profiling in elderly people has 
demonstrated higher levels of pro-inflammatory cytokines, such as IL-6, IL-15, IL-18, 
C-reactive protein (CRP), TNF-α, and coagulation factors (fibrinogen and von 
Willebrand Factor (vWF)). The ability of the immune system to counteract 
inflammaging, by the production of anti-inflammatory cytokines (e.g. IL-10, 
Transforming growth factor –beta (TGF-β) and cortisol), is of great relevance to 
survival and longevity and is observed in cohorts of centenarians who have immune 
system profiles similar to those observed in younger adults (72, 73).  
 
The changes in adaptive immunity have been well characterised, whilst innate 
immunity has only recently been investigated in terms of immunosenescence. A 
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summary of the changes observed is shown in the table 1.3 and figure 1.8. Overall, 
these changes result in a heightened baseline pro-inflammatory state, making the 
ageing individual prone to inflammatory diseases (e.g. atherosclerosis, rheumatoid 
arthritis) and potentially reduce their ability to fight new infections. Changes to 
adaptive immunity lead to reduced success of vaccinations, reactivation of latent 
viruses (e.g. cytomegalovirus (CMV)) and the increased prevalence of cancer in the 
elderly (73, 76-80). 
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Figure 1.8. The balancing between pro- and anti-inflammatory agents and 
relationship to immunosenescence 
 
A homeostatic balance exists between pro-inflammatory and anti-inflammatory 
factors in response to inflammation. Efficient pro-inflammatory responses lead to 
greater protection from infectious diseases in early life, but an increased 
susceptibility to inflammation-based diseases with advancing age. Conversely a 
predominant anti-inflammatory response, increases susceptible to infectious 
diseases in early life, but confers a survival advantage in old age. PG: 
prostaglandins; LT: leukotrienes; CRP: C-reactive protein; TNF-α: Tumour necrosis 
factor- alpha; TGF-β: Tumour growth factor- beta; IL-: Interleukin. Modified from 
Francheschi C. et al 2007 (73). 
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1.2.1. Impact of age on neutrophil function 
Alterations in the ability of neutrophils to migrate to sites of infection and contain and 
eliminate bacteria are likely to contribute to sepsis, multi-organ failure (MOF) and 
death. Age contributes to the prognosis of sepsis, with increasing age associated 
with poorer outcomes. The impact of ageing upon innate immunity, in particular 
neutrophil functions is poorly defined (3, 78, 80-82). 
 
The numbers of circulating neutrophils is not altered with age, nor is the ability of the 
bone marrow to generate an appropriate neutrophilla (increased neutrophil numbers) 
in response to G-CSF and GM-CSF. This implies that an adequate bone marrow 
response in the elderly is present and not a contributor to the poorer outcomes 
observed (78, 83). Functional studies on neutrophils from aged donors suggest that 
immunosenescence results in a reduced ability to migrate, phagocytose and 
generate a superoxide burst as described below.  
1.2.1.1. Ageing and Neutrophil Chemotaxis 
Studies on the impacts of age on neutrophil chemotaxis suggest that although 
neutrophil adherence is preserved with age, the ability of neutrophils to migrate to 
sites of infection is impaired. Sapey et al suggest that an age-related decline in 
neutrophil migration exists. This is based on data from 84 healthy controls between 
the ages of 25-94 showing a linear decline in directional migration with age 
(Spearman’s r=-0.690 95% CI= -0.790- -0.554, p=0.001, see figure 1.9). Although 
neutrophils are capable of reaching sites of infection they take longer due altered 
directional migration (78, 82, 84-86).  
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This has two potential consequences for the host. Firstly bacteria are able to rapidly 
multiple at sites of infection increasing the severity of the insult and resulting in a 
slower resolution of inflammation. Secondly, inaccurate migration may lead to an 
increase in proteinase release by neutrophils (NE, MMP-8 and MMP-9) leading to an 
augmentation of collateral tissue damage (78, 79, 82, 86).  
 
The mechanisms underpinning this are not fully understood, however Sapey E et al 
suggest that over-expression of PI3-kinase activity in elderly donor neutrophils is 
responsible for aberrant neutrophil chemotaxis. Inhibition of PI3-kinase with 
LY294002 corrected migration of neutrophils towards levels seen in healthy young 
donors (86). 
1.2.1.2 Ageing and Pathogen Killing 
Ageing reduces the ability of neutrophils to phagocytose bacteria with studies 
suggesting that the mechanistic ability to phagocytose is retained but with a reduced 
capability (less bacteria being ingested per cell). This has been demonstrated for 
both S.Aureus and E.Coli, both of which are responsible for significant infections in 
the elderly (81, 87, 88). 
 
The impact of age on ROS production from neutrophils remains ambiguous, with 
some authors showing a reduction in ROS generation, whilst other have shown no 
difference between young and old controls (84, 87, 89). 
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Figure 1.9. A correlation between age and neutrophil chemotaxis 
A Spearman’s correlation between age (in years) and neutrophil chemotaxis in 84 
healthy controls between the ages of 25-94. Data courtesy of Dr E Sapey and 
reproduced with her permission. (86) 
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1.2.1.3. Ageing and Neutrophil Extracellular Traps 
The impact of ageing on NETs has recently been investigated by Hazeldene et al, 
who demonstrated that primed (with TNF-α) neutrophils from elderly donors 
produced less NETs compared to young donors in response to fMLP and LPS. No 
differences were seen with PMA. They proposed the failure to produce NETs in the 
elderly as a potential mechanism for poorer containment and elimination of bacteria, 
which contributes to the poorer outcomes observed in the elderly (90).  
1.2.1.4 Summary 
The elderly are at increased risk of fatal sepsis and insights into innate immunity 
suggest that key neutrophil functions worsen with age, predisposing the elderly to 
increased severity of sepsis. The modulation of neutrophil responses by 
pharmacological agents towards a younger phenotype is a potential mechanism to 
improve outcomes in the elderly from infection and other neutrophil mediated chronic 
inflammatory diseases (80, 86). 
1.3. Sepsis 
Sepsis has been challenging medicine since the time of Hippocrates, who described 
sepsis as “by which flesh rots, swamps generate foul smells and wounds fester.” The 
development of the germ theory, by Pasteur suggested that sepsis resulted from the 
systemic dissemination of bacteria into the blood stream, termed septicaemia or 
“blood poisoning.” However, despite the advent of antibiotics and the adequate 
treatment of infection sepsis continues to develop and cause death. This lead to the 
concept of host mediated immune dysfunction in response to the invading pathogen 
driving the pathophysiology of sepsis (91, 92). 
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1.3.1. Definitions 
Sepsis was formally defined by a consensus group of experts in 1992, who stated 
that sepsis was a systemic inflammatory response to infection. They introduced the 
terms sepsis, severe sepsis and septic shock to describe the progression of the initial 
inflammatory response to MOF and refractory hypotension that is observed (93). 
These definitions were adopted by the Surviving Sepsis Campaign Guidelines 
(SSCG) in 2003 and have become an international standard for the diagnosis of 
sepsis (see tables 1.4 and 1.5). These guidelines have been updated in 2008 and in 
2013 and provide an evidence-based framework on the management of sepsis (94-
96). 
1.3.2. Epidemiology 
The exact incidence of sepsis is difficult to quantify due to variability in the coding 
mechanism of admissions and outcomes from hospitalisation and the associated 
pathologies that patients’ who develop sepsis present with. In the United States, 
sepsis is estimated to account for 2% of all hospital admissions and 10% of all cases 
admitted to Intensive Care Units (ICU), with a predicted incidence of 750,000 cases 
annually, whilst in the United Kingdom (UK) the annual incidence is approximately 
102,000. Similar incidences have been reported from European and Australian/New 
Zealand studies, although this is thought to be an under-estimate, with data 
suggesting the incidence is rising by 8-13% per year. Extrapolated data provides a 
conservative estimate of 20-30 million cases of sepsis per year worldwide (91, 97-
101). The rise in sepsis has been attributed to an ageing population, advances in the 
treatment of medical conditions predisposing patients to sepsis (e.g.: bone marrow 
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transplant and immunosuppressive agents) and an increased awareness of the 
condition (91, 102). 
 
Thirty years ago the mortality from severe sepsis was as high as 80%, however 
increased access to ICU care, the introduction of the SSCG and the earlier initiation 
of antibiotics has helped to reduce sepsis-related mortality. In the UK, sepsis is 
thought to account for 7.7% of all deaths in 2010, representing an estimated 23700 
people. In this UK based study, which used mortality data from the office of national 
statistics, mortality of sepsis peaked in 2006 and since an annual decrease in 
mortality has been observed despite an increasing incidence (91, 97, 102). A similar 
pattern in mortality was observed in an Australian & New Zealand study that 
analysed ICU mortality from sepsis over twelve years (2000-2012). They 
demonstrated that mortality from sepsis decreased by 16.7%, from 35% in 2000 to 
18.4% in 2012, representing an absolute annual reduction of 1.3% (103). 
 
Risk factors associated with the development of sepsis are extremes of age, with the 
very young (<1 year old) and old (>60 years old) having similarly high mortality from 
sepsis. Men also have poorer outcomes from sepsis compared with age-matched 
women and this is thought to be due to the protective effectives of oestrogens and 
the harmful effects of testosterone on inflammation. The presence of chronic 
diseases (chronic kidney disease and diabetes mellitus) and those patients that are 
immunosuppressed from disease (HIV and Cancer) or treatments (chemotherapy 
and steroids) predisposes them to sepsis and sepsis-related mortality (91, 97, 102, 
104-106).  
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Table 1.4. The diagnostic criteria for the systemic inflammatory response 
syndrome (95). 
2 or more of the following criteria 
Fever of more than 38.3°C or less than 36°C  
Heart rate of more than 90 beats per minute  
Respiratory rate of more than 20 breaths per minute or a PaCO2 level of less 
than 32 mm Hg 
Abnormal white blood cell count (>12,000/µL or <4,000/µL or >10% bands) 
 
 
Table 1.5. Surviving Sepsis Campaign Guideline Definitions of Sepsis(95).  
Sepsis SIRS + new/suspected infection 
Severe Sepsis Sepsis + sepsis-induced organ dysfunction 
Organ Dysfunction Sepsis-induced hypotension 
Lactate > normal laboratory results 
Urine output <0.5 mL/kg hr. for >2 hrs.,  
ALI with PaO2/FIO2 <250 in the absence of 
pneumonia as infection source 
ALI with PaO2/FIO2 <200 in the presence of 
pneumonia as infection source 
Creatinine >176.8 mmol/L) 
Bilirubin >34.2 mmol/L) 
Platelet count >100,000/mm3 
Coagulopathy (INR>1.5) 
 
Septic Shock Severe sepsis + hypotension not reversed by 
fluid resuscitation 
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Sepsis places a considerable burden on health care resources with patients admitted 
to hospital having longer hospital and ICU lengths of stay and costing more than 
those not admitted with sepsis. In the US conservative estimates suggest that $16.7 
billion is spent of treating sepsis, whilst in the UK, estimates based on the treatment 
of 100,000 patients with severe sepsis in ICU, suggests the National Health Service 
(NHS) spends £2.5billion/year managing sepsis (97, 99, 107). 
1.3.3. Pathophysiology of Sepsis 
Sepsis results from a host mediated immune response to infection. The pathogen 
load, its virulence and the subsequent host characteristics determine the extent of 
the response. Initial theories suggested that an exaggerated and dysregulated pro-
inflammatory response generated a cytokine storm that led to clinical features of 
fever, tachycardia, hypotension and MOF. Recent advances in sepsis biology have 
challenged this, with the current models suggesting a combined pro-inflammatory 
response (SIRS) that is counteracted by a compensatory anti-inflammatory response 
syndrome (CARS). See figure 1.10 (91, 108-111).  
1.3.3.1. Innate Immunity in Sepsis 
The innate immune system is responsible for the recognition and immediate 
response to pathogen invasion. This is achieved through specific PRRs, such as the 
TLR family, C-type lectin receptors, retinoic acid inducible gene-1-like receptors and 
nucleotide-binding oligomerization domain-like receptors. These PRRs recognise 
specific pathogen-associated molecular patterns (PAMPs), such as LPS from gram-
negative bacteria, which binds to TLR-4 and peptidoglycan from gram-positive 
bacteria, which binds TLR-2. PRRs also recognise host cellular damage from 
molecules known as danger-associated-molecular-patterns (DAMPs) or alarmins 
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such as high-mobility group protein B1 (HMGB-1), extracellular DNA, ribonucleic acid 
(RNA) and histones (91, 110, 112, 113).  
 
The activation of the PRR, TLR-4 by the PAMP, LPS, triggers a serious of 
intracellular signalling mechanisms resulting in the up-regulation of genes coding for 
pro-inflammatory cytokine production, such as TNF-α, IL-1β and IL-6, chemotactic 
signals and ROS intermediates and iNOS. The net result of this is the recruitment of 
neutrophils and other innate immune cells to the sites of infection and the 
enhancement of local immune cell function. Activation of PRRs not only enhances 
pro- inflammatory gene transcription but also anti-inflammatory transcription (e.g. IL-
10) ensuring a balanced immune response to contain and eliminate invading 
pathogen and minimising collateral tissue damage (91, 110, 114, 115). 
 
The systemic spread into the vasculature of these very same mediators is 
responsible for the vasodilation and subsequent hypotension that precipitates the 
MOF characteristic of sepsis (115).  
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Figure 1.10. The resolution of sepsis. 
  
Illustration of the current mechanism of sepsis resolution, showing an initial pro-
inflammatory response, which is counteracted by a compensatory immune response. 
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1.3.3.2 Coagulation in sepsis 
Disordered coagulation is a hallmark of severe sepsis characterised by platelet 
consumption and prolonged clotting times leading to disseminated intravascular 
coagulation (DIC) in 30-50% of patients with septic shock. The net result of sepsis 
upon the coagulation system is increased fibrin deposition due to increased thrombin 
generation, impairment of anticoagulation pathways and a reduction in the fibrinolytic 
system (91, 108, 116-118). 
 
Sepsis results in a state of micro-vascular thrombosis driven by the exposure of 
tissue factor (TF) to circulating blood cells after activation by TNF-α and bacterial 
products. TF binds and activates Factor  (F) VII, which activates FX and results in the 
conversion of prothrombin to thrombin. Thrombus formation decreases blood flow to 
septic tissues exacerbating hypo perfusion. The crucial role of this in sepsis has been 
demonstrated by the prevention of MOF and death by its inhibition in murine and 
primate models of LPS sepsis (91, 115, 118-121). 
 
Concurrently mechanisms to prevent thrombus formation are impaired. These are 
controlled by antithrombin, TF pathway inhibitor (TFPI) and activated protein C 
(APC). Pro-inflammatory cytokines in sepsis inhibit the production of intermediaries 
and thus impair the function of antithrombin and TFPI. APC is an important 
anticoagulant mechanism in sepsis as it inactivates FVa and FVIIIa. Levels of APC 
are substantially reduced in sepsis due to decreased production by the liver, 
increased consumption and by reduced activation due to lower levels of 
thrombomodulin and endothelial protein C receptors (91, 108, 118). 
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The protease-activated receptors (PARs) form an important link between coagulation 
and inflammation. Four have been identified to date with PAR-1 being of greatest 
importance in sepsis.  Thrombin is able to activate PAR1, whilst TF induces cell 
signalling via FXa and APC exerting cellular effects (117, 122).  
 
The central role of the coagulation system, and specifically APC, in sepsis led to the 
development of recombinant APC (Xigris, Eli Lily) as a treatment of severe sepsis. 
Pre-clinical studies demonstrated improved outcomes in animal model of sepsis 
infused with APC with the phase III PROWESS and ADDRESS trials showing 
improved clinical outcomes in patients with severe sepsis. Interestingly it was the 
anti-inflammatory effects of recombinant APC mediated via PAR1 that were 
attributed to the improvements rather than direct actions upon the coagulation 
system.  Recombinant APC was withdrawn from the market after a third Phase III 
trial (PROWESS-SHOCK) showed no benefit and an increase in fatal bleeding 
complications (91, 117, 118, 122-125). 
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Figure 1.11: A simplified diagram of the innate immune response to infection 
and tissue injury involving the inflammatory cytokines and the coagulation 
cascade.  
 
Pattern recognition receptors  (PRRs), such as TLRs on endothelial cells, on 
neutrophils and monocytes bind bacterial products resulting in an inflammatory 
cascade involving the coagulation systems and up-regulated cytokine gene 
production. The resultant microvascular occlusion and vascular instability 
leads to the characteristic coagulopathy increased capillary leak and 
vasodilation seen in sepsis. Adapted from Cohen J 2002 (126).  
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1.3.3.3 Immunosuppression in Sepsis  
There is increasing evidence that immunosuppression plays an important role in the 
pathogenesis of sepsis. It is uncommon for patients to die from sepsis in the pro-
inflammatory phase commonly seen in young patients with meningococcal sepsis, as 
advances in medicine ensure such patients receive timely treatment. Deaths from 
sepsis tend to occur in-patients who have often survived the initial insult only to 
succumb to secondary opportunistic infections (91, 127, 128). This has been 
attributed to state of relative immunosuppression that follows the initial pro-
inflammatory phase. Evidence from post-mortems and lung samples of patients with 
sepsis have shown that leucocytes develop a relative immunosuppressed phenotype 
and show reduced activity against bacteria. In addition death from sepsis is 
associated with apoptosis of both adaptive and innate immune cells (109, 127-129). 
 
Common nosocomial infections that cause secondary sepsis are of relatively low 
virulence (Strenotrophomonas spp, Actinobacter spp, Pseudomonas spp and 
Candida spp) and there is a high incidence of reactivation of latent viruses (CMV and 
herpes simplex) adding to evidence that hospitalised patients with sepsis are 
relatively immunosuppressed (128, 130-132). 
1.3.3.4 Multi-organ failure in Sepsis 
Organ failure, in particular of the cardiovascular system, leads to death from sepsis. 
The exact mechanism of organ failure is still not fully known, with tissue hypo-
perfusion, microvascular thrombi, endothelial, immune and organ cell death all 
involved. The increase in oxygen demand leads to oxidative stress, mitochondrial 
dysfunction and eventual death (91, 133, 134). 
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Figure 1.12 Potential inflammatory responses in sepsis 
 
 i) Early deaths from sepsis are driven by an overwhelming pro-inflammatory phase 
leading to refractory cardiovascular shock, metabolic derangements and multi-organ 
failure. ii) A large proportion of patients are elderly and present with complex 
comorbidities. These patients develop an initial blunted/absent pro-inflammatory 
response with an exaggerated anti-inflammatory phase. These patients may survive 
and recover or go onto develop a state of prolonged critical illness. iii) An additional 
suggested immunological response is characterised by cycling between pro-
inflammatory and anti-inflammatory states. In this response patients have an initial 
proinflammatory response followed by a hypo-inflammatory state. With secondary 
infection, patients have a repeat pro-inflammatory response from which they may 
recover or develop a further an anti-inflammatory phase. iv) Late deaths from sepsis 
may arise due to significant immunosuppression, the reactivation of latent viruses 
and the development of nosocomial infection. Modified from Hotchkiss et al, Lancet 
Infectious Diseases 2013 (128). 
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1.3.4. Treatment 
The SSCG break down sepsis management into bundles of care that have been 
shown to improve outcomes when applied. The initial sepsis bundle focuses on the 
resuscitation of the patients, source identification and control and the delivery of 
timely antibiotic therapy (see table 1.6) (94-96, 135-137). The importance of early 
detection of sepsis and the initiation of early antibiotic therapy is vital as delays in the 
initiation of appropriate therapy significantly increases mortality with one study 
suggesting that for every hour that antibiotics are delayed mortality is increased by 
10% (96, 138-140). 
 
A large part of sepsis management focuses on the restoration of circulating volume 
and the maximisation of oxygen delivery. This involves the administration of oxygen, 
intravenous fluids and where appropriate, the initiation of vasopressors and 
mechanical ventilation. The delivery of protocolised goal-directed therapy to achieve 
optimal oxygen delivery was proven by Rivers et al and has guided sepsis 
management since. However results from the PROCESS and ARISE trials has 
challenged this paradigm suggesting that targeting resuscitation to correct lactate 
levels is as effective as guiding resuscitation using central venous pressure (CVP) 
monitoring and central venous saturations (ScV02%) (96, 141-143).  
 
The SSCG’s second bundle incorporates management strategies on ICU and 
includes guidance on vasopressor use, mechanical ventilation, renal replacement 
therapy, sedation, nutritional support and the prevention of thrombo-embolic events 
and nosocomial infections (91, 96).  
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Trials on immunomodulatory drugs to treat sepsis have failed to show any benefits 
and at present, only a short course of hydrocortisone 200mg per day, has been 
suggested in patients who remain hypotensive despite adequate fluid resuscitation 
and appropriate vasopressor therapy to modulate immune responses in sepsis (91, 
96, 123, 124, 144-147). 
1.3.5. Summary 
Sepsis is a global health problem affecting millions of people worldwide, causing 
significant morbidity and mortality and places a great economic burden on health 
services. The incidence of sepsis continues to rise in part due to an ageing 
population. Sepsis arises due to an imbalance in the pro-inflammatory and anti-
inflammatory host response to infection and is a complex biological process. 
Treatment of sepsis is based on early recognition, initiation of antibiotics and 
optimisation of oxygen delivery. Although medical science has failed to develop any 
immunomodulatory therapies to tackle the immune dysfunction of sepsis, the 
application of the SSCG bundles and principles have seen sepsis-related mortality 
fall year upon year over the past decade (91, 96, 102, 103).  
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Table 1.6: Surviving Sepsis Campaign Guidelines for Initial Resuscitation 
Surviving Sepsis Campaign Bundles 
To be completed within 3 hours 
1. Measure lactate level 
2. Obtain blood culture prior to administration of antibiotics 
3. Administer broad spectrum antibiotics 
4. Administer 30ml/kg crystalloid for hypotension or lactate 
>4mmol/L. 
To be completed within 6hours 
5. Apply vasopressors (for hypotension that does not apply to 
initial fluid resuscitation 
x In the event of persistent arterial hypotension despite 
volume resuscitation (septic shock) or initial lactate >4 
mmol/L  
x Measure central venous pressure (CVP)* 
x Measure central venous oxygen saturation (ScvO2)*  
6. Re-measure lactate if initial lactate was elevated* 
 *Targets for quantitative resuscitation included in the guidelines are 
CVP of ≥8 mmHg, ScvO2 of 70%, and normalization of lactate. 
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1.4. Neutrophil Function in Sepsis 
Neutrophils are implicated in the pathogenesis of MOF in sepsis, with over activated 
neutrophils, at sites of infection, causing collateral tissue damage, whilst suppressed 
neutrophil function leads to ineffective pathogen elimination and dissemination of 
infection. Finally neutrophils may cause organ/tissue damage at sites remote to the 
infectious focus due to systemic activation of neutrophils leading to invasion and 
damage of highly vascular organs, such as the lungs, liver and kidney. The key 
changes in neutrophil function are summarised in table 1.7 (148-155).  
1.4.1. Impact of sepsis on neutrophil chemotaxis 
Neutrophil migration is essential for the elimination of pathogens, with impaired 
migration being linked with poorer outcomes from sepsis in murine models of sepsis 
and in humans. The mechanism is likely to be complex relationship between multiple 
pathways (2, 148, 154, 156-158).  
 
The inflammatory response of severe sepsis results in increased neutrophil rigidity, 
alteration in the expressions of adhesion molecules, the internalisation of chemokine 
receptors and changes in intracellular signalling, all of which contribute to a state of 
neutrophil desensitisation and resultant decrease in migration (2, 148, 159). 
Furthermore, pro-inflammatory cytokines (TNF-α) and bacterial products (fMLP) 
cause increased neutrophil cell membrane rigidity via the deposition of F-actin just 
below the cell membrane resulting in reduced deformability, preventing effective 
rolling and leading to neutrophil sequestration into capillary beds, which exacerbates 
tissue hypoxia. This process is mediated via peroxisome proliferator-activated 
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receptor (PPAR) γ, a group of nuclear hormone receptors. Reddy et al demonstrated 
that in patients with sepsis PPARγ receptor levels are higher and are associated with 
defective neutrophil chemotaxis. They also demonstrated that inhibition of PPARγ in 
a murine model of sepsis prevents the deposition of F-Actin in response to fMLP and 
improves neutrophil migration (2, 148, 160, 161). 
 
NO also plays a key role in altering the migratory dynamics of neutrophils in sepsis 
by reducing the expression of beta-2-integrins (LFA-1 and MAC-1) and selectins (L, 
P and E-Selectin) on neutrophils and endothelium adhesion molecules expression 
(ICAM-1 and VCAM-1). Studies in murine models of sepsis (caecal ligation and 
puncture {CLP}) have demonstrated that blocking iNOS either pharmacologically or 
genetically reverses the deleterious effects of sepsis on neutrophil migration, 
improves bacterial clearance and improves survival (2, 148, 154, 156, 162-164). 
 
The TLR family are important in the initiation of innate immunity and act as PRRs, 
which detect PAMPs and thus cause increased transcription of pro-inflammatory 
cytokines, however they have also been implicated in aberrant chemotaxis. A CLP 
model of murine sepsis with mice deficient in TLR-4 and -2 demonstrated improved 
chemotaxis and survival when TLR function was inhibited (2, 154, 156, 165, 166). 
 
A phenomenon observed in neutrophil studies in sepsis is a state of neutrophil 
paralysis or desensitisation leading to impairment of chemotaxis. It has been 
suggested that during sepsis neutrophils are persistently stimulated by high doses of 
pro-inflammatory cytokines leading to the activation of G-protein receptor kinase 
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(GRK). GRK-2 and GRK5 phosphorylate GPCRs, such as CXCR2 (CXCL-8 
receptor), resulting in their desensitisation and internalisation. TLR-4 activation has 
also been implicated in neutrophil chemokine internalisation with blockade of TLR-4 
using IL-33 preserving CXCR2 receptor expression and neutrophil chemotaxis in 
murine models of sepsis (148, 154, 155, 166-168). 
1.4.2. Impact of sepsis on neutrophil phagocytosis 
The effects of sepsis on neutrophil phagocytosis remain controversial, with evidence 
from the literature of reduced and increased phagocytosis. The ability of neutrophils 
to eliminate pathogens is crucial with several studies suggesting that neutrophils up-
regulate phagocytic receptors (CD64/ FcγRI) enabling greater bacterial ingestion (3, 
169-173). Studies have also suggested that the increased release of neutrophils in 
response to sepsis leads to an immature pool of neutrophils that are less capable 
than their mature counterparts.  Selective isolation of these immature neutrophils 
(bands) has demonstrated reduced CD64/FcγRI expression and reduced 
phagocytosis (174-178). Efficient neutrophils phagocytosis relies on the opsonisation 
of bacteria by IgG, and the failure to do so has also been implicated in the reduced 
phagocytosis observed in patients with sepsis (176, 179). 
1.4.3. Impact of sepsis on neutrophil degranulation and reactive oxygen 
species (ROS) production 
In infection and sepsis ROS and RNS is up regulated to allow effective pathogen 
elimination. However, the products of ROS (H2O2, HOCL), RNS (peroxynitrite) and 
degranulation (MPO and NE) are highly toxic to DNA, lipid membranes and the 
endothelium. In homeostatic responses to infection naturally occurring anti-oxidants, 
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such as glutathione, vitamin E and another micronutrients, neutralise these toxic 
substances (45, 53, 180, 181).  
 
In sepsis the generation of ROS is massively increased via stimulation of NADPH by 
pro-inflammatory cytokines and bacterial products. This combined with a state of 
tissue hypo-perfusion (hypoxia) and a consumption of anti-oxidants results in 
excessive ROS and RNS species, exacerbates cell-death and endothelial damage in 
sepsis. This has been termed oxidative stress and is implicated in the MOF observed 
in sepsis and other inflammatory conditions (46, 47, 133, 169, 182-184). 
 
Interventions aimed at reducing oxidative stress by the supplementation of anti-
oxidants directly or indirectly using N-Acetylcysteine (NAC) showed improved 
outcomes in murine models of sepsis and in phase II human trials. These have not 
translated into clinical practice as two large clinical trials with antioxidant therapy and 
a Cochrane Review on NAC suggest increased harm with their use (183, 185-191).  
1.4.4.  Impact of sepsis on neutrophil apoptosis 
The apoptosis of neutrophils is a complex process that is regulated by pro and anti-
apoptotic signals. The immune response of sepsis promotes both pro-apoptotic 
signalling via the ROS and phagocytosis and anti-apoptotic signalling via G-CSF, 
GM-CSF and LPS. Reduced neutrophil survival is associated with poorer outcome 
from sepsis as neutrophils are unable to adequately eliminate pathogens, whilst 
prolonged survival aggravates host tissue damage (8, 10, 192, 193). 
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Studies on neutrophils in patients from sepsis suggest that it is the anti-apoptotic 
signals that pre-dominate to prolong neutrophil survival, with high levels of G-CSF, 
GM-CSF, TNF-α and LPS inhibiting the process (192, 194-199).  
 
Neutrophil apoptosis promotes the resolution of inflammation causing macrophages 
to change to an anti-inflammatory phenotype and promoting the release of IL-10. In a 
variety of animal models of sepsis inducing apoptosis results in enhanced resolution 
of inflammation, leading many to suggest that targeting apoptosis is a viable 
therapeutic intervention (192, 195, 197, 200-204). 
1.4.5. Impact of sepsis on neutrophil extracellular trap (NET) formation 
The role of NETs in health and disease remains unclear. There is increasing 
evidence that in chronic inflammatory conditions, such as vasculitis and rheumatoid 
arthritis, increased NET release is correlated with increased disease severity and 
may be involved directly in disease pathogenesis. Kessenbrook et al proposed that 
the release of double stranded DNA, MPO and NE by neutrophils triggers an 
autoimmune response and damages the endothelial that is characteristic of these 
diseases (205-207). 
 
Current evidence suggests that NETs are a vital function of neutrophils, being found 
in a variety of infected sites, such as the lung, peritoneum and skin where they 
ensnare bacteria pathogens and deploy high concentrations of antimicrobial toxins. 
In murine models of sepsis mice unable to generate NETs demonstrated increased 
susceptibility to infection, reduced bacterial clearance, exacerbation of the original 
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pathology and decreased survival suggesting that NETs are an essential part of the 
innate immune response (16, 64, 208-210).  
 
Human studies regarding NET production in sepsis are lacking. Neutrophil studies in 
infants show preserved ROS generation and phagocytosis, but impaired NET 
production suggesting this may be implicated in their poorer outcomes. Meng et al 
found that NETs were raised in patients admitted to hospital following major trauma 
at admission and decreased over time. However in patients who subsequently 
developed sepsis, NET values rose again (211-213).  
 
NET formation is a process that requires tight homeostatic control, as the 
antimicrobial properties may be offset by unregulated NET production leading to 
collateral tissue damage from the proteases and histones that they contain. These 
molecules cause endothelial damage that is the hallmark of severe sepsis and 
subsequent MOF with evidence that NET production is involved in the pathogenesis 
of acute respiratory distress syndrome (ARDS), malaria falciparium and septic 
hepatic dysfunction (214-218). 
1.4.6. Neutrophils, tissue damage and multi-organ failure. 
Sepsis is characterised by immune dysfunction and tissue hypoperfusion that 
progresses to MOF. Although this process involves many facets of host innate and 
adaptive immunity, the role of the neutrophil is becoming increasingly evident (3, 91, 
108).  
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Sepsis results in altered chemotaxis preventing neutrophils reaching sites of 
infection. However neutrophils in the circulation become primed due to high 
concentrations of circulating pro-inflammatory cytokines. The activated but 
“paralysed” circulating neutrophils, with their reduced deformability get trapped within 
the vasodilated vascular beds distant to the site of infection. This exacerbates tissue 
hypo-perfusion by reducing blood flow and causing microvascular occlusion through 
interactions with fibrin. Activated neutrophils release ROS, MPO and NE within these 
vascular beds causing endothelial cell damage and death leading to capillary leak 
and further tissue/organ hypo-perfusion. The interaction between activated platelets 
and NETs further damages tissues and increases thrombus formation (3, 219-222).  
 
The net result is cells/organs downstream from this neutrophil-induced endothelial 
injury become increasingly hypoxic, aggravating oxidative stress, collateral tissue 
damage and eventually resulting in cell death and organ dysfunction (133, 134, 149, 
220, 222, 223).  
 
Within the pulmonary tissues the pattern of injury is different with a large numbers of 
neutrophils being extravasated into the lungs during systemic sepsis, directly injuring 
the lung tissue through degranulation, ROS generation, NET production and reduced 
apoptosis. These primed neutrophils have recently been shown to re-circulate within 
the systemic circulation and may be implicated in the distal organ damage seen in 
patients with severe pneumonia and ARDS (3, 198, 224-227). 
 
Page | 57 
 
This makes therapeutic intervention aimed at modifying neutrophil challenging, as 
benefits from enhanced neutrophil migration and microbicidal actions at sites of 
infection may be offset by systemic neutrophil activation within distal organs. In 
contrast therapies that reduce systemic neutrophil activation may reduce distal organ 
damage but at the expense of impairing the innate immune responses to infection 
(3). An ideal therapeutic agent would enhance migratory dynamics and neutrophil 
functions in the initial phases of infection to assist with pathogen elimination, but 
reduce neutrophil activation as the infection progresses to severe sepsis to avoid 
deleterious consequences.  
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Figure 1.13: Proposed mechanisms of neutrophil-mediated organ damage in 
sepsis 
 
The figure details potential mechanisms involved in the direct tissue damage caused 
by neutrophils within the lungs and the mechanisms thought to occur in the 
microvascularture and at distal organs. Both perhaps occur simultaneously. 
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1.5. Statins in Sepsis 
1.5.1. The Pharmacology of Statins 
HMG-CoA reductase inhibitors (commonly referred to as statins) are drugs primarily 
used in the lowering of blood cholesterol by inhibiting the enzyme 3-hydroxy-3-
methylglutaryl-coenzyme (HMG-CoA) reductase. This enzyme converts HMG-CoA to 
mevanolate and is an early rate–limiting step in the synthesis of cholesterol in the 
liver. Statins are effective in the primary and secondary prevention of cardiovascular 
disease and are widely prescribed to about 7 million people per year in the UK (228-
232). 
 
At present six statins are used in the UK, lovastatin, pravastatin, and simvastatin are 
fungal derived, whilst atorvastatin, rosuvastatin and fluvastatin are synthetically 
derived. Simvastatin and atorvastatin account for 85% of statin usage in the UK. 
Statins are safe and well-tolerated drugs with relatively low levels of drug 
discontinuation (3.9%); however hepatic dysfunction (incidence 1.7%) and muscle 
toxicity are the most serious side effects. Muscle toxicity is often asymptomatic with 
reversible rises in Creatinine kinase (CK). The incidence of rhabdomylosis is hard to 
estimate, but a recent study quantified the incidence as 0.3-8 cases per 10000 
person-years of statin exposure (230, 233-235).  
 
1.5.2. Pleiotrophic effects of statins 
Over the past decade several retrospective analysis of large cohorts of patients’ 
admitted to hospital demonstrated that statins were associated with a lower mortality 
and morbidity from infection and sepsis. This was followed by prospective 
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observational studies, most of which suggested that treatment with statins therapy 
prior to infectious insults improved mortality. However, some of the studies were 
equivocal with only one suggesting that statin therapy was harmful (236-245). 
 
These observational studies have led to further investigations into the mechanisms of 
immune modulation by statins and the development of statins as potential adjuvant 
therapy in sepsis.  
 
The inhibition of HMG-CoA reductase also prevents the synthesis of the important 
isoprenoid intermediaries, isopentenyl pyrophospate (IPP), farnesylpyrophosphate 
(FPP) and geranylgeranylpyrophosphate (GPP). These molecules play important 
roles in downstream protein prenylation via the small family of GTPases, Rho and 
Rac, and it has been postulated that the inhibition of these molecules are responsible 
for the pleiotrophic effects of statins (228, 229, 246-249). 
 
The inhibition of Rho and Rac GTPases results in significant downstream effects that 
may modulate multiple pathways in sepsis pathophysiology. It has been proposed 
that statins inhibit neutrophil migration into the lungs and endothelial adhesion via 
reductions in Selectins, LFA-1 and Mac-1 expression, whilst TLR-4 and 2 expression 
is down regulated through effects on monocytes. This may reduces inappropriate 
neutrophil migration and adhesion, whilst enhancing targeted migration into infected 
tissues (150, 248, 250-254). 
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Statins have been shown to reduce the release of pro-inflammatory mediators, such 
as CRP (released from hepatocytes in response to IL-6), TNF-α, IL-6 and CXCL-8. 
The reduction in CRP by statins has received great attention, as it widely measured 
and is a generic marker of inflammation. Evidence from randomised controlled trials 
show that lowering CRP is associated with improved outcome in cardiovascular 
disease and in bacterial pneumonia (249, 255-263). 
 
The coagulation cascade plays a crucial role in the pathogenesis of sepsis. Statins 
may prevent the pro-coagulant effects of sepsis by improving platelet function, 
reducing thrombin and fibrinogen formation. They also promote fibrinolysis via tissue 
plasminogen activator (tPA), platelet-activation inhibitor-1 (PAI-1) and by increasing 
endogenous protein C levels (264-270). 
 
Finally, statins may stabilise endothelial cell function by attenuating the response to 
inflammatory cytokines, which promotes leucocyte adhesion and iNOS activity. 
Reduced vasomotor tone is caused by reduced eNOS activity and an increase in 
iNOS resulting in hypotension. Statins reversed this by increasing endothelial derived 
NO by increasing eNOS activity (238, 246, 247, 271-273). 
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Figure 1.14: The pharmacology of statins/HMG-CoA reductase inhibitors. 
 
An illustration of the stages in cholesterol synthesis from Acetyl-CoA, the site of 
action of statins and the isoprenoid intermediaries that are responsible for the 
pleiotrophic effects of statins. PP= pyrophostate.. 
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1.5.3. Evidence for statin therapy in sepsis 
The first published evidence of improved outcomes from sepsis in patients receiving 
statins was in 2001, when Liappis et al demonstrated a 22% reduction in mortality 
from bacteraemia in patients receiving a statin. Almog et al followed this in 2004 with 
a prospective study showing that prior statin use significantly reduced the 
progression of bacterial infections to severe sepsis and reduced ICU admissions. 
Since, many retrospective and prospective studies have confirmed these findings 
and are supported by subsequent meta-analysis (236, 237, 239-242, 245, 274-279). 
1.5.3.1. Statin use in animal models of sepsis 
Ando et al in 2000 used an LPS model of sepsis to demonstrate that pre-treatment 
with cervistatin (20mg/kg) resulted in an attenuation of the proinflammatory response 
with a subsequent increase in 7-day survival. Merx et al followed this showing that 
mice pre-treated with 10μg/ml simvastatin had improved survival, preserved 
haemodynamics and reduced leucocyte adhesion compared to untreated mice in a 
CLP model of sepsis. A subsequent study demonstrated that simvastatin (40mg/kg) 
reduced mortality and attenuated sepsis induced acute kidney injury by preserving 
renal tubular function, reversing the renal microvascular hypo-perfusion and hypoxia 
associated with CLP mediated sepsis (280-282). 
 
Although the above models demonstrate significant benefits of statin therapy in 
murine models of sepsis, the doses used exceeded physiological doses (20-80mg 
per day in an adult = 0.25-1mg/kg for an 80kg human) making applications to human 
sepsis difficult.  
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Figure 1.15. The proposed mechanism of statins in sepsis. 
 
An illustration of the pathogenesis of sepsis leading to multi-organ failure with the 
pathways inhibited by statins shown by the red crosses. Statins are thought to exert 
effects beyond their lipid-lowering effects. These have been termed “pleiotrophic” 
effects and potentially modulate the inflammatory response of sepsis at multi-levels. 
Statins have effects upon the coagulation system inhibiting tissue factor (TF) and 
platelet activator inhibitor -1 (PAI-1), thereby preventing microvascular occlusion. 
Additionally via actions on innate immune cells and the complement system, the 
release of cytokines and chemokine expression is down regulated resulting in 
preservation of endothelial function. By suppressing these vital pathways in the 
development of multi-organ failure in sepsis, statins have been postulated as a 
potential immunomodulatory therapy in sepsis. Adapted form Cohen J et al, 2002 
(126). 
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1.5.3.2. Statin use in human sepsis 
Studies investigating the role of acute statin administration in human sepsis are 
inconclusive. Phase II studies suggest that the acute use of statins in sepsis 
attenuates the inflammatory response, with lower levels of IL-6, TNF-α and CRP 
observed and a reduction in pulmonary neutrophil infiltration (150, 152, 260, 283). 
 
Craig et al demonstrated that the use of simvastatin 80mg improved respiratory 
mechanics, oxygen index and Sequential Organ Failure Scores (SOFA) as well as 
pulmonary CXCL-8 levels and systemic CRP levels. This proof of concept trial 
demonstrated that statins were well tolerated in critical illness and had potential in 
showing real benefit to patients (284, 285)  
 
Kruger et al demonstrated in that low dose atorvastatin administered to patients with 
severe sepsis (randomised placebo-controlled trial) in the ICU did not improve 
mortality or length of stay, but subgroup analysis demonstrated that continuation of 
pre-admission statin therapy reduced mortality (286). Whilst another trial on statin 
use in the ICU was suspended early due to futility as no improvement in mortality 
was observed in patients acutely treated with statins for ventilator-associated 
pneumonia (VAP).  In fact mortality in the statin group was higher but did not reach 
significance (p=0.054) (287). 
 
Two further trials have questioned the rationale of acute statin administration in the 
context of acute illness. The first randomly assigned patients with ARDS to receive 
either rosuvastatin 20mg or placebo and was also terminated early due to futility with 
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no significant difference in 60-day mortality (p=0.21). However it suggested that 
rosuvastatin therapy was associated with a higher probability of developing hepatic 
and renal dysfunction and consequently statin use in ARDS could not be advocated 
(288). 
 
The second assessed the use of simvastatin 40mg on the exacerbation rate of 
patients with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD). This 
trial also demonstrated no benefit of simvastatin therapy on the rate of COPD 
exacerbations with no deleterious effects of statins observed (289). 
1.5.4. Summary 
Statins clearly have anti-inflammatory properties that are capable of modulating the 
inflammatory response at multi-levels, with evidence from retrospective and 
prospective cohort studies suggesting that statin use is associated with improved 
outcomes from sepsis. This is supported by human models of sepsis demonstrating 
an attenuation of the inflammatory release with statins (152, 230, 245, 289-291). 
 
Murine models have shown that pre-treatment improves mortality by modulating 
several pathways in the pathogenesis of sepsis. However, this so far has not been 
translated into successful human randomised controlled trials, with some of the data 
suggesting that statins may actually be harmful if administered in severe sepsis (280, 
281, 284, 286-289, 292). 
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1.6. Hypothesis 
It was hypothesised that sepsis would exaggerate the decline in neutrophil function 
observed with age.  
1.7. Aims of the thesis 
This thesis is a report of investigations studying the potential impact of statin therapy 
in the treatment of infections and sepsis. The specific aims of these investigations 
are: 
1. To investigate whether in-vivo treatment with statins corrects alterations in 
neutrophil function observed in healthy elderly participants. 
2. Characterise neutrophil function in terms of migration, ROS production, 
phagocytosis, apoptosis and NETs in patients with sepsis. 
3. Determine whether in-vitro treatment of neutrophils from sepsis patients with 
simvastatin improves any alterations observed in neutrophil functions. 
Page | 69 
 
 
 
 
 
 
 
 
 
Chapter 2: Methods 
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2.1: Ethical Approvals. 
All patients and healthy volunteers in the studies reported provided informed written 
consent. In circumstances where patients were unable to provide consent a legal 
representative (personal or designated consultee) provided assent. Retrospective 
consent was sought in cases where possible, when patients regained the ability to 
consent. All studies received the appropriate ethical and local approvals (Regional 
Ethics Committee references: 11/SC/0356 & 11/YH/0270) 
2.2: Recruitment of Healthy Controls 
Healthy volunteers were required to act as controls for patients. Young controls  (less 
than 45 years of age) were recruited from staff and students at the University of 
Birmingham via a poster advertisement. Elderly controls were recruited from the 
Birmingham 1000 Elders Cohort, a research cohort of healthy volunteers above the 
age of 60 willing to take part in medical research. To be considered healthy, 
participants were not suffering from serious debilitating acute or chronic illness. Well-
controlled health problems, such as hypertension and asthma did not preclude 
enrolment. 
2.3: Patient recruitment 
Patients enrolled for the sepsis study were recruited from the Heart of England NHS 
Foundation Trust and the University Hospital Birmingham NHS Foundation Trust 
between September 2011 and October 2013. Patients with sepsis were recruited 
from the acute medical admissions units  (AMU) and the ICUs at both sites.  
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The Heart of England NHS Foundation trust is a university affiliated teaching trust 
spread over three sites that geographically covers the north and east of Birmingham 
with a total of 1449 in-patient beds. Patients were recruited from the largest site, 
Birmingham Heartlands Hospital in the east of Birmingham. This site has a 44 bed 
AMU and a 19 bed general ICU. The new University Hospital Birmingham NHS 
Foundation Trust is the largest single site hospital in the UK with 1213 in-patient 
beds, an 84 bed AMU and a 100 bed ICU. It is the major tertiary referral centre for 
the region but also serves the population of central and southwest Birmingham.  
2.3.1. Diagnosis of Sepsis 
Sepsis, severe sepsis and septic shock were diagnosed according to the SSCG 
definitions (see table 1.4 and 1.5). Screening was performed daily on the AMUs and 
ICUs and patients who developed sepsis within 48 hours of admission were 
considered for enrolment. Exclusion criteria were pregnancy, age below 18 years of 
age, imminent withdrawal of treatment or refusal to gain consent.  
2.3.2. Data Collected 
Data collected from enrolled patients included demographic details, pre-existing co-
morbidities, drug history, their observations on admission, baseline haematology and 
biochemistry results. These are shown in table 2.1. Data was also collected for the 
first seven days of their hospital stay with physiological, haematological and 
biochemical data recorded. Antibiotic therapy, positive microbiology and organ 
support requirements were also collected. In addition outcome data, such as 
admissions to ICU, length of hospital stay and mortality were collected. 
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2.3.3. Severity Scores 
Data collected was used to calculate diseases severity using a variety of different 
schemes outlined below. They incorporate a variety of physiology and biochemical 
variables that impact on survival to enable risk stratification, prognostication and 
treatment effects. 
2.3.3.1. APACHE II Score 
The acute physiology and chronic health evaluation (APACHE) score is a severity 
scoring system applied to patients within 24hours of admission to ICU. The original 
score was developed in 1981 and since then has been modified several times. The 
APACHE-II score was first described in 1985 and is still the most widely used. It 
incorporates 12 routinely measured parameters allocating each one a score between 
0 and 4 (see table 2.2).  A total score between 0-71 is generated after accounting for 
age, past medical history and surgical conditions. A predicted mortality is also 
calculated. Higher scores correspond to increased severity and a higher probability of 
death. Although not all patients in the study were admitted to ICU, this scoring 
system was used to calculate disease severity (293, 294). 
2.3.3.2. SAPS-II Score 
The simplified acute physiology score (SAPS) II is a severity of diseases 
classification system and is also applied to patients admitted to the ICU within 24 
hours. It uses 12 physiological parameters, age, type of admissions and previous co-
morbidities to generate a score between 0-163 and also a predicted mortality score 
(see table 2.2). It is superior to the APACHE-II at comparing the disease severity in 
patients with different pathologies (295). 
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Table 2.1. Data collected on patients entered into the study 
 
 
 
* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MAP = mean arterial pressure **INR = International normalised ratio. Sepsis and 
severe sepsis classified according to international guidelines from the parameters 
recorded 
Data Collected on Entry into study 
Demographics Age 
Sex 
Date of admission 
Ethnicity 
Pre-existing co-morbidities 
Drug History 
Source of sepsis 
Baseline Physiology Temperature 
Pulse (bpm) 
Blood pressure and MAP* (mmHg) 
Respiratory rate (breaths/minute) 
Saturations (%) 
Inspired Oxygen Fraction (%) 
Glasgow Coma Scale 
Baseline Investigations White Cell Count  (x109/L) 
Platelets (x109/L) 
INR** 
Urea and Creatinine (µmol/L) 
Sodium (mmol/L) 
Potassium (mmol/L) 
Lactate (mmol/L) 
pH 
Standardised Base Excess 
Classification of sepsis Sepsis or Severe Sepsis  
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Table 2.2. Components of the Acute Physiology and Chronic Health Evaluation 
Score (APACHE II) and the Simplified Acute Physiology Score (SAPS II). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PaO2/FiO2 ratio: partial pressure of oxygen/fractional inspired oxygen concentration. 
GCS= Glasgow Coma Scale. 
APACHE II SAPS II 
Temperature Temperature 
Heart rate Heart rate 
Mean arterial pressure Systolic Blood Pressure 
Respiratory rate 
PaO2/FiO2 ratio 
PaO2/FiO2 ratio 
Serum Creatinine Serum Urea 
Urine Output 
Serum sodium Serum sodium 
Serum potassium Serum potassium 
Arterial pH or serum bicarbonate Serum bicarbonate 
White Cell Count White Cell Count 
GCS GCS 
Haematocrit Age 
Age Admission type 
Chronic Health Chronic diseases 
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2.3.3.3. SOFA Score 
The sequential organ failure assessment (SOFA) score classifies disease severity 
based upon six individual organ dysfunctions, with each organ receiving a score 
between 0-4, with a maximum score of 24. Higher scores are predictive of poor 
outcomes from disease. The organs assessed are the respiratory, cardiovascular, 
renal, coagulation, hepatic and neurological systems (see table 2.3) (296).  
 
The SOFA score is a dynamic score that be calculated serially, on admission to 
hospital or ICU and on subsequent days. A SOFA score of greater than 11 at any 
time correlates with poor outcomes, whilst change in SOFA score (delta SOFA score) 
have been shown to be a valuable predictor of mortality, with increases in the SOFA 
score by 4 or more points within 48hours of admission correlating with mortality. The 
SOFA score has been suggested as triage tool for assessment of survival and for 
rationing ICU resources in a pandemic situation. However, the H1N1 pandemic of 
2009 showed that using the SOFA score triage tool to ration ICU services was a poor 
predictor of outcome, with many patients surviving despite initial worsening of organ 
failure (296-299). 
 
The SOFA score is best used as a measure of treatment effect and to assess the 
resolution of disease. 
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2.4. Sample Collection 
Blood samples were collected at the time of recruitment (day 1), day 4 and day 7. 
Experienced medical practitioners took bloods peripherally or from in-situ arterial and 
central venous cannulae. A total of 36mls of blood was taken into 2 EDTA (4mls 
each) and 4 lithium heparin (7mls each) vacutainers (Becton-Dickinson, Oxford, UK). 
Samples were then placed on ice and transported to the laboratory for processing 
and analysis. 
2.5. Sample Processing 
2.5.1. Peripheral blood processing 
Blood samples were processed within 45 minutes of collection. 
2.5.2. Plasma sample 
A plasma sample was obtained by centrifuging blood from Lithium Heparin 
vacutainers at 800G for 10minutes at 4ºC. Plasma was stored in 500µl aliquots at -
80ºC until analysed. 
2.5.3. Isolation of Neutrophils 
Neutrophils were isolated on a Percoll (pH 8.5-9.5; Sigma-Aldrich, Dorset, UK) 
density gradient as previously described (87). Blood collected in Lithium Heparin and 
EDTA vacutainers (Becton Dickinson) were transferred into separate 50ml sterile 
FalconTM tubes (Becton Dickinson). 2% dextran (Sigma-Aldrich) was added (1ml for 
every 6mls of blood) and gently mixed prior to incubation for 30minutes at room 
temperature to sediment the erythrocytes. The leucocyte-rich plasma was carefully 
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layered on a Percoll (Sigma-Aldrich) density gradient consisting of 2.5mls of 80% 
Percoll (Sigma-Aldrich) and 5 mls of 56% Percoll (Sigma-Aldrich) (see figure 2.1).  
 
To prepare the gradients, a working stock of Percoll
 
was made by mixing 45 ml of 
Percoll
 
(Sigma-Aldrich) with 5 ml of 9% (v/v) sodium chloride (Sigma-Aldrich). The 
80% Percoll
 
was prepared by diluting 40 ml of the Percoll
 
stock with 10 ml 0.9% (v/v) 
sodium chloride (Baxter) whilst 56% Percoll
 
comprised of 28 ml of the working Percoll
 
stock and 22 ml of 0.9% (v/v) sodium chloride (Baxter). Gradients were then 
prepared by carefully layering 5 ml of 56% Percoll
 
on top of 2.5 ml 80% Percoll
 
in a 
15ml sterile FalconTM tube (Becton Dickinson).  
 
The gradients and leucocyte-rich plasma were centrifuged at 220G for 20 minutes 
with no acceleration and no brake at room temperature. Neutrophils were removed 
from the 80% and 56% gradient interface and re-suspended then washed in 
phosphate buffered saline (PBS; Gibco Invitrogen, Paisley, UK) at 440G for 
10minutes at room temperature. Post-centrifugation the supernatant was discarded 
and the cells re-suspended in either RPMI 1640 (Sigma-Aldrich) or in Hanks 
Balanced Salt Solution supplemented with calcium and magnesium (HBSS: Gibco 
Invitrogen; 12.61mM CaCl2, 4.93mM MgCl2, 4.07mM MgSO4) at the appropriate 
concentrations for the functional neutrophil assays. Purity was assessed by cytospin 
and staining with Giemsa stain (Diff-Qik; Gentaur Europe, Brussels, Belgium) 
routinely yielding neutrophil purity of greater than 95% and a viability of >98% as 
evaluated by tryptan blue exclusion 
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Figure 2.1. Isolation of neutrophils using a Percoll density gradient. 
 
Illustration showing the differential Percoll gradients on the left and the subsequent 
layers following centrifugation at 220G for 20 minutes on the right. The neutrophils 
were extracted from the 80% and 56% Percoll (Sigma-Aldrich) interface. 
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2.6. Functional Neutrophil Assays 
2.6.1. Neutrophil Migration 
Neutrophil migration was assessed using an Insall Chamber (Weber Scientific 
International Ltd, Teddington). This improved chemotaxis chamber (see figure 2.2) 
allows the migratory dynamics of individual cells to be assessed and provides greater 
information than traditional methods that provide only quantitative measures of cell 
migration (300-302). 
Isolated neutrophils from Lithium-Heparin vacutainers were re-suspended in RPMI 
1640 (Sigma-Aldrich) at a concentration of 5 x106/ml. Bovine Albumin Fraction V 
(Sigma-Aldrich) was added to the neutrophils at a final concentration of 1.125% v/v. 
Neutrophils were then placed on a cleaned (with 0.4M H2SO4) albumin coated 
coverslip (22x22mm, Surgipath Medical Industries Inc. Europe) and allowed to 
adhere for 20 minutes at room temperature. Once adhered the coverslip was inverted 
and placed on a clean Insall Chamber pre-filled with sterile RPMI 1640 (Sigma-
Aldrich). The RPMI 1640 (Sigma-Aldrich) was replaced with 100nM CXCL-8 (R&D 
systems, Abingdon, UK) or 10nM fMLP (Sigma-Aldrich) as chemoattractants. 
Gradients were allowed to develop for 5 minutes before assessment of migration. 
These doses were selected based on validation data performed by Hannah 
Greenwood (personal communication). 
 
Real-time video microscopy using a Leica DMI6000B with DFC360FX camera was 
used to capture neutrophil migration. Images were captured every 20 seconds for 
12minutes producing 36 frames. This time frame was considered optimal for 
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migration studies (personal communication with Dr. Elizabeth Sapey). Images were 
analysed using Image J software (Wayne Rasband, NIH, Bethesda) using vector 
analysis. Images were divided into ten individual segments and one cell randomly 
selected within each segment for analysis. Therefore ten randomly selected cells 
were analysed. 
2.6.1.1. Parameters used to assess neutrophil migration 
Three measures of migration were calculated based on the Image J software (Wayne 
Rasband). Firstly chemokinesis defined as the speed the neutrophil travels in any 
direction over time was calculated in μm/minute. Secondly directional migration or 
chemotaxis was measured in μm/minute. This was measured as the speed the 
neutrophil travelled in the direction of the chemotactic gradient. The measurements 
of distances was recorded in pixels and subsequently converted to μm following 
reference to the digital image and the magnification used. Thirdly the chemotactic 
index is calculated. This was an overall measure of the directional migration. This 
was calculated using the cosine of the angle between the cells direction and the 
orientation of the chemotactic gradient at each time frame forming a vector analysis 
of movement. A score of -1 to 1 was given to each cell, with a score of 1 representing 
perfect directional migration whilst -1 represents migration directly away from the 
chemo-attractant.  
 
In addition to the three neutrophil migration indices calculated, the adherence of 
neutrophils to the coverslip and the number of adherent cells migrating was 
calculated. Adherence was calculated by counting the number of neutrophils in the 
viewing plane that were adherent to the coverslip. This is expressed as a percentage 
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of the total number of neutrophils that were visualised in the viewing plane. The 
number of migrating neutrophils was calculated by counting the number of 
neutrophils in the viewing plane that initiated and subsequently moved in any 
direction. This is also expressed as a percentage of the total number of neutrophils 
visualised. 
2.6.2. Reactive Oxygen Species (ROS) measurement 
A luminol-based chemiluminescence assay was used to measure ROS as it detected 
both intracellular and extracellular free radicals (303). Freshly isolated neutrophils 
from Lithium-Heparin vacutainers (Becton Dickinson) were reconstituted to 1x106/ml 
in HBSS supplemented with calcium and magnesium (Gibco, Invitrogen). 1x105 
neutrophils were dispensed into wells of a 96-well white-bottomed flat plate (CoStar; 
Sigma-Aldrich) containing 25 μL of luminol (working concentration 100 µM; pH 7.3; 
Sigma-Aldrich) and 50 μL HBSS supplemented with calcium and magnesium (Gibco, 
Invitrogen). Cells were then treated with either 25 nM PMA (Sigma-Aldrich), 1.25µM 
CXCL-8 (R&D systems), 2.5µM fMLP (Sigma-Aldrich) or vehicle control and ROS 
generation assessed at 1 minute intervals for 60 minutes using a Berthold Centro LB 
960 luminometer (Berthold Technologies, Hertfordshire, UK). Experiments were 
performed in quadruplicate, with ROS production calculated as area under the curve 
(AUC) (see figure 2.3). The increase in ROS to stimuli was represented as the 
percentage change from baseline. 
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Figure 2.2. Diagram of the Insall Chemotaxis Chamber 
 
Migration experiments were performed by adhering extracted neutrophils on to an 
albumin-coated coverslip. This was then inverted and carefully placed over the Insall 
Chamber of the chemotaxis slide. The chemoattractant/control media was placed in a 
well. Time-lapse video microscopy was and the optimal viewing area is shown. 
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Figure 2.3. Reactive oxygen species production from neutrophils to the control 
media and 25nM PMA. 
 
The graph shows an example of the curves produced when reactive oxygen species 
(ROS) production was measured in neutrophils. ROS was measured in control media 
(HBSS) and to 25nM phorbol-12-myristate-13-acetate (PMA) every 1minutes for 
60minutes using a chemiluminescence technique. The area under the curve 
represented overall ROS production. 
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2.6.3. Phagocytosis 
Phagocytic function of neutrophils was assessed using a commercially available 
assay and was carried out as per the manufacturer’s instructions. The assay used E. 
coli and S. aureus bioparticles conjugated to a fluorescent dye pHrodo (Invitrogen) 
that only fluoresced once in an acidic environment, such as that of the 
phagolysosome. 
 
Freshly isolated neutrophils from Lithium-Heparin vacutainers (Becton Dickinson) 
were re-suspended at 1 x106/ml in RPMI 1640 (Sigma-Aldrich). 1 x105 cells were 
placed in a 96-well “U” bottomed plate (Becton Dickinson) and incubated at 37ºC with 
5% CO2 with 400µg/ml of the fluorescently labelled E.Coli  (pHrodo; Invitrogen) or 
S.Aureus (pHrodo; Invitrogen) for 60minutes, 45 minutes or 30 minutes. A negative 
control with the equal volume of cells were also incubated with E.Coli or S.Aureus 
(pHrodo; Invitrogen) and placed on ice for 60minutes. Following incubation, the cells 
were placed on ice to halt phagocytosis, were washed twice (250G at 4ºC for 5 
minutes) with 2% ice-cold PBS/BSA and transferred to flow cytometric tubes for 
analysis.  
 
Flow cytometry was carried out on a CyANADP (Beckman Coulter) with forward 
scatter and side scatter gating used to identify the neutrophil population and 
eliminate cell debris. The pHrodo beads were conjugated to Phycoerythrin (PE). Data 
was analysed using Summit v.4.3. (Dako, Colorado, USA). Three measures were 
used to quantify phagocytic function. Firstly the percentage of pHrodo “bright” cells, 
secondly the median fluorescent intensity (MFI) indicated the number of bacteria 
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phagocytosed by the cells. Lastly a phagocytic index (PI) was calculated by 
multiplying the percentage of pHrodo “bright” cells with the MFI (see equation below). 
This provided a quantitative measure of neutrophil phagocytic function (figure 2.4). 
 
Phagocytic Index = (Percentage of pHrodo “bright” cells/100) x MFI 
 
Data for the three indices of phagocytosis was represented as AUC (see figure 2.5). 
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Figure 2.4. Typical plots acquired from flow cytometry using for phagocytosis.  
A represents the gating based on forward and side-scatter to identify the neutrophil 
population. B represents the typical plot for the negative control. C represents 
phagocytosis at 60 minutes. 
A 
B 
C 
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Figure 2.5. Area under the curve calculations for phagocytosis indices. 
Phagocytosis indices were calculated at three time points (30, 45 and 60 minutes). 
Data for phagocytosis was expressed as area under the curve (AUC) for each of the 
indices’. This is shown in the above graph with the red area representing the AUC. 
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2.6.4. Quantification of Neutrophil Extracellular Traps (NETs) Formation 
Freshly isolated neutrophils from EDTA vacutainers (Becton Dickinson) were used in 
the quantification of NET formation. Neutrophils were re-suspended in RPMI 1640 
(Sigma-Aldrich) supplemented with 2nM L-Glutamine, 100U/ml Streptomycin and 
100ug/ml Penicillin (GPS; all purchased from Sigma-Aldrich), to ensure the culture 
remained sterile, at a concentration of 1 x106/ml. 1 x105 cells were placed in a 96-
well flat bottomed plate (Becton Dickinson) with an additional 75µl of RPMI 1640 with 
GPS (Sigma-Aldrich). Cells were then stimulated with 25nM PMA (Sigma-Aldrich) or 
an additional 25µl of the media was added for the negative control and incubated for 
3 hours at 37°C supplemented with 5% CO2. Experiments were performed in 
quadruplicate. 
 
Following incubation samples were treated with 200units of micrococcal nuclease 
(MNase; Sigma-Aldrich) and 1µM of SYTOX Green (Invitrogen) and incubated in the 
dark for 10 minutes at room temperature. This process stained and digested the 
extracellular DNA only. Samples were then transferred to into 500µl eppindorfs and 
pelleted at 5000rpm for 10minutes. The DNA containing supernatant was transferred 
(170µl) into a 96- well black flat-bottomed plate (CoStar; Sigma-Aldrich) and 
fluorescence measured in a BioTek Synergy 2 fluorometric plate reader (NorthStar 
Scientific Ltd, Leeds, UK) with a filter setting of 485nm excitation and 530nm 
emission. Background fluorescence from unstimulated negative controls was 
subtracted from the stimulated values. Figure 2.6 shows the production of NETs 
using 25nM PMA and a 3hour incubation period in healthy controls, whilst figure 2.7 
shows microscopy images of NET production using the above assay (303). 
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Figure 2.6: NET production in healthy volunteers.  
 
NET production was evaluated to the control media (RPMI 1640, Sigma-Aldrich) and 
25nM phorbol-12-myristate-13-acetate (PMA -Sigma Aldrich). The dot-plot 
represents individual values from 38 healthy donor neutrophils. Net production is 
represented on the y-axis and is expressed as AFUs. The greater the AFUs the 
greater the NETs production. The horizontal bar represents the median value.  
*p<0.001 in a Wilcoxon-signed rank test. 
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Figure 2.7. Fluorescent microscopy images of neutrophils extracellular trap 
formation in response to 25nM PMA. 
 
This shows a fluorescent image of neutrophils following 3hrs of incubation with 25nM 
phorbol-12-myristate-13-acetate. NETs are visible and are shown by the arrows 
within the image.   
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2.6.5. Neutrophil Apoptosis 
Freshly isolated neutrophils from EDTA vacutainers (Becton Dickinson) were 
suspended in RPMI 1640 with GPS (Sigma-Aldrich) at a concentration of 1x106/ml. 
2x105 cells were added to cytometric tubes and the cells pelleted by centrifugation at 
600G for 4minutes at 4°C. The pellet was washed twice and re-suspended (600G for 
4minutes at 4°C) in Annexin buffer (BD Biosciences, Oxford, UK).  
 
Apoptosis was assessed by flow cytometer using a CyANADP (Beckman Coulter). The 
washed cells were stained with Fluorescein Isothiocyanate (FITC) conjugated 
Annexin V (dilution 1:100; BD Biosciences) and incubated for 20 minutes at 4°C. Just 
prior to flow cytometric analysis SYTOX Blue (conjugated to violet, dilution 1:2000; 
Invitrogen) was added to the samples. Cell debris was eliminated using appropriate 
side and forward scatter gating. Data was analysed using Summit v.4.3. (Dako). The 
software carried out colour compensation automatically. Areas of cells that were 
negative for both (alive) Annexin V only positive (early apoptotic), positive for both 
(late apoptotic) and SYTOX Blue only positive (necrotic) were individually calculated 
(see figure 2.8). Data is represented as the percentage of cells in various stages of 
apoptosis. 
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Figure 2.8. Example flow cytometry plots for analysis of neutrophil apoptosis.  
 
A shows the typical gating strategy employed for using forward scatter and side 
scatter to identify the neutrophil population. B shows an example of the flow 
cytometry plot for neutrophil apoptosis with the various cell populations marked in the 
four quadrants. The percentage of cells within each quadrant was calculated and 
used for analysis 
A 
B 
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2.6.6. Neutrophil Receptor Expression 
The expression of various cell surface receptors on neutrophils was measured using 
flow cytometry. 100µl of whole blood was aliqoted into flow cytometry tubes and 
washed twice in 2mls of 1%BSA/PBS (250G for 5minutes at 4°C). The supernatant 
was discarded and the antibodies and relevant isotypes were added to the blood 
according to the manufacturers guidance and incubated in the dark for 60minutes on 
ice. The antibodies used are shown in table 2.4. Following incubation the solution 
was washed twice in 2mls of 1% PBS/BSA (250G for 5minutes at 4°C) and the 
supernatant carefully discarded. 2mls of FACS lysing solution  (eBiosciences, 
Hatfield, UK) was added to each tube and incubated for 15minutes in the dark to 
remove erythrocytes.  
 
Following erythrocyte lysis the cells were pelleted (250G for 5minutes at 4°C) and re-
suspended and washed twice in 2mls of 1% PBS/BSA (250G for 5minutes at 4°C). 
They were immediately run on the Accuri C6 flow- cytometer (BD Biosciences). Data 
was analysed using the Cflow Plus software (BD Biosciences). Colour compensation 
was carried out using a specific mathematical calculator provided by Accuri Cflow 
software (BD Biosciences). 
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Table 2.4. Primary antibodies and the isotype controls used to measure the 
neutrophil receptor expression. 
Antibody Isotype 
Control 
Colour Concentration Clone 
CD11a IgG1  FITC 1μg/ml HI 111 
CD14 IgG1  APC 0.25 μg/ml 61D3 
CD16 IgG1  FITC 1 μg/ml ebioCB16 
CD97 IgG1  APC 0.125 μg/ml VIM3b 
CD63 IgG1  PE 0.125 μg/ml H5C6  
CD45 IgG1  FITC 0.5 μg/ml 2D1 
CD62L IgG1  APC 0.5 μg/ml DREG-56 
CD18 IgG1  PE 0.25 μg/ml MHR73-11 
 
All products were bought from eBiosciences, Hatfield, UK. 
FITC: Fluorescein Isothiocyanate, PE: Phycoerythrin, APC: Allophycocyanin.  
TLR4: Toll-like receptor 4 
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2.7. In-vitro simvastatin experiments 
2.7.1. Statin dose-response 
A statin dose response was carried out using the neutrophil migration assays (see 
section 2.6.1) to select the most appropriate dose for the in-vitro experiments (see 
figure 2.9). These doses were chosen on the basis that 1µM is thought to reflect the 
approximate plasma concentration following 40-80mg oral simvastatin. This 
calculation is based on the premise that simvastatin has a high-first pass metabolism 
resulting in about a 5% bioavailability and is strongly protein bound. Therefore, the 
concentration of predicted is1: 
(40mg x 0.05)/5000ml (average blood volume) = 0.4 µg/ml, 
Molecular weight of simvastatin is 418 µg/ml, 
Therefore this is approximately 1µM. 
The dose response experiments suggested that the optimal in-vitro dose that can 
modify neutrophil migration is 1µM. Additionally a study in patients with ARDS 
following an oral dose of 80mg simvastatin suggested that the median plasma 
concentration of simvastatin was approximately 1µM (IQR 0.46-3.5µM) however, 
there was great variability (personal communication with Professor Danny McAuley). 
Recent evidence suggests that the anti-inflammatory effects of simvastatin are dose 
–dependent with larger effects seen at 40mg and 80mg compared to lower doses. 
Therefore based on the above calculation and these experiments this concentration 
                                            
1 Ghosh C et al, Drug repurposing screen identifies Foxo1-dependent Angiopoietin-2 
regulation in sepsis, critical care medicine, In Press 
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was chosen to investigate the in-vitro effects of simvastatin on neutrophil function in 
sepsis as it reflected an approximate dose of 40-80mg simvastatin (304-306). 
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Figure 2.9.Simvastatin dose-response 
 
The response of healthy control neutrophil chemotaxis to various doses of 
simvastatin (Sigma-Aldrich), negative (-ve) control and in the control media (RPMI 
1640). N=11. Bars represent the mean and the error bars SEM. 
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2.7.2. Effect of vehicle control (DMSO) and 1µM simvastatin on un-stimulated 
NET production 
 
Freshly isolated neutrophils were incubated with 1µM simvastatin (Sigma-Aldrich) for 
40 minutes prior to assessment of neutrophil function. Assays were then carried out 
as detailed above (section 2.6.1). 
 
The vehicle control for simvastatin (Sigma-Aldrich) was the solvent dimethyl sulfoxide 
(DMSO; Sigma-Aldrich). To test the potential confounding effect of DMSO on 
neutrophil function 10 separate NETs experiments were carried out (see section 
2.6.4). Neutrophils were incubated in 1µM simvastatin (Sigma-Aldrich) and an 
equivalent dilution of DMSO (Sigma-Aldrich). NETs were quantified to RPMI 1640 
with GPS (Sigma-Aldrich), DMSO (Sigma-Aldrich) and 1µM simvastatin (Sigma-
Aldrich). The addition of DMSO (Sigma-Aldrich) or 1µM simvastatin (Sigma-Aldrich) 
to unstimulated neutrophils did not significantly alter NET production compared to 
NET production in just the control media (p=0.436, Freidman’s Tests, N=10; see 
figure 2.10). 
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Figure 2.10 NET production in neutrophils to RPMI 1640 supplemented with 
GPS, DMSO and simvastatin 1µM.  
 
NET production was evaluated in 10 patients with to RPMI 1640 (Sigma-Aldrich) and 
dimethyl sulfoxide (DMSO; vehicle for simvastatin; Sigma-Aldrich) and simvastatin 
1µM (Sigma-Aldrich). Net production is represented on the y-axis as AFUs. The bars 
represent the median and the IQR and the error bars a Turkey distribution. 
Friedman’s test, p=0.436, N=10. 
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2.8. Statistical Analysis. 
Dr. Peter Nightingale, medical statistician at the University Hospital Birmingham NHS 
Foundation Trust, provided statistical advice for the data analysis. Statistical analysis 
was performed using GraphPad Prism Version 6 (La Jolla, California, USA) or PASW 
v.18.0 (Chicago, Illinois, USA).  
 
Continuous data was tested for normality using a Shapiro-Wilk, however when 
sample numbers were low a Kolmogorov-Smirnov test was used. Parametric data 
was analysed using a Student’s t-test for two independent samples or a paired t-test 
for matched samples. Where two or more groups were analysed a one-way analysis 
of variance (ANOVA) test was used for independent samples and a matched-pairs 
ANOVA for related samples. Non-parametric data were analysed with a Mann-
Whitney U test (independent samples) or a Wilcoxon signed rank test (related 
samples) for two groups. Analysis with two or more groups was performed using a 
Kruskal-Wallis test (independent samples) or a Freidmann’s test (related samples). 
Where two or more groups were analysed a relevant post-hoc test (ANOVA: 
Bonferroni test, Kruskal-Wallis test: Dunn’s test) were performed between all 
variables to determine where the significant differences lay. A Pearson or Spearman 
correlation was used for parametric and non-parametric data respectively. 
Categorical data was analysed using a Fisher’s exact test for two variables and a chi-
sqaured (χ2) used when greater than two groups were analysed. All tests were two-
tailed with results considered significant if p<0.05. 
Page | 102 
 
 
 
 
 
 
 
 
 
Chapter 3: Simvastatin 80mg for the modulation of 
neutrophil migration in the healthy elderly. 
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3.1. Introduction 
Elderly patients are at increased risk of developing severe infections and have a high 
morbidity and mortality from them. This has been attributed to a functional decline in 
innate and adaptive immune responses, termed immunosenescence, resulting in the 
poor containment and elimination of invading pathogens and an exaggerated host 
response. Neutrophils are an essential part of the innate immune response and 
alterations in their functions play a role in the pathogenesis of infection in the elderly. 
Functional neutrophil studies in the healthy elderly have demonstrated impaired 
chemotaxis, higher ROS production, reduced phagocytosis and NET production. 
Potential therapeutic options that improve neutrophil function in the elderly could 
potentially improve outcomes from infection in this susceptible group (72, 73, 75, 77, 
78, 80, 82, 85-88, 307, 308). 
 
HMG-CoA reductase inhibitors commonly referred to as statins, improve outcomes 
from infection in observational studies. Data from these studies suggest that statin 
users are older and have greater co-morbidities compared to non-statin users, but 
despite this they show a reduced mortality from severe infections suggesting that 
statins modulate the immune response (230, 236, 245, 309, 310).  
 
The effects of statins on neutrophil function remain controversial, with studies in both 
healthy volunteers and in those with severe infection suggesting that in-vivo statin 
therapy reduces neutrophil chemotaxis. These authors have suggested that reducing 
the number of migrating neutrophils into infected tissues suppresses collateral 
damage caused by excessive ROS and NET production and reduces the release of 
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pro-inflammatory cytokines preventing the inflammatory cascade that leads to 
eventual organ failure (150, 152, 311).  
 
However, recent data from our group, using time-lapse video microscopy 
demonstrated that neutrophils from healthy elderly donors retained their speed of 
migration (chemokinesis) but showed significant decreases in targeted migration 
(chemotaxis) compared to young controls. The in-vitro treatment of neutrophils with 
simvastatin restored the migratory dynamics of elderly donor neutrophils to values 
observed from young donors (86). 
 
Based on this evidence a trial was designed to test whether the treatment of healthy 
elderly participants with 80mg of simvastatin for 14 days would improve the migratory 
responses of their neutrophils. 
 
This trial was conducted in conjunction with Dr Hannah Greenwood, who assisted 
with the functional neutrophil assays and was overseen by Dr Elizabeth Sapey 
(principal investigator) and Professor David Thickett (chief investigator). 
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3.2. Methods 
3.2.1. Study Design 
This was a double-blind placebo controlled cross over randomised trial. All 
participants provided written consent prior to randomisation and the study received 
ethical approval (11/SC/0356). 
3.2.2. Study Participants 
Subjects were registered on the Birmingham1000 Elders database and were invited 
to take part in the study. No financial incentives were provided. Subjects were 
screened for eligibility by trained medical staff that took a medical history and 
examined them to rule out significant acute or chronic illnesses. Subjects had their 
body mass index (BMI) calculated, baseline blood tests taken for biochemistry and 
haematology and lung function tests performed. The inclusion and exclusion criteria 
are shown in table 3.1. Well-controlled hypertension, defined as participants with 
blood pressure recording within the normal range (systolic pressure less than 
159mmHg and a diastolic pressure less than100mmHg) and receiving treatment with 
anti-hypertensive agents, were not excluded, nor were participants with asthma who 
were only on beta-agonist inhalers (e.g. salbutamol) as required. 
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Table 3.1. Inclusion and exclusion criteria for entry into the study 
 
 
FEV1: Forced expiratory volume in 1 second. FVC: Forced vital capacity. 
COPD: Chronic obstructive pulmonary disease. 
CVD: Cardiovascular disease, defined as congestive cardiac failure (NYHA >II), 
angina (CCS>II), or previous documented ischaemic heart disease. Well-controlled 
hypertension was not an exclusion criterion. 
 
* Medications that would prevent entry into trial 
x HMGCoA reductase inhibitors 
x Insulin and oral medications for diabetes 
x Corticosteroids 
x Non-steroid anti-inflammatory drugs 
x Antibiotics 
x Theophyllines 
x PDE4 inhibitors 
x Anti-platelets 
x Anti-anginal drugs 
x Ciclosporin 
x Fibric acid derivates 
 
Inclusion Exclusion 
Age≥ 60 years Unable to provide consent 
Mentally competent to participate History of significant chronic 
illnesses (e.g. diabetes, COPD, 
cancer, CVD, auto-immune 
diseases) 
Able to provide written informed 
consent 
On regular medications listed 
below* 
MRC dyspnoea scale < 2 Clinical evidence of acute viral or 
bacterial infections 
Normal spirometry (FEV1 and FVC 
> 70% predicted). 
Statin intolerance or allergy 
Normal peripheral oxygen 
saturations (≥92%) 
Alcohol misuse 
Free of medications listed below*  
No clinical evidence of acute 
infections or chronic illnesses 
 
Normal liver, kidney function and 
Creatinine kinase 
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3.2.3. Randomisation and Blinding 
Study drugs were prepared, randomised and packaged identically by Bilcare Ltd 
(Powys, UK). Computer-based block randomisation was performed in a 1:1 method 
by Bilcare Ltd. (Powys, UK) and the pharmacy (University of Birmingham NHS 
Foundation Trust Pharmacy, Birmingham, UK) prescribed in a numerical order and 
held the randomisation code in a blinded fashion. Subjects eligible for entry were 
randomised into two groups. The first group were assigned to receive 80 mg daily of 
simvastatin for 14 days followed by the placebo for 14 days, whilst the second group 
received placebo (14 days) then the simvastatin (80mg daily for 14 days). The two 
treatment periods were separated by a 14-day wash out period, the time taken for the 
bone marrow to produce a new pool of circulating neutrophils (see figure 3.1).  
Subjects, medical staff, and laboratory staff were all blinded from treatment allocation 
and un-blinding performed only after all subjects had completed the trial and all data 
analysed. 
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Figure 3.1. A flowchart showing the two-randomisation pathways in the 
crossover trial design. 
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3.2.4. Study Protocol 
3.2.4.1: Participant Monitoring 
Following enrolment and randomisation into the study, subjects started their first 
treatment course (14 days). A member of trial’s team called them three times during 
the treatment to ensure compliance with medication and to monitor for serious 
adverse events. Subjects attended an appointment with the trial team after the 
completion of the first course of treatment. A medical history and examination was 
performed and bloods for safety and neutrophil experiments taken.  Subjects were 
next contacted by telephone prior to the commencement of the second treatment 
course, as a reminder. The same procedure occurred during the second treatment 
course with three telephone calls and an appointment with the trial’s team at the end.  
3.2.4.2. Blood Collection 
Bloods were collected from patients on entry into the trial and following the 
completion of each treatment course. Experienced nurses or doctors collected bloods 
from venous sites using a vacutainer system. Safety bloods were taken to monitor 
renal and liver function and CK. Lipid profiles were taken at each visit but were not 
reviewed by any member of the trial team until the end. This ensured that potential 
bias was eliminated and the trial remained blinded to investigators. Bloods for the 
functional neutrophil assays were taken simultaneously. 
3.2.4.3. Functional Neutrophil Assays 
Neutrophils were extracted from whole blood as described in section 2.5.3. 
Neutrophil migration was performed as described in section 2.6.1, ROS 
measurement as in section 2.6.2, phagocytosis as in section 2.6.3, and assessment 
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of NETS as in section 2.6.4. Experienced and trained staff performed all neutrophil 
assays in a blinded fashion. 
3.2.5. Study outcomes 
3.2.5.1 Primary outcome 
The primary outcome of the study was an improvement from baseline in neutrophil 
chemotaxis in subjects treated with simvastatin 80mg once daily for 14-days. 
Additional migratory dynamics assessed were chemokinesis (speed), chemotactic 
index, neutrophil adherence, the percentage of adhered neutrophils that migrated 
and the time (in seconds) to commence migrating.  
3.2.5.2 Secondary outcomes 
Secondary outcomes were changes in phagocytosis, ROS and NETs in neutrophils 
from subjects treated with simvastatin. Additional outcomes were the safety and 
tolerability of high dose simvastatin. 
3.2.6. Sample size calculation and statistical analysis. 
Based on in-vitro data suggesting statins improve neutrophil migration, it was 
assumed that a similar magnitude of effect would occur in-vivo. Eighteen participants 
would be required to complete each arm to detect a significant improved (p<0.05) in 
neutrophil chemotaxis (mean difference 1.8 μm/min, SD 0.6 μm/min) with a power of 
80%. To allow for dropouts, a target recruitment of 24 participants was selected for 
the study. 
  
Dr. Peter Nightingale (Medical Statistician, University Hospital Birmingham) provided 
statistical advice. Data collected whilst participants were on simvastatin and placebo 
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were taken away from baseline values collected prior to treatment. The differences 
between pre and post treatment values for each group were used for data analysis. 
Continuous data was tested for normality using a Shapiro-Wilk’s test. Parametric 
data was analysed using a paired t-Test and non-parametric data using a Wilcoxon’s 
signed rank test. Categorical data were analysed using a Fisher’s exact test or a χ2-
test. 
3.3. Results 
3.3.1. Subject Characteristics 
Twenty-four subjects in total were consented and randomised into the study with 20 
completing both treatment courses. Three subjects withdrew after initial 
randomisation and one after completion of the first treatment course, which was the 
placebo. A modified consort diagram (see figure 3.2) shows the flow of subjects in 
the study. 
 
The demographic details of subjects are shown in table 3.2. The mean age was 71.9 
years (range 60-94) with a similar number of men and women (9 vs. 11 p=0.752; χ2 
test).  
 
Compliance with treatment was excellent with only one subject forgetting a single 
dose. All others reported completing the allocated treatment courses. The total 
cholesterol of patients was measured as a surrogate marker of compliance and of 
drug effect and was studied post trial completion. Placebo had no impact on serum 
cholesterol levels whilst simvastatin treatment significantly reduced cholesterol levels 
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compared to baseline (see table 3.3). This confirms that the drug was taken and had 
a therapeutic effect. 
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Figure 3.2: Modified Consort Diagram.  
 
This modified consort diagram shows the screening and recruitment of subjects in 
the study. It also shows the number of subjects who had complete sets of functional 
neutrophil experiments carried out. 
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Table 3.2. The demographic, physiological and biochemical characteristics of 
subjects on recruitment into the trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All values represent the median (IQR), unless otherwise stated.  
PYH: pack year history. FEV1: Forced expiratory volume in 1 second. FVC: Forced 
Vital Capacity. BMI: Body mass index. ALT: Alanine Transferase. CK: Creatinine 
Kinase. ACEi =Angiotensin Converting Enzyme inhibitor. Ca2+: Calcium. 
* FEV1 measured in litres/sec and FVC measured in litres. 
 
  
Age, mean (range), years 71.9 (60-94) 
Gender, n (%), males 9 (45%) 
Smoker 
Never, n 
Ex-, n (PYH) 
Current, n (PYH) 
 
12 
6 (21.5) 
2 (21.5) 
Co-morbid conditions 
Hypertension 
 
6 
Medications 
Anti-hypertensive drugs 
ACEi 
Diuretics 
Ca2+ channel blocker + diuretic 
Beta-blocker  
 
 
 
1 
1 
3 
1 
Oxygen Saturations (%) 97 (96-98) 
FEV1*, mean ± SD  
(% predicted) 
2.67±0.7 (115.5±19.1) 
FCV*, mean ± SD  
(% predicted) 
3.57±0.8 (123.3±21.9) 
BMI, mean ± SD 26.04±3.7 
Blood Pressure (mmHg)  142 (132-149) 
Creatinine (μmol/L)  79 (69.5-80.5) 
ALT (μmol/L)  17 (15-22) 
Bilirubin (μmol/L)  8 (7-10) 
CK (IU/L)  80 (59.5-134.5) 
TSH (mU/L) 1.9 (1.1-3.7) 
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Table 3.3. Total serum cholesterols at baseline and following treatment with 
placebo and statin. 
 
 
 
 
*  
 
 
 
p-value represents Wilcoxon-signed rank test between baseline and the treatment 
group. N=20 in each group. 
 Baseline Placebo Simvastatin 
Total 
Cholesterol 
(mmol/L) 
5.7 (5.2-6.4) 5.8 (5.1-6.1) 3.8 (3.6-4.4) 
p-value*  0.100 <0.001 
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3.3.2. Primary Outcome: Neutrophil Migration 
3.3.2.1. Neutrophil chemotaxis 
Chemotaxis (directional migration) was significantly improved in subjects following 
simvastatin treatment towards CXCL-8 (0.26μm/min {IQR 0.01-0.61μm/sec} vs. 
0.03μm/sec {IQR -0.73 - 0.34μm/sec} p=0.042; Wilcoxon-signed rank test) and fMLP 
(0.34μm/sec {IQR 0.84-1.26μm/min} vs. 0.02μm/min {IQR -0.51-0.35μm/min} 
p=0.006 Wilcoxon-signed rank test). See figure 3.3. 
3.3.2.2. Neutrophil chemokinesis 
Neutrophil chemokinesis was unchanged towards CXCL-8 (0.33μm/sec {IQR -0.30 – 
0.78μm/min} vs. 0.15μm/min {IQR -0.38-0.94μm/min} p=0.890 Wilcoxon-signed rank 
test) and fMLP (-0.394μm/sec {IQR -1.77-1.0μm/sec} vs. 0.16μm/sec {IQR -0.46-
1.00μm/sec} p=0.349 Wilcoxon-signed rank test) following simvastatin or placebo 
treatment.  
3.3.2.3. Neutrophil Chemotactic Index 
The neutrophil chemotactic index was unchanged towards CXCL-8 (0.08 {IQR -0.02 
– 0.17} vs. -0.04 {IQR -0.12 – 0.10} p=0.123 Wilcoxon-signed rank test) and fMLP 
(0.05 {IQR -0.05 – 0.17} vs. -0.03 {IQR -0.14 – 0.06} p=0.105 Wilcoxon-signed rank 
test) following simvastatin or placebo treatment.  
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Figure 3.3. The effect of simvastatin and placebo treatment on neutrophil 
chemotaxis from healthy elderly subjects. 
 
The chemotaxis of neutrophils donated from healthy elderly participants towards 
100nM interleukin-8 (CXCL-8) and 10nM N-formylmethionyl-leucyl-phenylalanine 
(fMLP). Bars represent the median difference compared to baseline chemotaxis and 
IQR and the error bars a Tukey distribution. N=20 in each group. 
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3.3.2.4. Neutrophil adherence 
Simvastatin treatment significantly reduced the adherence of neutrophils in the 
control media (-10% {IQR -24 - -1.5%} vs. -4% {IQR -8.8 - -1.3%} p=0.033; Wilcoxon 
signed rank test), and to CXCL-8 (-18% {IQR -25 - -9.0%} vs. -1.0 {IQR -7.0 – 4.0%} 
p<0.001; Wilcoxon signed rank test). A reduction was also seen with fMLP but this 
did not reach significance (-4.0% {-11.5 - 3%} vs. 1% {IQR -2.0 – 5.0%} p=0.096; 
Wilcoxon signed rank test).   
3.3.2.5. Percentage of neutrophils migrating 
The percentage cells migrating was unchanged to CXCL-8 (19.5% {IQR -0.50 – 
33.8%} vs. 23% {IQR 7.5 – 47.3%} p=0.162 Wilcoxon-signed rank test) but reduced 
to fMLP (-7.0% {IQR -15.5 - -3.5%} vs. 1.0% {IQR -3.0 – 2.0%} p<0.001 Wilcoxon-
signed rank test) following treatment with simvastatin. 
3.3.2.6. Time to the Initiation of migration 
The time to first migration was increased with simvastatin therapy towards CXCL-8 
(20secs {IQR 0-35secs} vs. 0secs {IQR -20 -15sec} p<0.001; Wilcoxon signed rank 
test) and to fMLP (20secs {20-40secs} vs. 0secs {IQR -10-20sec} p<0.001 Wilcoxon 
signed rank test). 
3.3.2.7. Summary 
In-vivo simvastatin therapy for 14 significantly improved neutrophil chemotaxis 
towards both CXCL-8 and fMLP. The additional parameters assessed showed that 
simvastatin reduced neutrophil adherence and increased the time taken to initiate 
migration to both CXCL-8 and fMLP. 
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3.3.3. Secondary Outcomes 
3.3.3.1. Phagocytosis 
A total of 17 healthy elderly patients had successful phagocytosis experiments 
performed at baseline and following placebo and simvastatin therapy. The in-vivo 
treatment of healthy elderly subjects with simvastatin showed no effect of the 
phagocytosis of either E.Coli or S.Aureus in any of the three indices used to measure 
phagocytosis. This is shown in table 3.4  
3.3.3.2. ROS production 
No significant change was observed in basal neutrophil ROS production following 
simvastatin or placebo compared to baseline (285 ALU {-30377 -25922 ALU} vs. 
1985 ALU {-34495 – 28881, p=0.898; Wilcoxon signed rank test) or when neutrophils 
were stimulated with PMA, fMLP and CXCL-8 (see table 3.5). 
3.3.3.3. NET Production 
No significant change to the production of NETs was observed following simvastatin 
or placebo compared to baseline values in the basal state or when neutrophils were 
stimulated with PMA, fMLP, CXCL-8, or LPS (see table 3.6). 
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Table 3.4: The effect of simvastatin treatment on the phagocytosis of pHrodo 
labelled E.Coli and S.Aureus in healthy elderly subjects.  
 
 Placebo Simvastatin p-value 
E.Coli    
pHrodo 
“bright” cells 
67.5 
(-80.8-329.5) 
180.5 
(-140-277.5} 
0.980 
MFI 749.0 
(-48.0-1279) 
564.0 
(-439.0-1111.0)  
0.064 
PI 690.0 
(-79.0-1207) 
580.0 
(-22.0-1347) 
0.404 
S.Aureus    
pHrodo 
“bright” cells 
0.0 
(-141.0-167.8) 
-165.5 
(-293.0-74.8) 
0.108 
MFI 951 
(-1080.0 -1664.0) 
831 
(-254.1-951.5) 
0.562 
PI 1217 
(-588.7-2048.0) 
257 
(-616.7-1951.0) 
0.196 
Measures used to quantify phagocytosis were the pHrodo “bright” cells, the median 
fluorescent intensity (MFI) and the phagocytic index (PI). All values represent the 
change in the area under the curve (AUC) compared to baseline values following 
treatment with placebo or simvastatin. Values represent the median difference 
compared to baseline (IQR) with p-values from a Wilcoxon signed rank test. N=17 in 
each group. 
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Table 3.5: The percentage change in Reactive Oxygen Species (ROS) 
production to various stimuli in neutrophils from subjects at baseline and 
following treatment with simvastatin. 
 
 Placebo Simvastatin p-value* 
PMA  
 
-41.3 
(-295.8 – 640.0) 
284 
(-197.3 - -781.8) 
0.393 
fMLP  
 
-2.83 
(-129.2 – 311.2) 
63.0 
(-207.5 - 290.1) 
0.734 
CXCL-8  -79.2 
(-105.7- -40.1) 
-89.4 
(-113.6 - -32.5) 
0.946 
 
Values represent the percentage change in the area under the curve (AUC) 
compared to baseline values following treatment with placebo and simvastatin and 
are represented the median difference compared to baseline median (IQR), where 
N=20 in each group. AUC is a measure of ROS production over one hour. *Wilcoxon 
signed rank test. 
PMA: Phorbol-12-myristate-13-acetate, 25nM. 
fMLP: N-formylmethionyl-leucyl-phenylalanine, 2.5µM.  
CXCL-8: Interleukin-8, 1.25µM. 
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Table 3.6: Neutrophil extracellular trap formation in subjects at baseline and 
following treatment with simvastatin. 
 
 Placebo Simvastatin p-value 
Unstimulated 
 
1786 
(-2039 – 6254) 
1763 
(-765.1 – 5521) 
0.985 
PMA  
 
6964 
(-17992 – 22048) 
5985 
(-24415 - 30189) 
0.729 
fMLP  
 
1099 
(-2818 – 2719) 
1355 
(-2113 – 6518) 
0.216 
CXCL-8  1270 
(-1099 – 4473) 
2439 
(-2227 – 7062) 
0.522 
LPS 
 
4048 
(2833 – 6279) 
7115 
(-839.1 – 9851) 
0.596 
 
Values represent the change from baseline NET production following treatment with 
simvastatin and placebo (N=20 in each group). Values represent the median 
difference compared to baseline (IQR) with p-values from a Wilcoxon signed rank 
test. NET production is measured as Arbitrary Fluorescent Units (AFUs).  
PMA: Phorbol-12-myristate-13-acetate, 25nM. 
fMLP: N-formylmethionyl-leucyl-phenylalanine, 2.5µM.  
CXCL-8: Interleukin-8, 1.25µM. 
LPS: Lipopolysaccharide, 100ng/ml 
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3.3.3.4. Safety and Tolerability 
The drug was well tolerated with no serious adverse events during the treatments. 
One subject had an asymptomatic rise in their CK whilst two reported mild muscle 
aches during simvastatin therapy. Neither of these two subjects had rises in CK 
levels and did not miss any treatment doses. One patient had an acute migraine 
whilst on simvastatin, however was known to suffer with these. One patient 
developed an upper respiratory tract infection whilst on placebo. No rises in hepatic 
transaminases or deterioration in renal function was observed (see table 3.7). 
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Table 3.7. The liver function, Creatinine Kinase and renal function of subjects 
at baseline and on simvastatin therapy. 
 
 
 
 
 
 
 
 
 
 
 
ALT: Alanine Transferase.  
All values represent medians (IQR) and the p-value calculated using a Wilcoxon 
signed-rank test. 
 
 Placebo Simvastatin p-value 
 
ALT  
(μmol/L) 
17  
(13-21) 
17  
(15-21) 
0.942 
Bilirubin 
(μmol/L) 
7 
(6.5-10) 
7  
(2.3-10) 
 1.0  
Creatinine 
(μmol/L) 
74.5  
(64-81.3) 
74.5  
(68.5-80) 
0.668 
CK  
(mIU/L) 
78  
(56.5-104) 
74.5  
(64.8-115.3) 
0.909 
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3.4. Discussion 
This study is the first to our knowledge that has demonstrated improved neutrophil 
chemotaxis following treatment with simvastatin 80mg daily for two weeks in healthy 
elderly subjects. These modifications in neutrophil migration may help explain the 
improved outcomes seen in infection amongst patients on statin therapy. Importantly 
high dose simvastatin proved to be safe and well tolerated by subjects with no 
deleterious effects exerted upon the other neutrophil functions assessed (ROS 
production, phagocytosis and NETs). 
 
The improvement seen in neutrophil migration with in-vivo simvastatin therapy 
replicates the effects observed with in-vitro therapy in neutrophils donated from 
healthy elderly subjects within our group. Closer analysis of migratory dynamics 
demonstrated that simvastatin reduced neutrophil adherence and slowed the 
initiation of migration (both to CXCL-8 and fMLP).  
 
The albumin-coated cover slip used in the chemotaxis assay is a surrogate for ICAM-
1, which binds to β2 integrins MAC-1 and LFA-1 and are essential for the adhesion of 
neutrophils to the endothelium. Migration of neutrophils in this assay relies on 
neutrophils crawling along the coverslip and is dependent on MAC-1 and LFA-1 
expression. Statins have been shown in multiple studies to reduce binding of 
neutrophils to the endothelium by down regulating LFA-1 and MAC-1 expression. 
Additionally statins also reduce ICAM-1 expression on the endothelium itself to 
further reduce neutrophil adhesion (254, 312-314).    
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The reduction in adhesion results in fewer neutrophils transmigrating across the 
endothelium into the infected site. However, statins improve the chemotactic 
dynamics of the adhered neutrophils enabling them to take a direct route to the 
infected site and potentially resulting in their earlier arrival. The shorter route taken 
may also reduces collateral tissue damage, as neutrophils would release less MPO, 
NE and ROS to assist with migration through the endothelium and tissues to reach 
the sites of infection. This is supported by several studies that have shown that 
statins attenuate neutrophil chemotaxis into infected tissues. No study has assessed 
the individual migration of cells as in-vitro studies have used modified-Boyden 
chambers to determine the number of cells that migrate through an extracellular 
matrix, whilst in-vivo studies quantify neutrophil migration by counting the numbers of 
cells in aspirates from infected tissue, such as peritoneal fluid or BALF (150, 152, 
256, 280, 315, 316).  
 
A similar study in healthy male volunteers (mean age 31.6 years, age range 23-48 
years) studied the effects of in-vivo atorvastatin 40mg daily, on neutrophil 
chemotaxis. Migration was assessed using human pulmonary artery endothelial cell 
(HPEAC) monolayer to replicate an extracellular matrix within a Boyden chamber. 
Chemotaxis was significantly reduced following statin therapy in response to LPS 
leading the authors to conclude that attenuating neutrophil chemotaxis contributes to 
the improved outcomes from sepsis in patients on pre-existing statin therapy. The 
two studies have several key methodological differences, firstly the populations were 
markedly different in gender and age, with our study representative of an at risk 
population. Secondly the methods used to assess chemotaxis were different. Finally 
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the statins used and the doses were different. The choice of statin for immune 
modulation remains unclear at present with evidence to suggest that the various 
statins differ in their ability to modulate the immune system. A recent study has 
suggested that rosuvastatin was better than simvastatin in modulating the adaptive 
immune system whilst another demonstrated improved T-cell responses with 
simvastatin compared to lovastatin and atorvastatin (261, 311, 317, 318). 
 
Murine models of sepsis have demonstrated that pre-treatment with statins 
attenuates neutrophil recruitment to sites of sepsis and is associated with reduced 
disease severity and improved survival (150, 256, 315). This has been replicated in 
an LPS model of pulmonary inflammation in humans where 30 healthy individuals 
were randomly allocated to placebo or simvastatin for 4 days prior to inhalation of 
LPS. Subjects pre-treated with statins had fewer neutrophils in BALF samples and 
produced less MPO and MMP-7, 8 and 9 compared to placebo, suggesting that 
simvastatin not only attenuates neutrophil migration but also the inflammatory 
response that leads to ARDS (152). 
 
Reduced adhesion seen with simvastatin treatment may also prevent the 
accumulation of neutrophils within vascular beds attenuating tissue damage and 
hypoxia that is caused by excessive neutrophil adherence to within micro-vascular 
beds. Neutrophils release ROS and NETs within these narrow vessels damaging the 
endothelium and occluding blood flow (3).  
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It had been proposed that the anti-inflammatory actions of statins would inhibit 
bacterial clearance and phagocytosis but in-vitro and in-vivo studies have failed to 
show this. The effect of various in-vitro statins upon leucocyte function in healthy 
individuals demonstrated that lovastatin, simvastatin and atorvastatin up-regulated 
phagocytosis in a dose dependent manner, whilst pravastatin had no effect. The 
mechanism is still unclear, but it has been suggested that reduction in cell membrane 
cholesterol with statin therapy increases its fluidity and thus assists with 
phagocytosis. Studies on macrophages suggest that statins enhance phagocytosis 
via the RhoGTPases, and inhibition of sterol metabolism. Although this study failed to 
replicate the previous beneficial effects of statins on phagocytosis, importantly no 
deterioration in phagocytosis was seen either (40, 150, 319-322). 
 
Statins have been shown to cause a dose-dependent reduction in ROS production by 
inhibition of NADPH oxidase and through anti-oxidants properties. Although ROS is 
essential for pathogen killing, excessive production leads to collateral tissue injury. 
With age and infection ROS production in enhanced and can lead to unnecessary 
tissue damage. Reducing ROS production via statins may provide a mechanism to 
reduce their harmful effects. Although the study was not powered to detect a change 
in ROS production, it was expected that a decrease would be seen. A possible 
reason for this was the reliability of the assay with very large inter-assay variability 
and poor reproducibility (75, 76, 78, 150, 183). 
 
The impact of simvastatin on NET formation has not been previously described in-
vivo in healthy elderly patients. The mechanism of NETosis is closely linked with 
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ROS production. It was postulated that perhaps if a reduction in ROS was seen a 
parallel reduction in NET formation might also have been observed. In keeping with 
the ROS results no change in basal or stimulated (PMA, CXCL-8 or LPS) NET 
formation was observed following treatment with simvastatin compared to placebo.   
 
The cross-over design of the study was chosen to allow participants to act as their 
own control, thereby reducing variability between the treatment groups. Additionally 
this methodology permitted a reduction in the overall numbers that needed to be 
recruited. One of the main disadvantages of this form of trial design is the potential 
for a “carry-over” effect, where the first treatment may alter the results of the second 
treatment. This was accounted for by the washout period of 14-days that was long 
enough for the bone marrow to generate a new pool of circulating neutrophils. 
Additionally, simvastatin has a short half-life (2-3hrs) and therefore theoretically no 
residual effects of the drug should have been seen following the second treatment (1, 
323). Secondly temporal effects of the treatments (i.e. in which order the treatments 
were allocated) may have been a potential confounder. However, all participants and 
investigators, including those performing the neutrophil assays were blinded to 
treatment allocations. This, as well as the washout period, should have ensured that 
any temporal effects were accounted for.   
 
In conclusion, this study has demonstrated that high dose simvastatin can improve 
neutrophil migration and potentially attenuate excessive neutrophil migration. 
Simvastatin therapy in-vivo reduces the number of adherent and migrating 
neutrophils, but improves the directional migration of these neutrophils ensuring they 
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arrive at the sites of infection faster and cause minimal collateral tissue damage by 
taking a direct route. Once at the site of infection anti-microbial toxicity is unaffected 
by simvastatin therapy. This suggests that the improved outcomes from sepsis in 
patients on statin therapy may in part due to improved neutrophil migration leading to 
the earlier containment and elimination of pathogens. Further research is required to 
confirm whether simvastatin can modulate the functions of neutrophils in patients 
who have an established infection.  
 
The studies that follow will assess whether simvastatin therapy in-vitro can modulate 
neutrophil functions of patients admitted to hospital with sepsis. 
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Chapter 4: Neutrophil migration in sepsis and the 
effect of in-vitro simvastatin exposure on their 
migratory dynamics. 
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4.1. Introduction 
The preceding chapter (Chapter 3) demonstrated that 80mg simvastatin improved 
neutrophil chemotaxis to CXCL-8 and fMLP in a cohort of healthy elderly participants 
and replicated the in-vitro effects previously observed. 
 
Aberrant neutrophil chemotaxis has been well described in sepsis and is associated 
with poorer containment and elimination of pathogens allowing dissemination of 
infection, and exaggerating the host’s response (2, 148, 154, 159). 
 
The vital role of neutrophil migration in infection has lead to it being an attractive 
target for therapies in infections. It was proposed that the beneficial effects of statin 
therapy observed in patients with sepsis might in part be due to improved neutrophil 
migration and bacterial elimination. The experiments described in this chapter 
investigate neutrophil migration in sepsis using time-lapse video microscopy and the 
potential effects of in-vitro simvastatin therapy.  
4.1.1. Hypothesis 
Based on the literature and on previous results reported it was hypothesised: 
1. Neutrophil migration would be significantly reduced in patients with sepsis. 
2. In-vitro simvastatin therapy would improve the migratory dynamics of 
neutrophils from patients with sepsis. 
3. Adhesion molecules would be up-regulated in sepsis potentially contributing to 
aberrant neutrophil migration. 
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4.1.2. Aims 
The aims of the experiments were to: 
1. Characterise neutrophil migration in sepsis 
2. To investigate the effects of in-vitro simvastatin therapy on neutrophil 
migration in sepsis 
3. Characterise the cell surface expression of adhesion receptors in neutrophils 
in healthy controls and in patients with sepsis (L-Selectin/CD62L, Beta-2-
integrin/Cd11b-Cd18, and CD63).  
4.2. Methods 
4.2.1. Healthy control recruitment 
Healthy controls were recruited into the study as described in section 2.2. The 
baseline data from healthy elderly subjects recruited into the statin trial described in 
chapter 3 were used as controls. 
4.2.2. Patient recruitment 
Patients with sepsis were entered into the trial as described in section 2.3. The 
SSCG definitions for sepsis were used to screen eligible patients  (see tables 1.4 and 
1.5). Exclusion criteria were as described in section 2.3.1. 
4.2.3. Data collected 
Data collected is described in section 2.3.2.  
4.2.4. Sample collection 
Blood samples for the chemotaxis experiments were taken in Lithium heparin 
vacutainers (Becton Dickinson) as described in section 2.4. 
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4.2.5. Neutrophil isolation 
Neutrophils were extracted using a Percoll gradient as described in section 2.5.3. 
Once isolated neutrophils were suspended in RPMI 1640, which will be referred to as 
the “basal state” for the remainder of this chapter. 
4.2.6. Neutrophil migration experiments 
Neutrophil migration was assessed using an Insall Chamber (Weber Scientific) to the 
chemoattractants 100nM CXCL-8 (R&D systems) and 10nM fMLP (Sigma-Aldrich). A 
detailed description of the experiment methodology is provided in section 2.6.1. 
Migration was assessed using three parameters, chemokinesis (speed in any 
direction), chemotaxis (directional migration) and the chemotactic index (see section 
2.6.1.1.). The number of neutrophils adhering to the coverslip was also calculated. 
Adherence was calculated by dividing the number of adherent cells by the total 
number of cells in the original viewing plane. Adherence was expressed as the 
percentage of neutrophils that adhered compared to the total neutrophil count in the 
viewing plane. 
4.2.7. Simvastatin Experiments 
Freshly isolated neutrophils were incubated with 1µM simvastatin (Sigma-Aldrich) for 
40minutes prior to migration being assessed as described in section 2.7. All 
neutrophil assays were performed un-blinded. 
4.2.8. Cell surface receptor expression experiments 
The expression of the cell surface receptors CD18, CD11a, CD62L and CD63 were 
quantified from whole blood using flow cytometry analysis. The detail methods are 
described in section 2.6.6. 
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4.2.9 Statistical Analysis 
Continuous data was tested for normality a Shapiro-Wilk’s test, however if sample 
sizes were too small a Kolmogorov-Smirnov test. All continuous data are represented 
as median (IQR), with non-parametric statistical tests performed as described in 
section 2.9. Where two or more were analysed using a Kruskal-Wallis test, Dunn’s 
post-hoc tests were performed to identify the nature of the statistical differences 
between the groups. Categorical data were analysed using a Fisher’s exact test for 
two groups and a χ2-test for more than two groups.  
 
No current data exists regarding neutrophil migration in sepsis using the technique 
employed within this study. It was therefore difficult to accurately determine the 
number of patients that would be required to be recruited. However based on in-vitro 
data from healthy participants suggesting that ageing reduces chemotaxis, it was 
estimated that a total of 40 patients with sepsis would have to be recruited for any 
differences to be seen. Therefore to allow for a 10% experimental failure rate, it was 
proposed that 45 patients with sepsis be recruited. The data that would be generated 
would be used to power future neutrophil functional studies in patients with sepsis. 
4.3. Results 
4.3.1. Demographics of all participants recruited  
In total thirty-seven healthy controls, consisting of the twenty healthy elderly 
participants described in chapter 3 and seventeen young controls and forty-five 
patients with sepsis were recruited into the studies described within the remainder of 
the thesis. The demographic characteristics of the two groups are shown in table 4.1. 
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The groups were well matched for age and gender, however the sepsis patients had 
a greater number of co-morbidities and were taking more medications than healthy 
controls. The functional neutrophil assays performed on the recruited sepsis cohort 
are shown in figure 4.1.  
4.3.2. Healthy Elderly Controls 
Twenty healthy elderly controls had their neutrophils assessed for migration. The 
demographic details for these controls have been described in section 3.3.1 and 
table 3.2. In summary the mean age was 71.9 years (range 60-94) with 9 (45%) 
males and 11 (55%) females. 
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Table 4.1. The demographic details of the healthy controls and sepsis patients. 
All values represent the median (IQR), unless otherwise stated. *Represents a Mann-
Whitney-U test, #represents a Fisher’s exact test and Φ a χ2-test. §Patient’s may 
have more than one co-morbidity and may have been on more than one class of 
medication. 
 
 
 
Controls 
N=37 
Sepsis 
N=45 
p-value 
Age 62  
(32.5-71.0) 
66.5  
(48.8-75.0) 
0.125* 
Sex, male (%) 17 (45.9%) 29 (64.4%) 0.119# 
Number of Co-
morbidities/participant, n 
0 
1 
2 
3+ 
 
 
31 
6 
0 
0 
 
 
16 
14 
12 
3 
 
 
 
 
 
<0.001ϕ 
Co-morbidities§, n 
None 
CVS disease 
Respiratory disease 
Chronic renal disease 
Diabetes 
 
31 
6 
0 
0 
0 
 
16 
11 
3 
2 
15 
 
 
 
 
 
<0.001ϕ 
Medications§, n 
None 
Anti-hypertensive 
Beta-blocker 
Anti-platelet 
Oral hypoglycaemic 
Insulin 
Inhaled beta-agonist 
Statins 
 
31 
6 
1 
0 
0 
0 
0 
0 
 
16 
13 
8 
6 
10 
8 
3 
17 
 
 
 
 
 
 
 
 
<0.001ϕ 
Severe sepsis  31 (68.9%)  
APACHE II score  11 (5.8-32.2)  
SAPS II score  33 (13-40)   
ICU Admission, N 
Inotropes alone 
Respiratory support 
Multi-organ support 
 14 (31.1%) 
4 
2 
8 
 
WCC (109/L)     16.5 (13.3-21.8)  
CRP (mg/L)     152 (82-307)  
SOFA Score  4 (1-6.5)  
Length of Stay,  10 (6-23.5)  
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4.3.2. Impact of sepsis on neutrophil migration 
A total of 16 patients recruited with sepsis had migration experiments performed on 
their isolated neutrophils. The demographic details are shown in table 4.2. There was 
a similar gender split between the healthy controls and the sepsis patients recruited, 
however the healthy elderly controls were significantly older (p=0.002, Mann-Whitney 
U test). The majority of patients recruited had evidence of severe sepsis (N=11, 
68.8%) with 6 (37.5%) requiring admission to ICU. Pneumonia was the commonest 
source of sepsis (9 patients, 56.2%) followed by UTI (4 patients, 25%). Mortality was 
37.5% with a median length of stay in the survivors of 12 days (range 2-153 days).  
 
In the basal state neutrophils do not migrate directionally and show limited random 
movement. Sepsis did not alter this, with no meaningful migration seen in neutrophils 
from sepsis patients and healthy controls (see table 4.3 and figure 4.2).  
4.3.2.1. Chemokinesis 
Chemokinesis (speed in any direction) towards CXCL-8 and fMLP was significantly 
reduced in neutrophils from sepsis patients (see table 4.3 and figure 4.2). 
4.3.2.2. Chemotaxis 
As with chemokinesis, neutrophil chemotaxis (directional migration) towards CXCL-8 
and fMLP was significantly impaired in patients with sepsis compared to healthy 
controls (see table 4.3 and figure 4.2). 
4.3.2.3. Chemotactic Index 
The chemotactic index (overall measure of migration) was significantly impaired 
towards CXCL-8 and fMLP (see table 4.3 and figure 4.2). 
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Table 4.2. Characteristics of healthy controls and sepsis patients for the 
neutrophil migration experiments. 
All values represent the median (IQR), unless otherwise stated. *Represents a Mann-
Whitney-U test, #represents a Fisher’s exact test and Φ a chi-sqaured test. §Patient’s 
may have more than one co-morbidity and may have been on more than one class of 
medication. 
  
 
 
Controls 
N=20 
Sepsis 
N=16 
p-value 
Age, years 69  
(67-78) 
59  
(35.8-71) 
0.002* 
Sex, male  9 (45%) 10 (62.5%) 0.335# 
No. of Co-morbidities 
0 
1 
2 
 
14 
6 
0 
 
5 
9 
2 
 
 
 
0.039Φ 
Co-morbidities§, n 
None 
CVS disease 
Respiratory disease 
Chronic renal disease 
Diabetes 
 
14 
6 
0 
0 
0 
 
6 
5 
3 
1 
3 
 
 
 
 
 
<0.001Φ 
Medications§, n 
None 
Anti-hypertensive 
Beta-blocker 
Anti-platelet 
Oral hypoglycaemic 
Insulin 
Inhaled beta-agonist 
Statins 
 
14 
6 
1 
0 
0 
0 
0 
0 
 
7 
5 
2 
2 
3 
1 
1 
5 
 
 
 
 
 
 
 
 
<0.001Φ 
Severe Sepsis, n  11 (68.8%)  
APACHE II  14.1±2.2   
SAPS II  29.3±3.9   
ICU admission, n 
Inotropes alone 
Respiratory support 
Multi-organ support 
 6 (37.5%) 
1 
1 
4 
 
WCC, median (IQR)  19.8 (14.8-22.7)  
CRP,   169.1±30.3  
SOFA Score,  
median (IQR) 
 3 (0-7)  
Length of Stay, median (IQR)  12 (6.0-45.5)  
Mortality, n (%)  6 (37.5%)  
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Table 4.3. The chemokinesis and chemotaxis of neutrophils from healthy 
controls and sepsis patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table above illustrates the chemokinesis, chemotaxis and chemotaxis of 
neutrophils in healthy controls and sepsis patients in their basal state and towards 
100nM Interleukin-8 (CXCL-8) and 10nM N-formylmethionine-leucyl-phenylalanine 
(fMLP). Values are shown as median (IQR) with p-values from a Mann- Whitney U 
test.  
  
 Healthy Controls 
N=20 
Sepsis p-value 
Chemokinesis 
(μm/min) 
   
RPMI 2.89  
(2.36-3.22) 
2.57 
(1.82-3.30) 
N=16 
0.774 
CXCL-8 3.71 
(3.39-4.74) 
 
3.09 
(2.14-3.76) 
N=14 
0.015 
fMLP 3.97 
(3.49-4.48) 
2.28 
(1.98-3.11) 
N=15 
<0.001 
Chemotaxis 
(μm/min) 
   
RPMI -0.03  
(-0.19-0.30) 
0.01 
(-0.13-0.19) 
N=16 
0.778 
CXCL-8 0.86 
(0.40-1.82) 
0.38 
(0.08-0.70) 
N=14 
0.031 
fMLP 0.70 
(0.21-1.35) 
0.24 
(-0.08-0.64) 
N=15 
0.025 
Chemotactic 
Index 
   
RPMI 0.00 
(-0.05-0.05) 
 
-0.05 
(-0.21-0.01) 
N=16 
0.08 
CXCL-8 0.17 
(0.10-0.30) 
0.06 
(0.03-0.10) 
N=14 
0.005 
fMLP 0.15 
(0.03-0.25) 
0.02 
(-0.04-0.10) 
N=15 
0.001 
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Figure 4.2. The chemokinesis, chemotaxis and chemotactic index of 
neutrophils in healthy controls and patients with sepsis. 
  
The upper plot shows the chemokinesis of neutrophils in the basal state, to 100nM 
Interleukin-8 (CXCL-8) and 10nM N-formylmethionine-leucyl-phenylalanine (fMLP). 
The middle plot shows the chemotaxis of neutrophils whilst the lower plot shows the 
chemotactic index of neutrophils in the basal state and to CXCL-8 and fMLP. Bars 
represent the median and IQR with the whisker’s a Tukey distribution. P-values are 
from a Mann-Whitney U test. N=20 for healthy controls. N=16 in the basal state, 
N=14 for CXCL-8 and N=15 for fMLP in the sepsis cohort. 
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4.3.3. Sequential changes in neutrophil migration in patients with sepsis. 
The data above has shown that sepsis reduces the ability of neutrophils to migrate. 
Neutrophils from sepsis show reduced chemokinesis and chemotaxis resulting in a 
poorer chemotactic index suggesting that neutrophils are “paralysed” and are unable 
to effectively migrate towards sites of infection. 
 
Of the 16 sepsis patients recruited, 13 had migration experiments performed on day 
4 and 12 had experiments on day 7. Three patients showed worsening of sepsis 
related organ dysfunction with increases in their SOFA score by day 7 compared to 
their admission scores. The remainder displayed evidence of improved organ 
dysfunction where present at baseline (indicated by a SOFA score greater than 1). 
This suggests that the majority of patients (75%) were in resolving phase of sepsis by 
day 7. To assess whether sepsis resolution improves migration, neutrophils from 
sepsis patients were isolated on days 4 and 7 following admission and migration 
assays performed.  
4.3.3.1. Chemokinesis 
Compared to healthy controls the chemokinesis of neutrophils remained significantly 
suppressed on all three days to CXCL-8 (Kruskal-Wallis, p=0.005) with a Dunn’s 
multiple comparison post-hoc test demonstrating that a significant difference between 
healthy controls and the chemokinesis of neutrophils on day 4 was present 
(p=0.013). Neutrophil chemokinesis towards fMLP was also significantly reduced on 
sequential day analysis (Kruskal-Wallis, p<0.001) with a Dunn’s multiple comparison 
post-hoc tests demonstrating a significant difference between healthy controls and 
chemokinesis on day1 (p<0.001) and day4 (p=0.015). (See table 4.4). 
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4.3.3.2. Chemotaxis 
Neutrophils from sepsis patients showed suppressed chemotaxis on sequential days 
compared to healthy controls towards CXCL-8 and fMLP, however this did not reach 
significance. See table 4.4.  
4.3.3.3. Chemotactic Index 
The chemotactic index was significantly reduced towards CXCL-8 (Kruskal-Wallis 
p=0.025) with a Dunn’s multiple comparison post-hoc tests demonstrating a 
significant difference between healthy controls and the chemotactic index of 
neutrophils on day 7 (p=0.026). The chemotactic index of neutrophils towards fMLP 
was also significantly reduced (Kruskal-Wallis p=0.008) over the three days with a 
Dunn’s multiple comparison post-hoc tests demonstrating a significant difference 
between healthy controls and the chemotactic index of sepsis neutrophils on day 1 
(p=0.017). See table 4.4. 
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4.3.4.5.Patient migration based on sepsis resolution. 
Patients with sepsis were classified as resolvers of sepsis and non-resolvers based 
on changes in their SOFA scores. The changes in chemotaxis towards CXCL-8 and 
fMLP between day 1 and 7 in patients who had sequential samples was analysed. In 
total 12 patients had sequential samples for migration towards CXCL-8, with 9 
“resolvers” and 3 non-resolvers, whilst 10 patients had sequential samples for 
migration towards fMLP (3 “non-resolvers” and 7 “resolvers”). 
 
These patients had their chemotaxis plotted for day1 and 7 to see whether a trend to 
improvement was seen in resolvers and a continued deterioration observed in the 
non-resolvers (see figure 4.3). This demonstrated that some of the resolvers show 
improvements in migration, whilst others do not change or in a few cases worsen. 
Non-resolvers, although limited by number (N=3) all showed continued deterioration 
in their chemotaxis at day 7 towards both CXCL-8 and fMLP. 
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Figure 4.3. Chemotaxis in non-resolvers and resolvers of sepsis. 
 
The line chart shows the individual chemotaxis of neutrophils from sepsis donors with 
day 1 shown on the left and day 7 shown on the right. The blue lines represent 
patients who demonstrated resolution of sepsis, whilst the red lines represents non-
resolvers of sepsis based on changes in their SOFA scores. A, represents 
chemotaxis towards 100nM Interleukin-8 (CXCL-8; N=12) and B represents 
chemotaxis towards 10nM N-formylmethionine-leucyl-phenylalanine (fMLP; N=10). 
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4.3.5. The effect of in-vitro simvastatin treatment on neutrophil migration in 
sepsis. 
In summary these experiments have shown that as sepsis resolves (from day 1 to 
day 7) neutrophil migration remained impaired, with non-resolvers from sepsis 
showing worsening of migration. The following experiments investigated whether in-
vitro simvastatin therapy could potentially improve neutrophil migration.  
 
Ten patients with sepsis had their neutrophils treated with 1 μM in-vitro simvastatin 
and assessed for migration towards the chemoattractants CXCL-8 and fMLP. No 
effect of in-vitro simvastatin treatment was observed when neutrophils migration was 
assessed to CXCL-8. See table 4.6. However, when neutrophils migration was 
assessed to fMLP, deterioration in chemotaxis (-0.09 {-0.19-0.18}, vs. 0.38 {0.11-
0.74} p=0.045, Wilcoxon signed rank test) was seen. Although a significant reduction 
in the chemotactic index was observed (-0.09 {-0.27 - -0.02} vs.0.01 {-0.22-0.12} 
p=0.049, Wilcoxon signed rank test) the neutrophils in neither group were moving 
directionally and this probably does not reflect a true impact of simvastatin. No effect 
was observed for chemokinesis. See table 4.5 and figure 4.4.  
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Table 4.5. The effect of 1μM in-vitro simvastatin exposure on the migration of 
neutrophils from sepsis patients to CXCL-8 and fMLP. 
 
 
 
 
 
 
 
 
 
 
 
 
The table illustrates the four migratory parameters assessed in neutrophils from 10 
patients with sepsis to 100nM interleukin-8 (CXCL-8) and 10nM N-formylmethionine-
leucyl-phenylalanine (fMLP) with and without incubation with 1μM simvastatin. The 
vehicle control was an equivalent concentration of dimethyl sulfoxide (DMSO). Data 
are represented as the median (IQR) with p-values from a Wilcoxon-signed rank test. 
CI= Chemotactic Index  
  
 Vehicle 
Control 
N=10 
 
Simvastatin 
Treated 
N-10 
p-value 
CXCL-8  
 
   
Chemokinesis 
(μm/min) 
3.09 
(2.61-3.61) 
3.02 
(2.57-3.79) 
0.695 
Chemotaxis 
(μm/min) 
0.38 
(0.27-0.70) 
0.51 
(0.07-0.78) 
0.625 
CI 
 
0.06 
(0.03-0.12) 
0.06 
(-0.05-0.16) 
1.0 
fMLP 
 
   
Chemokinesis 
(μm/min) 
2.41 
(1.94-3.28) 
2.62 
(2.44-3.44) 
0.311 
Chemotaxis 
(μm/min) 
0.38 
(0.11-0.74) 
-0.09 
(-0.19-0.18) 
0.045 
CI 
 
0.01 
(-0.22-0.12) 
-0.09 
(-0.27- -0.02) 
0.049 
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Figure 4.4 The effect of in-vitro simvastatin on the chemotaxis of neutrophils 
from sepsis patients towards fMLP.  
 
The effect of in-vitro simvastatin therapy on neutrophils chemotaxis towards 10nM N-
formylmethionine-leucyl-phenylalanine (fMLP) in 10 sepsis patients. Each line 
represents the chemotaxis of neutrophils from an individual patient in an untreated 
state and following incubation for 40minutes with simvastatin 1μM.  
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4.3.6. Neutrophil Adherence 
The adherence of neutrophils from patients with sepsis was increased compared to 
healthy-aged controls in the neutrophils basal state (92% {IQR 89-100%} vs. 81% 
{IQR 74-83%) p<0.001 Mann-Whitney U test), and when CXCL-8  (94.1% {IQR 93-
100%) vs. 92% {IQR 86-95%) p=0.022 Mann-Whitney U test) and fMLP (100% (IQR 
97-100%) vs. 87% {IQR 82-92%} p<0.001 Mann Whitney U test) were used as 
chemoattractants (see figure 4.5). 
 
In-vitro simvastatin incubation reduced the adhesion of neutrophils to the albumin-
coated cover slip, replicating the in-vivo data from Chapter 3. Analysis of individual 
slides demonstrated reduced adhesion of neutrophils treated with simvastatin both 
when CXCL-8 (83.8% {IQR 72.8-91.7%} vs. 94.7% {IQR 92.1-98.6%} p=0.027 
Wilcoxon signed rank test, N=10) and fMLP (91.7% {IQR 84.5-100%} vs. 100% {IQR 
97.4-100%} p=0.016 Wilcoxon signed rank test, N=10) were used as 
chemoattractants (see figure 4.5). 
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Figure 4.5. Neutrophil adherence in patients with sepsis.  
 
A shows the percentage of neutrophils adherent to the albumin coated cover slip in 
19 healthy controls and in patients with sepsis (sepsis N=16 in basal state, N=14 in 
CXCL-8 and N-15 in fMLP. B shows the effects of in-vitro simvastatin exposure on 
neutrophil adherence in 10 sepsis patients. The bars represent the median and IQR 
with the error bars from a Tukey distribution.  p-values from a Mann-Whitney U test. 
CXCL-8: Interleukin-8, 100nM. fMLP = N-formylmethionine-leucyl-phenylalanine, 
10nM. 
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4.3.7. Cell surface receptor expression in neutrophils  
The data above have shown that in sepsis neutrophil migration towards common 
chemoattractants is significantly reduced and that as sepsis resolves no 
improvement in migration is observed. Statins did not improve migration towards 
CXCL-8 and may further impair directional migration in neutrophils towards fMLP. 
Adhesion of neutrophils was increased in sepsis with in-vitro simvastatin reducing 
overall adherence.  
 
To explore the potential mechanisms underlying this impaired migration the cell 
surface receptor expression of neutrophils in sepsis was investigated. The 
expression of the adhesion molecules L-Selectin (CD62L), Beta-2-Integrin 
(CD11b/CD18) and the adhesion/activation receptor CD63 were investigated in 17 
healthy controls and 14 patients with sepsis. (See figure 4.6). 
4.3.7.1. L-Selectin expression in sepsis. 
The number of neutrophils expressing L-Selectin was significantly reduced in sepsis 
patients compared to healthy controls (77.3% {IQR 55.5-93.3%} vs. 94.4% {IQR 
87.1-98.3%} p=0.047, Mann-Whitney U test). The number of receptors being 
expressed by neutrophils (represented by the MFI) was lower in the sepsis cohort, 
however this failed to reach significance (19792 AFUs {IQR 9279-29913 AFUs} vs. 
27731 AFUs {IQR 22893-39937AFUs} p=0.116, Mann-Whitney U test). 
4.3.7.2. Beta-2-Integrin expression in sepsis 
Beta-2-Integrin is composed of the receptors Cd11b and CD18. Neutrophils broadly 
express Cd11b/CD18 and this was unchanged in sepsis with virtually all neutrophils 
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expressing CD11b (97.6% {IQR 84.2-99.3%} vs. 96.9% {IQR 68.7-99.7%}, p=0.914, 
Mann-Whitney U Test) and CD18 (99.6% {98.9-100%} vs. 99.8 {99.6-99.9}, p=0.230, 
Mann-Whitney U Test). The MFI was significantly greater in sepsis for CD18 
indicating greater receptors expression per cell in sepsis compared to healthy 
controls (36618 AFUs {IQR 21759-52923 AFUs} vs. 21492 AFUs {IQR 13344-24453 
AFUs}, p=0.023, Mann-Whitney U test). The MFI for CD11b was unaffected by 
sepsis in relation to levels of expression in healthy controls (7868 AFUs {IQR 7274-
8654 AFUs} vs. 8479 AFUs {IQR 7389-9438} p=0.374, Mann-Whitney U test). 
4.3.7.3. Expression of the activation marker CD63. 
The percentage of neutrophils expressing the activation and adhesion marker CD63 
was greater in sepsis patients compared to the healthy controls (77.1% {IQR 53.9-
94.2%} vs. 45.5% {IQR 29.1-68.5%} p=0.040, Mann Whitney U test). Despite a 
greater percentage of cells expressing CD63 a trend towards reduced receptor 
expression was observed in sepsis compared to the healthy controls (3869 AFUs 
{IQR 2111-4571} vs. 5109 AFUs {IQR 3403-5581}, p=0.052, Mann-Whitney U Test). 
   
Page | 155 
 
  
Figure 4.6. The cell surface expression of chemokine and adhesion receptors 
on neutrophils from healthy controls and sepsis patients.  
 
A shows the percentage of neutrophils expressing the relevant named cell surface 
receptors and B shows the median fluorescent intensity of the expression and 
represents the overall number of receptors. The box-whisker plots represent the 
median and IQR with the whiskers a Tukey distribution with p-values from a Mann-
Whitney U test. N=17 for the healthy controls and 14 in the sepsis cohort. 
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4.4. Discussion 
The ability of neutrophils to migrate to sites of sepsis is of critical importance to 
enable the phagocytosis and killing of invading bacteria. The consequences of 
impaired neutrophil migration are thought to allow the rapid replication and 
dissemination of pathogens, promote an exaggerated host response, which can, 
eventually lead to the death of the host. Previously, Sapey el al have shown that 
healthy ageing is associated with a functional decline in the migratory dynamics of 
neutrophils suggesting poor neutrophil function contributes to the increased 
incidence of sepsis and the poorer outcomes in this group (3, 78, 148, 159).  
 
Neutrophils from sepsis patients caused a further deterioration in neutrophil migration 
resulting in a state of neutrophil “paralysis” which persisted despite sepsis resolution. 
Neutrophil “paralysis” resulted from reduced chemokinesis (speed in any direction) 
and a reduction in directional migration (chemotaxis and chemotactic index). Based 
on results from Chapter 3, in-vitro simvastatin therapy was used to pharmacologically 
modulate the migratory dynamics of neutrophils in sepsis, however these 
experiments suggest that in-vitro simvastatin therapy during sepsis does not improve 
migration and may further impede it. 
 
Neutrophil “paralysis” in sepsis has been previously reported with the findings here 
confirming them. However, this is the first study to replicate these using time-lapse 
video microscopy to determine the alterations that occur in the migratory dynamics of 
neutrophil in sepsis. The Insall Chamber used in these experiments allows individual 
neutrophils to be tracked over time providing greater information compared to the 
Page | 157 
 
modified Boyden chambers used in other studies that merely provides data on 
numbers of cells that cross an artificial endothelial barrier (2, 154-156, 301).  
 
The sequential analysis of neutrophil migration was limited due to a small sample 
size, especially for migration towards fMLP. However the analysis indicated that 
despite physiological and biochemical improvements in patients observations 
neutrophil function remained impaired with similar migratory dynamics observed on 
admission and by day 7. In the small number of non-resolvers from sepsis (N=3) 
sequential analysis showed a worsening of neutrophil chemotaxis, which may be 
contributing to the failure of sepsis resolution. Placing these results together, it 
seems probable that in sepsis neutrophil migration is inhibited by the primary 
inflammatory response, but that this persists beyond the initial early recovery phase. 
The exact mechanism for this are unclear, however it could be that a new pool of 
“healthy” circulating neutrophils is required to be generated by the bone marrow, and 
the septic process impairs this. The initial bone marrow response to an inflammatory 
stimulus is the release of mature neutrophils into the circulation. However with 
persistent inflammation the effectiveness of the bone marrow to adequately meet 
demand is reduced, with immature cells being released. On going inflammation may 
cause bone marrow suppression and this may account for the poor resolution of 
neutrophil migratory dysfunction observed in these experiments. Perhaps an 
additional assessment of neutrophil migration in survivors following complete 
resolution of the inflammatory process would have demonstrated significant 
improvements in migration(109, 128, 324-326). 
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An alternative explanation could be that patients who develop sepsis may have pre-
existing aberrant neutrophil migration predisposing them to developing severe 
infections and the changes may perhaps just reflect this, with poor migration at 
baseline and on sequential analysis.  
 
To explore the mechanisms contributing to altered migration neutrophil adherence, 
the expression of the adhesion molecules CD18, CD11b and CD63 along with the L- 
selectin (CD62L) were quantified. Overall the data suggested increased neutrophil 
adhesion with corresponding increases in the expression of the CD18 and CD63. No 
change in CD11b was seen, with it being broadly expressed in neutrophils from 
healthy controls and in patients with sepsis.  
 
Neutrophil adhesion is an integral step in the transmigration of neutrophils from blood 
into tissues. Adhesion is mediated by integrins that bind to ICAM-1 and 2 on the 
endothelium. Integrins consist of an alpha and beta chain with CD18 being the 
common beta chain that binds with the alpha chains CD11a to form the LFA-1 or to 
CD11b to form MAC-1. Both these integrins (LFA-1, MAC-1) bind ICAM-1 to facilitate 
neutrophil adhesion and subsequently mediate crawling. The migration model used 
in these experiments uses a human albumin coated coverslip that acts as a 
surrogate for ICAM-1, thus any changes seen in neutrophil migration and adhesion 
would reflect altered LFA-1 or MAC-1 expression by neutrophils (19, 22, 24, 25).  
 
The significant rise in CD18 expression suggests an overall increases in adhesion 
mediated by LFA-1 and MAC-1. Recent studies propose that LFA-1 mediates firm 
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adhesion to the endothelium whilst MAC-1 mediates crawling and transmigration. 
Therefore the increased adhesion and the corresponding rise in CD18 expression, 
with no increase in Cd11b may indicate a preference for LFA-1 up-regulation in 
sepsis leading to increased neutrophil adhesion at the expense of MAC-1 mediated 
crawling and hence account for the reduction in migration observed in these 
experiments (20, 327).  
 
Increased neutrophil adhesion combined with migratory failure could lead to an 
accumulation of activated neutrophils in micro-vascular beds. These aggregated 
neutrophils may occlude vascular beds potentially causing distal hypoxia, release 
ROS and granules leading to local and distal tissue damage precipitating organ 
dysfunction in sepsis. This is postulated as a mechanism whereby migratory failure of 
neutrophils contributes to the pathophysiology of sepsis and MOF (3). 
 
L-Selectin is involved in the capturing free flowing neutrophils to the endothelium and 
their slowing prior to firm adhesion. The reduction in L-Selectin has been previously 
documented with experiments showing that sepsis causes shedding of L-selectin 
possibly mediated via increased TNF-alpha converting enzyme (TACE) activity. 
Experimental models of sepsis have demonstrated that increased sepsis severity is 
associated with increased L-selectin shedding, suggesting that this as a contributor 
factor in reduced migration due to failure of endothelial-neutrophil interactions. If 
taken in conjunction with increased adhesion and reduced chemokine receptor 
expression (CXCR-2), it can be postulated that neutrophils fail to adequately respond 
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to the chemoattractants leading to migratory failure and thus aggregate and occlude 
vascular beds due to their increased propensity to adhere (166, 328-334).  
 
In-vitro simvastatin therapy did not improve the migratory dynamics of neutrophils as 
predicted but did reduce neutrophil adherence. Studies in patients with acute lung 
injury (ALI) and in CLP models of sepsis have demonstrated reduced neutrophil 
infiltration into pulmonary and peritoneal tissues with statin therapy. Reduced 
infiltration was associated with a reduction in the inflammatory response and an 
improved survival in the ALI cohort.  Reduced neutrophil infiltration with statins has 
been attributed to reduction in LFA-1, MAC-1 and their endothelial ligand ICAM-1 and 
would explain the decrease in adherence seen in these experiments. Neutrophils 
from the sepsis patients can become overwhelmed by the “cytokine storm” resulting 
in a desensitisation to chemoattractants and the internalisation of chemokine 
receptors, perhaps accounting for the poor response of simvastatin therapy in 
established sepsis on neutrophil function. Emerging evidence suggests that the 
activation of the PPAR-gamma system is involved in inhibiting migration in sepsis. 
Statins up-regulate PPAR expression and this may partially explain abrogation of 
migration with statins seen in these experiments and those previously reported (150, 
152, 253, 254, 280, 284, 312, 313, 315).  
 
The incubation period of 40minutes was chosen based on healthy control data 
demonstrating this as the optimal time frame for chemotaxis to be improved. The lack 
of effect of in-vitro simvastatin in the sepsis cohort may be related to this, however 
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the reduction observed in adhesion would suggest that simvastatin was biological 
effective at the dose and incubation time chosen.  
 
There is compelling evidence that effective neutrophil migration is required in 
infection and that sepsis impairs migratory function. The exact mechanism of sepsis-
induced migratory failure is complex, with excess cytokine and NO production, 
altered expression of chemokine receptors, adhesion receptors and TLR, as well as 
changes in actin assembly all being implicated. Therapies aimed at improving 
chemotaxis in experimental sepsis have demonstrated increased influx of neutrophils 
to sites of infection, an exaggerated pro-inflammatory response and bacterial 
clearance within these sites and an attenuated systemic response, suggesting that 
improved migration should improve sepsis outcomes. In contrast many clinical 
studies suggest that reducing neutrophil influx is beneficial as this attenuates both 
local and systemic inflammatory responses and therefore improves survival. 
Perhaps, effective early migration to infected sites is optimal to allow effective 
elimination and containment whilst in sepsis reducing migration may prevent 
exacerbating tissue injury and thereby improve outcomes (2, 148, 154-156, 159, 160, 
165-167). 
 
In conclusion, the experiments above used time-lapse video-microscopy for the first 
time to demonstrate neutrophil “paralysis” in sepsis patients. This may be mediated 
by an increase in LFA-1 expression leading to increased cell adherence but reduced 
migration. The incubation of sepsis neutrophils with therapeutic concentrations of 
simvastatin did not improve the migration of “paralysed” neutrophils but did reduce 
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their adherence. This reduced adherence may lead to reduced micro-vascular 
occlusion by aggregated neutrophils and may explain the improvements in organ and 
endothelial function observed with statins in sepsis.  
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Chapter 5: Neutrophil phagocytosis in sepsis and 
the potential for in-vitro simvastatin exposure to 
modulate phagocytosis.  
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5.1. Introduction 
Once neutrophils have migrated to the sites of migration they must eliminate the 
invading pathogens. This is achieved through the ingestion of pathogens via 
phagocytosis and intracellular killing by the release of granules into the 
phagolysosome. The mechanism of phagocytosis is described in detail in section 
1.1.2.2 (38-40, 335). 
 
The efficiency of phagocytosis is impaired with age, with neutrophils ingesting fewer 
bacteria and this impairment has been proposed as a mechanism leading to the 
poorer outcomes during infective episodes observed in the elderly (81, 87, 88, 336, 
337). In sepsis phagocytosis is poorly characterised, with both suppressed 
phagocytosis and enhanced phagocytosis being reported. Like with many neutrophil 
functions a balanced response under tight homeostatic control would be ideal, as 
poor phagocytosis leads to the rapid dissemination of the infection. Increased 
phagocytosis, if contained within the cell with effective maturation of the 
phagolysome should eliminate bacteria faster and theoretically lead to earlier 
resolution of infection. However cells can be activated but unable to ingest and 
intracellularly kill bacteria effectively (termed frustrated phagocytosis) leading to 
collateral tissue damage via neutrophil degranulation and ROS production (38, 169, 
173, 179, 338-340). 
 
Phagocytosis is dependent on the recognition of pathogens and related products by 
a variety of cell surface receptors. Some key receptors are CD16 (FcγRIIIb) and 
CD14 (LPS-receptor). Additional receptors that are closely linked with phagocytosis 
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are CD63, a marker of degranulation into the phagolysosome and CD11b (CR3), 
which binds C3a to induce phagocytosis (40, 341-343) 
 
Observational data demonstrates that statins (HMG-CoA reductase inhibitors) 
improve outcomes in infection and sepsis, however recent randomised controlled 
trials have failed to demonstrate any clear benefit of simvastatin therapy in acutely ill 
patients. In-vivo 80mg simvastatin showed a trend towards improved phagocytosis of 
E.Coli in the healthy elderly with no changes in the phagocytosis of S.Aureus 
(Chapter 3). It is unclear whether statin therapy would modulate neutrophil 
phagocytosis in sepsis, which could lead to the improved outcomes observed seen in 
some studies (237, 245, 277, 309, 310). 
5.1.1. Hypothesis 
It was hypothesised that phagocytosis would be: 
x Impaired with age 
x That sepsis would cause a further decline in phagocytosis 
x That in-vitro simvastatin therapy would enhance neutrophil phagocytosis. 
x That neutrophils would show reduced expression of cell surface receptors 
indicating an immunosuppressed phenotype. 
5.1.2. Aims 
The aims of this study were to: 
1. Characterise the effects of age on neutrophil phagocytosis. 
2. Characterise neutrophil phagocytosis in a population with sepsis 
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3. Assess whether in-vitro simvastatin could modulate neutrophil phagocytosis 
in sepsis. 
4. Phenotype neutrophils from healthy controls and sepsis patients by cell 
surface expression of CD16, CD11b, CD63 and CD14 on neutrophils to 
reveal potential mechanisms of altered phagocytosis in sepsis. 
5.2. Methods 
5.2.1. Healthy control recruitment 
Healthy young controls were recruited into the study as described in section 2.2. The 
baseline data from healthy elderly subjects recruited into the statin trial described in 
chapter 3 were also used as controls. 
5.2.2. Patient recruitment 
Patients with sepsis were entered into the trial as described in section 2.3. The 
SSCG definitions for sepsis were used to screen eligible patients  (see tables 1.4 and 
1.5). Exclusion criteria were as described in section 2.3.1. 
5.2.3. Data collected 
Data collected is described in section 2.3.2.  
5.2.4. Sample collection 
Blood samples for the phagocytosis experiments were taken in Lithium heparin 
vacutainers (Becton Dickinson) as described in section 2.4. 
5.2.5. Neutrophil isolation 
Neutrophils were extracted using a Percoll gradient as described in section 2.5.3. 
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5.2.6. Phagocytosis experiments 
Phagocytosis experiments were performed using a flow cytometer and fluorescent 
labelled E.Coli and S.Aureus (pHrodo; Invitrogen) according to the manufacturers 
instructions as detailed in section 2.6.3. 
 
Phagocytosis was measured as the percentage of pHrodo “bright” neutrophils and 
the median fluorescent intensity (MFI) representing the number of bacteria 
phagocytosed. The phagocytic index (PI) was calculated by multiplying the 
percentage of fluorescent positive neutrophils by the MFI. This provided an overall 
quantification of phagocytic capacity. The AUC for each parameter was calculated as 
described in section 2.6.3.  
5.2.7. Simvastatin Experiments 
Freshly isolated neutrophils were incubated with 1µM simvastatin for 40minutes prior 
to phagocytosis being assessed as described in section 2.7. All neutrophil assays 
were performed un-blinded. 
5.2.8. Cell surface receptor expression experiments 
The expression of the cell surface receptors CD16, CD11a, CD14 and CD63 were 
quantified from whole blood using flow cytometry analysis. The detail methods are 
described in section 2.6.6. 
5.2.9 Statistical Analysis 
Continuous data were tested for normality using a Shapiro-Wilk’s test, however if 
sample sizes were too small a Kolmogorov-Smirnov test. All continuous data are 
represented as median (IQR), with non-parametric statistical tests performed as 
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described in section 2.9. Where two or more were analysed using a Kruskal-Wallis 
test, Dunn’s post-hoc tests were performed to identify the nature of the statistical 
differences between the groups. Categorical data were analysed using a Fisher’s 
exact test for two groups and a χ2-test for more than two groups. Correlations were 
performed using a Spearman correlation test, with results represented as the 
correlation co-efficient and the 95% confidence interval.  
5.3. Results 
5.3.1. Healthy Controls 
Twenty-four healthy controls had their neutrophils characterised for phagocytosis to 
un-opsonised pHrodo labelled E.Coli and S.Aureus (Invitrogen). The median age of 
the healthy controls was 68 (range 22-94) with 12 males and 12 females. 
5.3.2. Age and Phagocytosis 
Within the healthy controls there was no correlation between the subjects’ age and 
phagocytosis of E.Coli as measured by percentage of pHrodo “bright” cells, the MFI, 
or the PI (see table 5.1). Healthy controls were further divided into young (age 
<45years) and old (age >60) cohorts. No difference between young and elderly 
cohorts was observed for E.Coli phagocytosis for pHrodo “bright” neutrophils (AUC: 
2665 {IQR 2472-2837} vs. 2533 {IQR 2256-2722} p=0.262 Mann Whitney U test), 
MFI (1265 {IQR 838-2032} vs. 1141 {IQR 614-2013} p=0.625, Mann Whitney U test) 
or PI (1172 {IQR 662-1911} vs. 928 {IQR 503-1852} p=0.473, Mann Whitney U test) 
(see figure 5.1). 
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When S.Aureus was used, there was an age-related decline in phagocytosis with a 
significant negative correlation for the MFI (Spearman’s correlation, p=0.032) and PI  
(Spearman’s correlation, p=0.020). No changes related with age were seen for the 
pHrodo “bright” neutrophils (see table 5.1).  
 
When divided into young (age <45years) and elderly healthy cohorts (age >60), age 
was associated with a decline in phagocytosis. The MFI (1638 {IQR 900-3175} vs. 
2892 {IQR 2421-4180} p=0.026, Mann Whitney U test) and the PI (1550 {IQR 723-
2827} vs. 2729 {IQR 2189-3893} p=0.022, Mann-Whitney U) were significantly lower 
in the elderly. The number of pHrodo “bright” neutrophils was reduced in the elderly 
but this failed to reach significance (2662 {IQR 2431-2862} vs. 2798 {IQR 2701-2892} 
p=0.077, Mann Whitney U test. See figure 5.1.) 
5.3.3. Gender and Phagocytosis  
Gender impacts upon outcomes from sepsis, with females less likely to die compared 
to age-matched males. Therefore the effect of age upon neutrophil phagocytosis was 
investigated(106). No difference was seen between neutrophils from healthy male 
and female donors to E.Coli or S.Aureus (see table 5.2). 
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Table 5.1. Correlation between age and phagocytosis of pHrodo labelled 
(Invitrogen) E.Coli and S.Aureus 
 
 
 
 
 
 
 
 
 
 
Correlations between age and the three measures of phagocytosis, the “pHrodo” 
bright neutrophils, median fluorescent intensity (MFI) and the phagocytic index (PI). 
The co-efficients (r) and p-values are from a Spearman’s correlation. The 95% 
confidence interval (CI) is shown for each correlation. 
 
 R 95% CI p-value* 
E.Coli    
pHrodo 
“bright” 
-0.329 -0.648-0.088 0.108 
MFI -0.169 -0.538-0.254 0.419 
PI -0.250 -0.596-0.173 0.227 
S.Aureus    
pHrodo 
“bright” 
-0.341 -0.662-0.085 0.103 
MFI -0.438 -0.721- -0.023 0.032 
PI -0.473 -0.742- -0.073 0.020 
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Figure 5.1. Differences in phagocytosis between young and elderly controls.  
 
The graphs show the differences in the neutrophil phagocytosis of young controls 
(age less than 45 years, N=7) and elderly controls (age greater than 60, N=17). The 
three indices used are the pHrodo “bright” neutrophils, the median fluorescence 
intensity (MFI) and the phagocytic index (PI) and are represented as the area under 
the curve (AUC). A shows E.Coli phagocytosis and B S.Aureus phagocytosis. The 
bars represent the median and IQR with the whiskers representing a Tukey 
distribution. p-values from a Mann-Whitney U test. 
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Table 5.2. Neutrophil phagocytosis of healthy elderly controls split by gender 
to pHrodo (Invitrogen) labelled E.Coli and S.Aureus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measures used to quantify phagocytosis were the pHrodo “bright” neutrophils, the 
median fluorescence intensity (MFI) and the Phagocytic Index (PI). All data is 
expressed as area under the curve (AUC) with values representing the median (IQR) 
and with p-values from a Mann-Whitney U test.  
  
 Males 
N=12 
Females 
N=12 
p-value* 
E.Coli    
pHrodo “bright”  2597 
(2387-2768) 
2542 
(2445-2752) 
0.875 
MFI 1276 
(710-2279) 
1349 
(816-2124) 
0.458 
PI 1045 
(485-2126) 
1171 
(658-1897) 
0.525 
S.Aureus    
pHrodo “bright” 2713 
(2610-2892) 
2691 
(2562-2872) 
0.743 
MFI 2692 
(764-3401) 
2295 
(1622-3068) 
0.786 
PI 2380 
(647-3278) 
2019 
(1356-2839) 
0.718 
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5.3.3. The impact of sepsis on phagocytosis 
The experiments reported above suggest that increasing age is associated with a 
decline in the phagocytosis of un-opsonised S.Aureus by neutrophils. Gender did not 
impact upon the neutrophil phagocytosis of E.Coli or S.Aureus. The studies below 
investigated the effect of sepsis on the neutrophil phagocytosis of these bacteria. 
 
Fifteen of the recruited sepsis patients had phagocytosis experiments carried out on 
their neutrophils. The demographics are shown in table 5.3. The sepsis and healthy 
controls were well matched for age and gender. The majority of patients recruited (12 
{80%}) met the criteria for severe sepsis with pneumonia being the commonest 
source of sepsis (9 {60%} patients), followed by urinary tract infections (3 {20%} 
patients). Five patients (33%) were admitted to ICU. Mortality was 33.3% (5 deaths) 
with a median length of hospital stay of 9 days (range 5-57). 
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Table 5.3. Characteristics of healthy controls and sepsis patients that had 
neutrophil phagocytosis experiments performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values represent the median (IQR) unless otherwise stated. * Mann-Whitney U test, 
#Fisher’s exact test and Φ χ2-test. § Patients may have more than one co-morbidity 
and be taking more than one medication. 
 
 
Controls 
N=24 
Sepsis 
N=15 
p-value 
Age  68 (33-72) 57 (32-74) 0.502* 
Sex, male (%) 12 (50%) 9 (60%) 0.742# 
No of Co-morbidities 
0 
1 
2 
 
18 
6 
0 
 
5 
7 
3 
 
 
 
0.012Φ 
Co-morbidities§, n 
None 
CVS disease 
Respiratory disease 
Chronic renal disease 
Diabetes 
 
18 
6 
0 
0 
0 
 
6 
6 
1 
0 
4 
 
 
 
 
 
0.039Φ 
Medications§, n 
None 
Anti-hypertensive 
Beta-blocker 
Anti-platelet 
Oral hypoglycaemic 
Insulin 
Inhaled beta-agonist 
Statins 
 
18 
6 
1 
0 
0 
0 
0 
0 
 
5 
6 
3 
1 
2 
3 
1 
5 
 
 
 
 
 
 
 
 
0.005Φ 
APACHE II  11 (5.8-32.2)  
SAPS II  33 (13-40)   
ICU Admission, N 
Inotropes alone 
Respiratory support 
Multi-organ support 
 5 (33.3%) 
1 
1 
3 
 
WCC  14.4 (12.3-22.6)  
CRP  222 (92-407)  
SOFA Score  6 (2-9)  
Length of Stay,   9 (6-25)  
Mortality, n (%)  5 (33.3%)  
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5.3.3.1. Sepsis increases the phagocytosis of E.Coli by neutrophils 
Neutrophils donated from patients with sepsis showed significant up-regulation of un-
opsonised E.Coli phagocytosis compared to healthy elderly controls (see table 5.4 
and figure 5.2). The percentage of pHrodo “bright” neutrophils was unchanged at 
either time point, however the number of bacteria phagocytosed per neutrophil 
(represented by the MFI) was significantly higher at all three times points, resulting in 
a greater PI (overall measure of phagocytosis) for E.Coli in sepsis patients. 
5.3.3.2. Sepsis does not alter the neutrophil phagocytosis of S.Aureus bacteria. 
Donor neutrophils from sepsis patients did not display any differences in the 
phagocytosis of un-opsonised S.Aureus compared to healthy controls in any of the 
three indices of phagocytosis (see table 5.4 and figure 5.2). This suggests that sepsis 
increases the capability of neutrophils to ingest un-opsonised gram-negative bacteria 
but not gram-positive bacteria. 
5.3.3.3. The effect of age on neutrophil phagocytosis in sepsis. 
An age-related decline was observed in healthy controls. To assess the impact of 
age on the phagocytosis of neutrophils in sepsis a correlation was performed 
between age and markers of neutrophil phagocytosis. No association was seen 
between age and the neutrophil phagocytosis of E.Coli or S.Aureus. (See table 5.5). 
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Table 5.4. Phagocytosis of pHrodo (Invitrogen) labelled E.Coli and S.Aureus by 
neutrophils from healthy controls and sepsis patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measures used to quantify phagocytosis were the number of pHrodo “bright” 
neutrophils, the median fluorescence intensity (MFI) and the Phagocytic Index (PI) 
and all are expressed as area under the curve (AUC) with values representing the 
median (IQR) and with p-values from a Mann-Whitney U test.  
 Healthy 
N=24 
Sepsis 
N=15 
p-value 
E.Coli    
pHrodo “bright” 
cells 
2547 
(2419-2747) 
2439 
(1943-2781) 
0.554 
MFI 1161 
(693-2013) 
2124 
(1772-4412) 
0.001 
PI 1012 
(607.4-1852) 
1926 
(1263-3619) 
0.008 
S.Aureus    
pHrodo “bright” 
cells 
2693 
(2611-2870) 
2664 
(1864-2825) 
0.180 
MFI 2365 
(1171-3267) 
3000 
(1980-3629) 
0.227 
PI 2125 
(958-3062) 
2606 
(1153-3284) 
0.676 
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Figure 5.2. Phagocytosis to pHrodo labelled E.Coli and S.Aureus in healthy 
controls and in sepsis patients. 
 
The graphs above show the differences in phagocytosis between healthy controls 
(N=24) and sepsis patients (N=15). The three indices used are the pHrodo “bright” 
neutrophils, the median fluorescence intensity (MFI) and the phagocytic index (PI) 
and are represented as the area under the curve (AUC). A shows E.Coli 
phagocytosis and B S.Aureus phagocytosis. The bars represent the median and IQR 
with the whiskers representing a Tukey distribution. p-values from a Mann-Whitney U 
test. 
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Table 5.5. Correlation between age and neutrophil phagocytosis in sepsis 
patients 
 
 
 
 
 
 
 
 
 
 
Correlations between age and the three measures of phagocytosis, pHrodo “bright” 
neutrophils, median fluorescent intensity (MFI) and the phagocytic index (PI). The co-
efficients (r) are from a Spearman’s correlation. The 95% confidence interval (CI) is 
shown for each correlation. 
  
 r 95% CI p-value* 
E.Coli    
pHrodo 
“bright” cells 
-0.080 -0.616-0.507 0.788 
MFI -0.267 -0.722-0.349 0.370 
PI -0.275 -0.726- 0.342 0.356 
S.Aureus    
pHrodo 
“bright” cells 
-0.013 -0.552-0.534 0.960 
MFI -0.048 -0.576-0.508 0.864 
PI -0.048 -0.576-0.508 0.864 
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5.3.3.4. Neutrophil phagocytosis in patients with sepsis on sequential days. 
The results describe enhanced neutrophil phagocytosis of E.Coli and unchanged 
S.Aureus phagocytosis in sepsis compared to healthy controls. To assess the 
changes that occur over time in sepsis, phagocytosis was measured on sequential 
days (day1, day 4 and day7) where possible.  
 
Patients with sepsis showed improvements in their SOFA score  (median SOFA 
score 6 {IQR 2-9} vs. 0 {IQR 0-4} p=0.045 Wilcoxon signed rank test) and a trend 
towards a reduction in CRP by day 7 (165 {IQR 60.7-165} vs. 29 {IQR 15.5-152.5} 
p=0.054 Wilcoxon signed rank test) compared to baseline indicating sepsis 
resolution. No change in WCC was seen (14.4 {IQR 10.9-22.2} vs. 12.6 {IQR 8.8-
19.4} p=0.492 Wilcoxon signed rank test). No change in SOFA score, CRP or WCC 
was observed at day 4 compared to baseline (see table 5.6). Not all patients had 
sequential sampling due to patient discharges (N=3), deaths (N=2) and consent 
withdrawal for venesection (N=1). 
 
No change in the overall number of neutrophils (pHrodo “bright) ingesting E.Coli was 
observed on sequential day analysis. The MFI was significantly greater on all three 
days a compared to healthy controls (Kruskal-Wallis p=0.005) resulting in a raised PI 
on all three days compared to healthy controls (Kruskal-Wallis p=0.029). Dunn’s post 
hoc tests demonstrated a significant difference between healthy controls and the MFI 
(p=0.006) and PI (p=0.046) on day 1 in sepsis patients. No changes in the 
phagocytosis of S.Aureus were observed with any of the measures of phagocytosis 
(see table 5.7).  
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5.3.4. In-vitro simvastatin therapy does not affect neutrophil phagocytosis. 
Neutrophils from sepsis patients were incubated with 1μM simvastatin for 40minutes 
prior to the phagocytosis experiments to assess whether statins could modulate 
neutrophil phagocytosis in sepsis. Simvastatin did not alter any of the parameters 
used to quantify neutrophil phagocytosis to either E.Coli or S.Aureus at any time 
point assessed (see table 5.8). 
5.3.5. Surface Expression of phagocyte receptors in healthy controls and 
sepsis patients. 
The experiments above have shown that the phagocytosis of E.Coli is enhanced in 
sepsis and that in-vitro simvastatin therapy does not modulate phagocytosis in these 
patients. No change in the phagocytosis of S.Aureus by neutrophils from sepsis 
patients was observed. To investigate the potential mechanisms that may increase 
phagocytosis the surface expression of CD16, Cd11b, CD14 and CD63 in neutrophils 
from healthy controls (N=17) and sepsis patients (N=14) were evaluated. The healthy 
controls were significantly younger (33.0 years {IQR 28.0-40.5years} vs. 57.0 years 
{IQR 32.0-74.0years} p=0.039 Mann Whitney U) with no significant gender 
differences (9 males vs. 9 males p=1.00 Fisher’s Exact test). 
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Table 5.8. The effect of in-vitro 1μM simvastatin exposure on the phagocytosis 
of E.Coli and S.Aureus (Invitrogen) by neutrophils from sepsis patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measures used to quantify phagocytosis were pHrodo “bright” cells, the median 
fluorescence intensity (MFI) and the Phagocytic Index (PI). All are expressed as area 
under the curve (AUC) with values representing the median (IQR) and with p-values 
from a Wilcoxon ranked sum test. The vehicle control was RPMI 1640 with the 
equivalent concentration of dimethyl sulfoxide (DMSO).  
 Vehicle 
Control  
N=12 
Simvastatin  
 
N=12 
p-value 
E.Coli    
pHrodo 
“bright” cells 
2562 
(2330-2813) 
2625 
(2534-2835) 
0.622 
MFI 3956 
(2473-4661) 
3834 
(2510-4827) 
0.970 
PI 3741 
(1917-4135) 
3472 
(1943-3898) 
0.970 
S.Aureus    
pHrodo 
“bright” cells 
2730 
(2345-2859) 
2729 
(2382-2875) 
0.424 
MFI 3371 
(2403-4571) 
3252 
(2588-4452) 
0.146 
PI 2809 
(2078-4127) 
3042 
(2226-3992) 
0.151 
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5.3.5.1. Sepsis reduces CD16 expression on neutrophils 
CD16 is also known as FcyIIIB, a receptor that binds to IgG and is involved in the 
phagocytosis of bacteria by neutrophils. CD16 is expressed avidly by neutrophils and 
no difference was seen on the percentage of cells positive for CD16 between healthy 
controls and sepsis patients (95.5% {IQR 90.4-97.0%} vs. 96.1% {IQR 89.4-97.6%} 
p=0.883, Mann Whitney U test). However the median MFI (a measure of the level of 
expression per cell) was significantly lower in sepsis patients (77791 AFUs {IQR 
68061-111644 AFUs} vs. 59683 AFUs {IQR 40799-73306 AFUs} p=0.014, Mann 
Whitney U) representing reduced overall expression of CD16 on neutrophils. 
5.3.5.2. Sepsis does not alter Cd11b expression on neutrophils. 
Cd11b is the receptor for C3a that coats invading pathogens. The binding of C3a to 
CD11b triggers phagocytosis. The expression of CD11b was unchanged in sepsis 
patients compared to healthy controls. Almost all neutrophils expressed Cd11b in 
both the controls and the sepsis patients (97.6% {IQR 84.2-99.3%} vs. 96.9% {IQR 
68.7-99.7%} p=0.914 Mann Whitney U) with similar median MFI values (7868 AFUs 
{IQR 7274-8654 AFUs} vs. 8494 {IQR 7389-9438 AFUs} p=0.374, Mann Whitney U). 
5.3.5.3. Sepsis up-regulates CD14 expression in neutrophils 
CD14 is the LPS receptor and has been implicated in the phagocytosis of un-
opsonised gram-negative bacteria. The number of neutrophils expressing CD14 in 
sepsis patients is significantly higher than in healthy controls (35.1% {IQR 17.8-
49.3%} vs. 4.6% {IQR 3.5-12.3%} p<0.001 Mann Whitney U). No difference was 
seen in the number of receptors per cell represented by the MFI (2134 AFUs {IQR 
1358-15572 AFUs} vs. 2069 {IQR 1696-3247 AFUs} p=0.940, Mann Whitney U). 
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5.3.5.4. Sepsis up-regulates CD63 expression in neutrophils 
CD63 is a marker of granule release and is a marker of neutrophil degranulation into 
a phagosome. Its expression has been closely linked with phagocytosis. More 
neutrophils from sepsis patients expressed CD63 compared to healthy controls 
(77.1% {IQR 53.9-94.2%} vs. 45.5% {IQR 29.1-68.5%} p=0.040, Mann Whitney U), 
with a trend towards a decrease in the MFI observed between the groups (3869 
AFUs {IQR 2111-4571 AFUs} vs. 5109 {IQR 3403-5581 AFUs} p=0.052, Mann 
Whitney U).  
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5.4. Discussion 
Neutrophil phagocytosis is vital for the effective containment and elimination of 
bacteria. Advancing age is associated with an increased incidence of sepsis with the 
elderly having poorer sepsis-related outcomes. It has been proposed that an age-
associated decline in phagocytic function contributes to the dissemination of infection 
and the development of sepsis and MOF (344).  
 
Several studies have demonstrated that although neutrophils retain their ability to 
phagocytose bacteria, their efficiency is significantly reduced with advancing age. 
The experiments reported replicate the age-associated decline in phagocytosis with 
un-opsonised S.Aureus but not to un-opsonised E.Coli.  It is difficult to account for 
the lack of reduction in phagocytosis with age in E.Coli as previous studies have 
suggested that impairment is seen with both species. Additionally both E.Coli and 
S.Aureus infections are associated with a high mortality in the elderly, and it has 
been suggested that the poor phagocytosis of both species may contribute to this 
(87, 88, 179, 307, 336, 337, 345-347). 
 
The changes in phagocytosis in patients with established sepsis remain 
controversial. The data here suggests that in sepsis neutrophils increase their 
phagocytic capacity towards the gram-negative anaerobe E.Coli but not to S.Aureus 
(gram-positive aerobe). Martins et al who demonstrated that patients with severe 
sepsis and septic shock up-regulate phagocytosis by increasing the number of 
bacteria ingested per cell support this. There is also evidence to suggest bacterial 
species may affect phagocytosis dynamics following inflammation with enhanced 
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E.Coli phagocytosis seen in patients following trauma. In these patients the 
phagocytosis of S.Aureus was unaltered, as in these experiments, but was down 
regulated to Klebsiella pneumoniae. It is suggested that the priming of neutrophils in 
sepsis by circulating cytokines (e.g. LPS) are responsible for the enhanced 
phagocytosis in circulating neutrophils, with blockade of these priming mechanisms 
leading to down-regulation of the phagocytosis (169-171, 173, 348-350).   
 
Other authors have found that phagocytosis is reduced in sepsis suggesting that 
impairments lead to the dissemination of bacteria and death of the host. Wenisch et 
al demonstrating that in patients with gram-negative severe sepsis neutrophils 
showed reduced phagocytosis of E.Coli compared to matched healthy controls. 
Danikas et al also showed reduced neutrophil phagocytosis and dysfunctional 
monocyte function in sepsis and associated this with an increased mortality from 
sepsis (338, 344). 
 
Phagocytosis is triggered by the recognition of pathogens by specific receptors. Two 
important receptors are CD11b and CD16, which recognise bacteria coated with C3 
and IgG respectively. In agreement with other studies no difference in CD11b (C3R) 
was seen between healthy controls and sepsis patients suggesting that altered 
recognition of complement opsonised bacteria is unaffected in sepsis (87, 351).  
 
As previously demonstrated, the experiments here showed a reduction in CD16 
expression in patients with sepsis compared to healthy controls. CD16 expression 
has been linked to the age-related decline in E.Coli phagocytosis. However the 
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precise role of reduced CD16 expression in inflammation is complex. It is clear that 
CD16 is intimately involved in phagocytosis with neutrophil activation leading to 
increased expression of internalised CD16 receptors to the cell surface. This may be 
counteracted however, by increased shedding of the receptor once it has bound and 
ingested the pathogens. In addition the neutrophilla induced by sepsis causes the 
mass release of neutrophils from the bone marrow.  These neutrophils are immature 
and have been characterised to express lower levels of CD16 than fully matured 
neutrophils. These immature cells are capable of phagocytosis and intracellular 
pathogen killing, but are less efficient than their mature counterparts. These findings 
suggest that perhaps the lower CD16 levels seen are due to receptor shedding by 
phagocytosing neutrophils and the reduced expression seen in immature neutrophils 
(87, 175, 351). 
 
The LPS receptor, CD14 is an important mediator of the cellular response to sepsis 
interacting with TLR-4 and 2 to initiate the intracellular signalling response that 
triggers cytokine release from leucocytes. Recent evidence suggests that CD14 is 
important in the phagocytosis of un-opsonised gram-negative bacteria. In this study 
neutrophils from sepsis patients had increased expression of CD14. This may explain 
the differences observed between E.Coli and S.Aureus seen in the results, with 
increased phagocytosis of E.Coli being mediated via a CD14 pathway. The relevance 
of adequate CD14 expression remains under investigation with conflicting results. A 
murine model of sepsis demonstrated that CD14 knockout mice had an increased 
susceptibility to gram-negative sepsis and a reduced phagocytosis of E.Coli by 
neutrophils. Blockade of CD14 has also been suggested as a potential therapeutic 
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target for sepsis, with murine models suggesting an improved survival and 
attenuated host inflammatory response to caecal ligation in CD14 knockout mice. 
This study did not investigate phagocytosis but evaluated the host’s inflammatory 
response. Blockade of CD14 may be useful in established septic shock where 
reducing the host response may be beneficial, but in the early stages of sepsis 
potential blockade risks bypassing an important mechanism of phagocytosis (342, 
343, 352-357).  
 
The mechanism involved in the increased phagocytosis of E.Coli by neutrophils in 
sepsis is likely to be multi-factorial. Taking all the data in context with the current 
literature, the experiments here suggest that circulating neutrophils adopt a pro-
inflammatory phenotype, evidenced by raised CD14 and CD63 receptor expression 
and this may account for the increased phagocytosis of E.Coli (53, 335). 
 
Although levels of phagocytosis of E.Coli remained elevated throughout the course of 
sepsis at days 4 and 7, this was not significant in the post-hoc analysis, suggesting 
that neutrophils show a trend towards resolution as sepsis resolves. Neutrophils have 
a short circulating life span and despite the prolonged survival initiated by the initial 
response to sepsis it is probable a new, younger pool of neutrophils are predominant. 
It is possible, that due to decreased levels of inflammation these left-shifted show 
lower levels of activation and thus there phagocytic capacity is comparable to healthy 
controls. 
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The in-vivo study on the effects of simvastatin therapy upon healthy elderly neutrophil 
function reported in Chapter 3 showed a trend towards increased neutrophil 
phagocytosis of E.Coli following simvastatin treatment in the healthy elderly. The in-
vitro exposure of neutrophils from patients with sepsis to therapeutically relevant 
concentrations of simvastatin therapy did not alter neutrophil phagocytosis. The time 
frame of incubation used was 40minutes and should have been long enough to 
cause a biological effect, as previous in-vitro studies with simvastatin have 
demonstrated improvements in neutrophil function within this time. Neutrophil 
phagocytosis in sepsis seems to be normal if not up regulated in sepsis and therefore 
additional modulation with statins may not be possible in these circumstances. 
Importantly, in-vitro simvastatin did not have any deleterious effects upon 
phagocytosis, 
 
There were several limitations within the experiments carried out here. Firstly un-
opsonised bacteria were used to determine the phagocytic efficiency of neutrophils. 
This does not truly reflect a physiological model as the vast majority of organisms are 
opsonised by complement or immunoglobulins prior to ingestion. These opsonised 
mediated phagocytic pathways result in rapid and effective phagocytosis. The 
mechanisms of un-opsonised phagocytosis in relation to E.Coli have been partially 
explained by a CD14 expression, however the mechanisms involved with S.Aureus 
remain poorly understood. This may explain why no differences in either direction 
were observed. Secondly, the cell-surface expression of neutrophils was not 
performed on the same cohort of healthy controls, with the controls being significantly 
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younger than the sepsis cohort. In addition, neutrophil cell surface expression was 
not performed sequentially.  
 
In conclusion, the experiments suggest that increasing age was associated with a 
decline in the phagocytosis of S.Aureus and may explain why the elderly are prone to 
developing serious sepsis from it. In the context of sepsis, the phagocytosis of E.Coli 
by neutrophils was up regulated and this is potentially mediated by the adoption of a 
pro-inflammatory phenotype via an increase in CD14 and CD63 expression. The use 
of in-vitro simvastatin did not modulate neutrophil phagocytosis in sepsis.  
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Chapter 6:Neutrophil extracellular traps in patients 
with sepsis and the effect of in-vitro simvastatin on 
their production. 
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6.1 Introduction 
Neutrophils are essential to host defence against invading organisms. They migrate 
to sites of infection, where they phagocytose bacteria and other pathogens to kill 
them. The two preceding chapters investigated neutrophil migration and 
phagocytosis in patients with sepsis, demonstrating aberrant neutrophil migration and 
a retained phagocytic ability and possible up-regulation of E.Coli phagocytosis. 
 
The resolution of inflammation relies on the eventual death of neutrophils and other 
innate immune cells. Neutrophil extracellular traps (NETs) have recently being 
described as a novel form of cell death distinct from apoptosis, whereby the 
extracellular release of nuclear DNA laden with histones and granule products 
enables neutrophils to continue their antimicrobial functions after their own death (16, 
59).  
 
The mechanisms of NETosis have been described in detail in section 1.1.2.4. NETs 
can be generated by both oxidant-dependent mechanisms that rely on ROS 
production via NADPH and via oxidant independent pathways. Additionally NETosis 
is a distinct from apoptotic cell death that needs to be distinguished in experimental 
studies on NETs. Therefore investigations of NETosis require the evaluation of ROS 
production, and apoptosis. To clearly investigate potential mechanisms involved the 
quantification of certain activation markers on neutrophils would be valuable. The 
expression of CD63, CD45 and CD14 are closely linked with neutrophil activation, 
degranulation and ROS, whilst CD16 can be used to identify neutrophil maturity (175, 
358-360)  
Page | 194 
 
 
The exact role of NETs in health and disease remains under investigation. There is 
evidence to suggest that an inability to generate NETs results in an increased 
vulnerability of infection and an exacerbation of sepsis, whilst others suggest that 
NETosis causes tissue damage and worsens organ dysfunction in inflammation. 
NETs may also possess some anti-inflammatory properties by neutralising circulating 
cytokines and chemokines. Emerging evidence in NETs biology has suggested that 
NET production is impaired with age and may contribute to the increased incidence 
of sepsis in this group. Whilst in sepsis, the inflammatory mediators in infection are 
thought to increase the production of NETs both locally and systemically (211, 214, 
303, 361-363).   
 
As previously stated, the use of statins prior to the development of infections is 
associated with improved outcomes. Recent RCTs have failed to prove that the acute 
administration of statins can improve outcomes in the critically ill. In chapter 3, the 
oral administration of simvastatin 80mg daily for 14 days did not alter NET 
production. However, Chow et al’s initial data demonstrated that statins increase 
NET production and they postulated that this may contribute to the mechanism by 
which statins modulate inflammation (364). 
6.1.1. Hypothesis 
Based on the current evidence it was hypothesised that: 
1. Neutrophils from healthy elderly donor would produce fewer NETs compared 
to healthy young donors. 
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2. Neutrophils from sepsis patients would produce greater NETs compared to 
controls and that resolution of sepsis will result in NET production returning to 
levels seen in controls. 
3. In-vitro treatment with simvastatin would up-regulate NET formation further. 
4. ROS production would be up regulated in sepsis and this would correlate with 
increased NETosis. 
6.1.2. Aims 
The studies in this chapter aimed to: 
1. Establish NET production in health and the impact of healthy aging on NET 
production.  
2. Determine NET production in sepsis patients. 
3. Determine any sequential changes in NET production with sepsis resolution. 
4.  Determine the effect of in-vitro simvastatin therapy upon NET production in 
sepsis.  
To explore the mechanism of any changes observed: 
1. ROS production in healthy controls and in patients with sepsis was measured. 
2. The effect of in-vitro simvastatin therapy upon ROS production was 
determined. 
3. Apoptosis was measured in healthy controls and in patients with sepsis 
4. The expression of CD16, CD45, CD14 and CD63 was measured. 
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6.2. Specific Methods 
6.2.1. Healthy control recruitment 
Healthy young controls were recruited into the study as described in section 2.2. The 
baseline data from healthy elderly subjects recruited into the statin trial described in 
chapter 3 were also used as controls. 
6.2.2. Patient recruitment 
Patients with sepsis were entered into the trial as described in section 2.3. The 
SSCG definitions for sepsis were used to screen eligible patients  (see tables 1.4 and 
1.5). Exclusion criteria were as described in section 2.3.1. 
6.2.3. Data collected 
Data collected is described in section 2.3.2.  
6.2.4. Sample collection 
Blood samples for the NETs and apoptosis experiments were taken in EDTA 
vacutainers (Becton Dickinson), whilst the experiments for ROS were collected in 
Lithium Heparin vacutainers (Becton Dickinson) as described in section 2.4. 
6.2.5. Neutrophil isolation 
Neutrophils were extracted using a Percoll gradient as described in section 2.5.3. 
6.2.6. Neutrophil Extracellular Traps Experiments 
Freshly isolated neutrophils were stimulated to generate NETs by incubating them 
within the control media (RPMI 1640 Sigma Aldrich) or in the positive control 25nM 
PMA (Sigma-Aldrich) as described in section 2.6.4. Following incubation for 3 hours 
NET production was quantified by the degree of fluorescence measured in a BioTek 
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Synergy 2 fluorometric plate reader (NorthStar Scientific Ltd, Leeds, UK) with a filter 
setting of 485nm excitation and 530nm emission. Background fluorescence from 
unstimulated negative controls was subtracted from the stimulated values. 
 
NET production was measured as arbitrary fluorescent units (AFUs). The greater the 
degree of fluorescence the higher the AFU value which in turn corresponded with 
greater NET production. 
6.2.7. Simvastatin Experiments 
Freshly isolated neutrophils were incubated with 1μM simvastatin (Sigma-Aldrich) at 
37C̊ with 5% CO2 for 40minutes (see section 2.7) prior to the NETs experiments as 
described above (section 6.2.6). All neutrophil assays were performed un-blinded. 
6.2.8. Apoptosis Experiments 
Apoptosis was measured in freshly isolated neutrophils immediately following 
isolation, 4 hours and 24hours later. Apoptosis was measured using flow cytometry 
and staining of the neutrophils with Annexin V (BD) and Sytox Blue (Invitrogen) as 
detailed in section 2.6.5. The percentage of cells that were alive (negative for 
Annexin V and Sytox Blue), in early apoptosis (Annexin V positive only), late 
apoptosis (Annexin V and Sytox Blue positive) and necrotic (Sytox Blue positive only) 
were recorded.  
6.2.9. Statistical Analysis 
Continuous data were tested for normality using a Shapiro-Wilk’s test, however if 
sample sizes were too small a Kolmogorov-Smirnov test. All continuous data are 
represented as median (IQR), with non-parametric statistical tests performed as 
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described in section 2.9. Where two or more were analysed using a Kruskal-Wallis 
test, Dunn’s post-hoc tests were performed to identify the nature of the statistical 
differences between the groups. Categorical data were analysed using a Fisher’s 
exact test for two groups and a χ2-test for more than two groups. Correlations were 
performed using a Spearman correlation test, with results represented as the 
correlation co-efficient and the 95% confidence interval.  
6.3. Results 
6.3.1. NET production in healthy volunteers 
NET production was assessed in 37 healthy individuals who acted as the healthy 
controls for the sepsis patients. The participants had a median age of 62 years (age 
range 20-94years), with 17 males and 20 females (p=0.642, Fisher’s exact test) 
making up the cohort. Health was defined as individuals that were systemically well 
and not suffering from any significant chronic or acute illness. Only two of the healthy 
controls were smokers. 
6.3.1.1 Ageing and NET Production 
Immunosenescence causes alteration in neutrophil function and is proposed as one 
of the mechanisms leading to the increased rates of sepsis with advancing age. 
There is data to suggest NET production is reduced with healthy ageing (303). We 
assessed NET production in the young and elderly to assess whether 
immunosenescence altered NET production in our participants, to replicate 
previously published data. 
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6.3.1.2. Baseline Characteristics 
Twenty healthy elderly (age>60) and seventeen young participants (age<45) had 
NETs assays performed on extracted neutrophils. The participants were well 
matched for gender (8 males vs. 10 males, p=0.330, Fisher’s exact test). A deliberate 
difference in age (32 years {28.5-35.5} vs. 70 years {66.3-77} p<0.001; Mann-
Whitney U Test) was present. 
6.3.1.3. NET formation between young & elderly healthy donors 
Neutrophils extracted from healthy elderly donors produce more NETs when 
stimulated with 25nM PMA (Sigma-Aldrich) compared to healthy young donor 
neutrophils (50411 AFUs {IQR 41407-65974 AFUs} vs. 37562 AFUs {IQR 29386-
41748 AFUs}, p=0.003, Mann-Whitney-U test). Although baseline NET formation to 
the control media was greater in the elderly controls, this did not reach statistical 
significance (8679 AFUs {IQR 6312-12114 AFUs} vs. 7085 AFUs {IQR 5341-9712 
AFUs}, p=0.217, Mann-Whitney U test). 
 
To assess whether age was a predictor of increased NET production, a Spearman’s 
correlation was performed. This demonstrated no correlation between age and the 
ability of neutrophils to generate NETs in the control media (r=0.099 95% CI -0.242-
0.418, p=0.560) or in response to stimulation with 25nM PMA (r=0.283 95% CI -0.05-
0.563, p=0.090). 
6.3.1.4. Gender and NET production 
Gender has been shown to impact upon survival from sepsis, with females having 
better outcomes compared to age-matched males. These has been attributed to the 
protective roles of oestrogen, which enhance innate immunity and the deleterious 
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role of male androgens in suppressing cell-mediated immunity (106). Therefore the 
role of gender was explored in regards to NETs from healthy donors. The same 
cohorts of healthy volunteers described above were used and separate according to 
gender, with 17 males and 20 females (p=0.642, Fisher’s exact test). The two groups 
were well matched for age (64 years (IQR 33-70years} vs. 66 years {IQR: 32-71 
years}, p=0.884, Mann-Whitney U test). No differences in NET production in relation 
to gender were observed in the control media (7595 AFUs {IQR 5603 vs. 11732 
AFUs vs. 8382 AFUs {IQR 5219 vs. 12092 AFUs} p=0.807, Mann-Whitney U test) or 
to 25nM PMA (41666 AFUs {IQR 30139-56068} vs. 41695 {IQR 32923-52206}, 
p=0.832, Mann-Whitney U). 
6.3.2. The impact of sepsis on NET production 
The previous experiments demonstrate no age or gender related effects upon NET 
formation. The studies below investigate the impact of sepsis upon NET formation 
using a cohort of twenty-nine age-matched healthy controls. Sepsis patients recruited 
were well matched for age, however a significantly greater number of males were 
recruited into the sepsis population (72.5% vs. 44.8% p=0.026, Fisher’s exact test). 
See table 6.1. 
 
Patients with sepsis showed similar baseline NET production compared to healthy 
controls (7633 AFUs {6149-7633 AFUs} vs. 7587 AFUs {5675-12058 AFUs} p=0.728, 
Mann-Whitney U). On stimulation with 25nM PMA (Sigma-Aldrich) neutrophils from 
patients with sepsis produce less NETs compared with healthy controls (28994 {IQR 
17613 – 41237} vs. 42475 {IQR 38728-57645} p<0.001, Mann-Whitney U test) on 
their admission to hospital (see figure 6.1.).  
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Table 6.1. NET production in age-matched healthy controls and sepsis patients  
 Healthy Controls Sepsis p-value 
N 29 40  
Age 67  
(37-73.5) 
65  
(43.5-74.5) 
0.880* 
Sex, male (%) 13 (44.8) 29 (72.5) 0.026# 
No. of Co-morbidities 
0 
1 
2 
3+ 
 
23 
6 
0 
0 
 
17 
14 
6 
3 
 
 
 
 
0.009Φ 
Co-morbidities§, n 
None 
CVS disease 
Respiratory disease 
Chronic renal disease 
Diabetes 
 
23 
6 
0 
0 
0 
 
17 
13 
3 
2 
11 
 
 
 
 
 
0.002Φ 
Medications§, n 
None 
Anti-hypertensive 
Beta-blocker 
Anti-platelet 
Oral hypoglycaemic 
Insulin 
Inhaled beta-agonist 
Statins 
 
23 
6 
1 
0 
0 
0 
0 
0 
 
17 
11 
6 
5 
7 
4 
3 
15 
 
 
 
 
 
 
 
 
<0.001Φ 
APACHE II  15 (8.3-19.8)  
SAPS II  32 (18.8-42)  
ICU Admission, N 
Inotropes alone 
Respiratory support 
Multi-organ support 
 13 (32.5%) 
2 
3 
8 
 
WCC (109/L)  16.8 (13.1-22.6)  
CRP (mg/L)  139.5 (81-302.5)  
SOFA Score  4 (1-7)  
Length of Stay, days  10 (6-19.5)  
Mortality, n (%)  11 (27.5%)  
Values represent the median (IQR) unless otherwise stated. * Mann-Whitney U test, 
#Fisher’s exact test and Φ χ2-test. § Patients may have more than one co-morbidity 
and be taking more than one medication   
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Figure 6.1. NET production from healthy controls and sepsis patients.  
 
NET production was evaluated to the control media (RPMI 1640 Sigma-Aldrich) and 
25nM phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich) in 29 healthy age-
matched controls and 40 patients with sepsis. Net production is represented as 
arbitrary fluorescent units (AFUs). Boxes represent the median and IQR with the 
whiskers representing a Tukey distribution. p-value from a Mann-Whitney U test.  
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6.3.2.1 Sequential Day NET Production in Patient’s with Sepsis. 
In order to investigate the dynamic changes that may occur with NET production over 
the course of the sepsis episode, NETs were analysed on sequential days. NET 
production was assessed at baseline (day1) and subsequently on day 4 and 7 where 
possible. Due to discharges home, in-hospital deaths, refusal to consent to 
venesection and inadequate neutrophils not all eligible patients had NETs performed 
at each time point. This is shown as a modified flow diagram in figure 6.2. 
 
Compared to admission, by day 7 patients overall were showing improvements in 
biochemical markers of sepsis (CRP: 139.5 {IQR 81-302.5} vs.104 {IQR 23-130} 
p=0.003 Mann-Whitney U test) and in their physiological scores (SOFA: 4 {IQR 1-7} 
vs. 0 {IQR 0-5} p=0.016 Mann-Whitney U test). Only 7 patients had persistent organ 
dysfunction by day 7 as measured by either increases or in SOFA scores or less than 
3-point reduction in SOFA.  
 
Overall a significant difference between PMA-derived NET production in sepsis 
patients on sequential days (day1, 4 and 7) and healthy controls (Kruskal-Wallis 
p<0.001) was observed. A Dunn’s post-hoc multiple comparison test, demonstrated 
that NET production (PMA-derived) on day 1 (p<0.001) and day 4 (p=0.004) was 
significantly suppressed compared to age-matched controls. Although NETs on day 7 
were lower and had not returned to baseline levels, this did not reach statistically 
significance (p=0.124). No difference in NET production in the control media was 
observed. This is illustrated in table 6.2 and in figure 6.3. 
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Figure 6.2. A modified consort diagram showing the neutrophil extracellular 
trap (NETs) experiments performed on patients with sepsis. 
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Figure 6.3: NET production in healthy controls and in patients with sepsis on 
sequential days.  
 
NET production was evaluated in 29 age-matched healthy controls and in sepsis 
patients on day 1 (n=40), day 4 (n=20) and day 7 (n=27). NET production is in 
response to 25nM phorbol-12-myristate-13-acetate (PMA, Sigma Aldrich) and is 
represented as arbitrary fluorescent units (AFUs). Bars represent the median (IQR) 
and the whiskers a Tukey distribution. A Kruskal-Wallis test demonstrated a 
significant difference (p<0.001). The p-values shown in the graph represent the 
results of the Dunn’s post-hoc test. 
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The results above demonstrate a reduction in NETosis in sepsis and shows that 
despite resolution of sepsis NET production at day 7 remains lower than levels 
observed in healthy controls. As sepsis encompasses a spectrum of illness, with a 
heterogeneous affected population and with variability in the severity of the insult a 
univariate analysis was carried out to see whether some of the principle factors that 
affect sepsis outcomes correlated with NETs in sepsis.  
 
Univariate analysis was performed with NET production to 25nM PMA (Sigma-
Aldrich) as the dependent variable and independent variables were age, sex, severity 
of sepsis (based on the SSCG definitions (96)), APACHE II and SAPS II Score, 
length of hospital stay, ICU admission and mortality. This suggested that severity of 
sepsis (Spearman’s r= -0.336, p=0.024), APACHE II (Spearman’s r=-0.333, p=0.035) 
and SAPS II (Spearman’s r= -0.408, p=0.011) correlated with suppression of NET 
formation. All these three factors are surrogates for sepsis severity, suggesting that 
the increased severity of sepsis reduces NET formation. Therefore patients were 
categorised according to sepsis severity (SSCG definition (96)) and NET formation 
further analysed. 
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6.3.2.2. Severity of Sepsis and NET Formation 
The demographics, physiological severity scores and outcomes for patients admitted 
with sepsis and severe sepsis are shown in table 6.3. 
 
Patients with sepsis without organ dysfunction showed no change in 25nM PMA 
(Sigma-Aldrich) induced NET production compared with healthy controls on 
sequential day analysis (p=0.360, Kruskal-Wallis). However patients with severe 
sepsis showed a significant and persistent reduction in PMA induced NET production 
(p<0.001, Kruskal-Wallis), with a Dunn’s post hoc analysis demonstrating that NETs 
are reduced on day1 (p<0.001) and day4 (p<0.001) compared to healthy controls.  
 
When NET production between healthy controls, sepsis patients and severe sepsis 
were compared, a significant difference was seen on each day (Kruskal-Wallis, day 
1: p<0.001, day 4: p<0.001 and day 7:p=0.036). Post-hoc analysis revealed similar 
results with the difference on each sequential day being between the healthy controls 
and severe sepsis patients (day 1: p<0.001, day 4: p<0.001 and day 7: p=0.036). 
Additionally the post-hoc analysis on day 1 between the groups demonstrated that 
patient with severe sepsis have reduced NET production compared with sepsis 
patients (p=0.022). This is illustrated in table 6.4 and in figure 6.4. 
 
Further analysis of patients with sepsis, severe sepsis and those with septic shock 
was carried out to assess whether increased severity of sepsis was associated with 
greater NET suppression. The demographics, physiological severity scores and 
outcomes for patients with severe sepsis and septic shock are shown in table 6.5.  
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A significant difference was observed between healthy controls and patients with 
sepsis, severe sepsis and septic shock on day 1 and 7 (Kruskal-Wallis, day 1: 
p<0.001 and day 7: p=0.002). Post-hoc analysis using a Dunn’s test demonstrated 
that both severe sepsis and septic shock were associated with a reduction in NETs 
compared to healthy controls on day 1. On day 7, post-hoc analysis revealed that 
only severe sepsis was associated with a reduction in NETs. No difference between 
severe sepsis and septic shock were seen. See table 6.6 and figure 6.5. 
 
These results suggest that the severity of septic insult alters NET production, with no 
effect on NETs observed in patients with sepsis compared to healthy controls. 
However in patients with severe sepsis and septic shock NET production in response 
to PMA (Sigma-Aldrich) is significantly suppressed. Recovery from sepsis was not 
associated with the return of stimulated NET formation to levels observed in healthy 
controls in patients with severe sepsis. 
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Figure 6.4. NET production in patients with sepsis and severe sepsis on 
sequential days.  
 
NET production was evaluated to 25nM phorbol-12-myristate-13acetate (PMA, 
Sigma-Aldrich) in 29 age-matched healthy controls and in patients with sepsis and 
severe sepsis on day 1 (n=12 vs. n=28), day 4 (n=7 vs. n=13) and day 7 (n=9 vs. 
n=18). NET production is represented as arbitrary fluorescent units (AFUs). The bars 
represent the median and IQR and the whiskers a Tukey distribution.  
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Figure 6.5. NET production in patients with sepsis, severe sepsis and septic 
shock on days 1 and 7.  
 
NET production was evaluated to 25nM phorbol-12-myristate-13-acetate (PMA, 
Sigma-Aldrich) in 29 healthy age-matched controls and in patients with sepsis, 
severe sepsis and septic shock on day 1 (n=12 vs. n=15 vs. n=13) and day 7 (n=9 
vs. n=9 vs. n=9). NET production is represented as arbitrary fluorescent units 
(AFUs). The bars represent the median and IQR and the whiskers a Tukey 
distribution.   
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6.3.3. The effect of simvastatin 1μM on NET production in neutrophils from 
sepsis patients. 
Neutrophils from sepsis patients incubated with 1μM simvastatin showed an increase 
in basal NET production to the control media on day 1, but this failed to reach 
significance (p=0.060, Wilcoxon signed rank test). However, by day 7, a small but 
significant increase in basal NET production was seen in cells treated with 
simvastatin (p=0.013, Wilcoxon signed rank test). No differences were observed on 
day 4 (p=0.893 Wilcoxon signed rank test). Simvastatin 1μM significantly reduced 
PMA induced NET production in neutrophils from sepsis patients on days 1 (Mann-
Whitney U, p=0.024) and 4 (Mann-Whitney U, p=0.001) and 7 (Mann-Whitney U, 
p=0.034). This is shown in table 6.7 and figure 6.6. This suggests that simvastatin 
therapy potentially increases basal NET production but further suppresses PMA 
induced NET production in sepsis patients on days 1, 4 and 7. 
 
In summary NETs are reduced in patients with increasing severity of sepsis and this 
suppression persists despite physiological resolution of sepsis. Simvastatin therapy 
in-vitro further attenuates PMA-induced NET formation in these patients, but in the 
basal state seems to slightly increase NET production.  
 
NETs production in the assay used is dependent on activity of NADPH oxidase to 
generate ROS and on the induction of neutrophil death. Alterations in either of these 
factors would affect NET production seen in these experiments. The subsequent 
experiments were performed to assess whether changes in ROS or apoptosis of 
neutrophils could explain the changes seen in sepsis patients. 
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Table 6.7. NET production in neutrophils from sepsis patients in response to 
in-vitro treatment with 1μM simvastatin.  
Neutrophils from sepsis patients on day 1, 4 and 7 were treated with or without 
simvastatin 1µM simvastatin and NET production evaluated in the control media and 
to 25nM phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich). NET production 
expressed as arbitrary fluorescence units (AFUs) with values represented as median 
(IQR) with the numbers of samples tested. p-values from a Wilcoxon signed rank 
test. The vehicle control was RPMI 1640 supplemented with an equivalent 
concentration of dimethyl sulfoxide (DMSO). 
        Vehicle Control Simvastatin 
Treated 
          p-value 
Unstimulated   
Day 1 
N=21 
7227 
(6117- 9903) 
9955 
(6615-12509) 
0.060 
Day 4 
N=16 
7341 
(6219-10542) 
7653 
(6276-9352) 
0.893 
Day 7 
N=12 
6459 
(5488-8972) 
8452 
(7677-10088) 
0.014 
25nm PMA Stimulated   
Day 1 
N=21 
32489 
(21887-47290) 
31322 
(14329-39289) 
0.024 
Day 4 
N=16 
29091 
(19939-42446) 
19789 
(10808-29402) 
0.001 
Day 7 
N=12 
38592 
(33345-67159) 
32398 
(21206-49799) 
0.034 
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Figure 6.6: NET production in response to in-vitro treatment with 1 µM 
simvastatin.  
 
Neutrophils from sepsis patients on day 1 (N=21), 4 (N=16) and 7 (N=12) were 
treated in the vehicle control (RPMI 1640 with DMSO) or with simvastatin 1µM 
simvastatin. NET production is represented as arbitrary fluorescent units (AFUs). A 
represents NET production in the vehicle control (RPMI 1640, Sigma-Aldrich). B 
represents NET production in response 25nM phorbol-12-myristate-13-acetate (PMA, 
Sigma-Aldrich). Bars represent the median and IQR with the whiskers a Tukey 
distribution. * represents a p<0.05 in a Wilcoxon signed rank test. 
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6.3.4. Reactive Oxygen Species (ROS) Production of Neutrophils 
6.3.4.1. ROS production in the healthy elderly controls and sepsis patients 
ROS production was measured in 21 healthy elderly controls and 20 patients with 
sepsis. Their demographics are shown in table 6.8. ROS production in neutrophils 
from sepsis patients in the control media showed lower levels of ROS compared to 
those from the healthy elderly controls (AUC: 9415 {IQR 5451-18696} vs. 45275 {IQR 
20865-54064} p<0.001, Mann-Whitney U test). However when neutrophils were 
stimulated with 25nM PMA (Sigma-Aldrich) and fMLP (Sigma-Aldrich) sepsis patients 
showed significant increases in ROS production compared to healthy controls. See 
table 6.8.  
6.3.4.2. Sequential changes in ROS production during sepsis 
NET production was persistently lower in sepsis patients on sequential days despite 
evidence of physiological resolution of sepsis. ROS was measured sequentially to 
assess whether elevated ROS production persisted. A significant difference was 
seen in the ROS production of patients with sepsis on sequential days compared to 
healthy controls (Kruskal-Wallis, p<0.001) in response to 25nM PMA (Sigma-Aldrich). 
A Dunn’s post-hoc test revealed that ROS production was significantly elevated in 
sepsis patients on day1 (p<0.001), day 4 (p<0.001) and day 7 (p<0.001). No 
difference was seen in response to fMLP (Sigma-Aldrich). See table 6.9. 
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Table 6.8. The demographics and the ROS production in healthy controls and 
sepsis patients 
 
Demographic details of the healthy controls and sepsis patients that donated 
neutrophils and had reactive oxygen species (ROS) measured. ROS production to 
25nM phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich) and 2.5μM fMLP are 
shown. ROS values are displayed as the percentage increase in the area under the 
curve (AUC) from baseline. *represents a Mann-Whitney U test, **represents a 
Fisher’s exact test. 
 Healthy 
Controls 
Sepsis p-value 
N 21 20  
Age, median (Range) 69.0 
(60-94) 
60.5 
(18-89) 
0.015* 
Sex, male (%) 9 (43) 10 (50) 0.758** 
PMA (% change) 
Median (IQR) 
576.3  
(482-756.3) 
3684 
(1269-10972) 
<0.001* 
fMLP (% change) 
Median (IQR) 
339.9±53.5 1084.0±283.8 0.020* 
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6.3.4.3. Correlation between ROS production and NET formation. 
As described earlier, this NETs assay is dependent on ROS production. Therefore a 
correlation between these two variables in healthy controls and in sepsis patients 
was performed. A negative correlation between ROS and NETs in both healthy 
controls (Spearman’s r=-0.477, 95% CI: -0.743 to -0.001; p=0.042) and in sepsis 
patients (Spearman’s r=-0.618, 95% CI: -0.837 to -0.228; p=0.004) was observed, 
suggesting neutrophils that produce lower ROS are able to generate more NETs (see 
figure 6.7). 
6.3.4.4. The effect of simvastatin on ROS production in sepsis neutrophils 
Simvastatin potentially reduces ROS production by direct inhibition of NADPH 
oxidase and via anti-oxidant properties. The incubation of neutrophils with 
simvastatin 1μM significantly reduced baseline ROS production (AUC: 14030 {IQR 
5565-20529} vs. 9126 {IQR 4026-20900}, p=0.023, Wilcoxon signed rank test, N=20) 
and ROS production following PMA stimulation (% change from baseline: 3625% 
{IQR 1670-9193%} vs. 2010% {IQR 1275-4108%} p=0.011 Wilcoxon signed rank 
test). See figure 6.8. 
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 Figure 6.7 Correlation between ROS production and NETs in healthy controls 
and in patients with sepsis. 
 
A shows the Spearman’s correlation between ROS production and NETs in 21 
healthy controls. B shows the Spearman’s correlation between ROS production and 
NETs in 20 sepsis patients. 
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Figure 6.8. The effect of in-vitro 1μM simvastatin on ROS production in 
neutrophils from sepsis patients stimulated with 25nM PMA.  
 
The effect of incubation of sepsis neutrophils with 1μM simvastatin for 40 minutes on 
reactive oxygen species (ROS) production in response to stimulation with 25nM 
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich). ROS is measured as the 
percentage change in the area under the curve from baseline. The bars represent the 
median and IQR and the whiskers a Tukey distribution. p-value is from a Wilcoxon-
signed rank test, where N=20. 
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6.3.5. Apoptosis of Neutrophils 
Apoptosis was measured in neutrophils from healthy and sepsis donor on immediate 
isolation from whole blood (approximately 90 minutes). Apoptosis experiments were 
repeated at 4 hours, as this directly corresponded to the time at which NET formation 
was assessed. A 24-hour apoptosis measurement was also performed to determine 
the impact of sepsis on neutrophil apoptosis. 
6.3.5.1. Apoptosis in Healthy Donor Neutrophils 
Neutrophils from 19 healthy donors had apoptosis experiments performed. The mean 
age of these healthy donors was 43.4 years (range 21-71 years) with   9 males and 
10 females. At baseline almost all the neutrophils extracted were alive (92.6%) with a 
5.5% shift of neutrophils into early apoptosis (Annexin V positive) by 4 hours. At 24 
hours the vast majority of neutrophils were in early or late apoptosis (72.7% and 
21.1% respectively) with only 4.7% of neutrophils still alive. Very few cells underwent 
necrosis in healthy donors (0.5% vs. 1.4% vs. 1.6%). See figure 6.9. No differences 
were observed in apoptosis when corrected for age (young vs. old) and for sex (male 
vs. females). 
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Figure 6.9. Neutrophil apoptosis in healthy donors.  
 
Neutrophil apoptosis in 19 healthy controls measured at the time of isolation, at 4 
hours and 24 hours after isolation by flow cytometry. The y-axis represents the 
percentage of cells alive (negative for Annexin V and Sytox Blue), in early apoptosis 
(positive for Annexin V) and those in late apoptosis (positive for Annexin V and Sytox 
Blue). The bars represent the median with the error bars the IQR.  
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6.3.5.2. Impact of sepsis on neutrophil apoptosis 
Apoptosis from 17 patients with sepsis was measured and compared to the results 
from healthy controls. At the time of neutrophil isolation, sepsis patients had fewer 
“alive” cells (79.5% {IQR 70.7-83.3%} vs. 92.3% {IQR 90.4-92.3%} p<0.001, Mann-
Whitney U test) compared to healthy controls. A greater numbers of the neutrophils 
were in early (18.8% {IQR 12-23.2%} vs. 5.3% {IQR 3.9-6.7%} p<0.001, Mann-
Whitney U test) and late apoptosis (2.8% {IQR 1.0-3.6%} vs. 1.2% {IQR 0.5-2.1%}. 
p=0.03, Mann-Whitney U). See figure 6.10. 
 
The rate of apoptosis was calculated by taking the percentage of Annexin V positive 
neutrophils at selected time point after isolation away from the percentage of Annexin 
V positive neutrophils at the time of isolation. This demonstrated no significant 
change in the rate of apoptosis in sepsis patients compared to healthy controls at 
4hours (3.4% vs. 5.2% p=0.230 Mann-Whitney U).  
 
At 24hours a significantly greater number of neutrophils from sepsis patients were 
alive (38.2% {IQR 19.2-48.5%} vs. 3.2% {IQR 1.5-7.3%} p<0.001, Mann-Whitney U). 
Patients with sepsis had fewer neutrophils in early (53.0% {IQR 33.2-62.6} vs. 73.6% 
{IQR 65.7-88%} p=0.002 Mann-Whitney U) and late apoptosis (10.1%  (IQR 6.9-
19.4%} vs. 21.6% {IQR 15.7-26.4%} p=0.027, Mann-Whitney U). 
  
These results suggest that in patients with sepsis a pool of apoptotic neutrophils are 
circulating within the systemic circulation. However the viable neutrophils seem to be 
programmed to resist apoptosis and have prolonged ex-vivo survival. NETs are 
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produced from viable cells, and the assay used with PMA induces NETosis. It was 
hypothesised that the reduction in NETs may be related to the increased rate of 
apoptosis on isolation. 
 
A correlation between the number of “alive” cells at 4 hours and the NET production 
was performed to test this. The 4 hours apoptosis time point was selected to reflect 
the point at which NETs were measured following isolation. A positive correlation 
between the number of neutrophils of "alive" cells at 4hours and NETs (Spearman’s 
r=0.500, 95% CI= 0.01-0.796, p=0.043) was found suggesting that the reduced 
NETosis in sepsis patients may be related to a reduced number of circulating "alive" 
cells. See figure 6.11  
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Figure 6.10. Neutrophil apoptosis in healthy donors and sepsis patients.  
 
Neutrophil apoptosis in 19 healthy controls and 17 sepsis patients measured at the 
time of isolation, at 4 hours and 24 hours after isolation by flow cytometry. The y-axis 
represents the percentage of cells alive and in early apoptosis (positive for Annexin 
V). The bars represent the median with the error bars the IQR. *represent a p<0.05 
between the corresponding time points for the healthy controls and sepsis patients.
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Figure 6.11. Correlation between "alive" neutrophils and NET production in 
sepsis patients.  
 
Scatter graph showing the relationship between NET production in 17 sepsis patients 
and the percentage of "alive" neutrophils at 4 hours after isolation. A linear trend line 
is shown, with a “r” and p-value represented by a Spearman’s correlation co-efficient.  
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6.3.6. Cell surface receptor expression. 
The cell surface expression of CD16 and the activation markers CD45, CD14, CD63 
and the expression were measured in healthy controls and sepsis patients.  
6.3.6.1. CD16 expression is reduced in sepsis 
CD16 binds IgG coated bacteria and is in involved in the phagocytosis of bacteria. It 
can also be used as a marker of neutrophil age and apoptosis with recently mobilised 
neutrophils and apoptotic cells expressing low levels of CD16. As previously reported 
in section 5.3.5.1, the overall number of cells expressing CD16 was unchanged, 
however overall receptor expression, represented by the MFI, was significantly 
reduced (59682 AFUs {IQR 40799-73306 AFUs} vs. 77791 AFUs {IQR 68081-
111644 AFUs} p=0.014 Mann-Whitney U test) in sepsis patients. 
6.3.6.2. Neutrophils in sepsis showed increased expression of CD45, CD14 and 
CD63. 
The expression of key activation markers was significantly increased in sepsis 
patients compared to healthy controls. The number of neutrophils expressing CD45 
in sepsis patients was significantly increased (99.9% {IQR 99.7-100.0%} vs. 99.6% 
{IQR 95.4-99.9%} p=0.011, Mann Whitney U) as was the median MFI (32808 AFUs 
{IQR 20685 vs. 45370 AFUs} vs. 21988 AFUs {IQR 14161 vs. 30313 AFUs} p=0.038 
Mann Whitney U) representing the number of receptors per cell. As reported in 
section 5.3.5.3 and 5.3.5.4 the percentage of cells expressing CD14 (35.1% {IQR 
17.8-49.3} vs. 4.6% {IQR 3.5-12.3%}. p<0.001 Mann Whitney U) and CD63 (77.1% 
{IQR 53.9-94.2%} vs. 45.5% {IQR 29.1-68.5%} p=0.040, Mann Whitney U) was 
significantly increased in sepsis but no significant changes in the MFI were observed. 
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6.4. Discussion 
The chapter describes NET production in healthy donor neutrophils using PMA and 
demonstrated that increasing age is associated with increased NET formation. 
Sepsis resulted in a reduction in NET production with persistent suppression of NETs 
despite sepsis resolution. The severity of the sepsis insult was found to have 
significant relevance, with severe sepsis and septic shock resulting in reduced NET 
production compared to both healthy controls and those patients with “mild” sepsis. 
Finally the in-vitro simvastatin therapy increased basal NET production, but further 
reduced NET production in response to 25nM PMA in sepsis patients. These finding 
are the opposite to the original hypothesis that predicted an increase in NET 
production in response to sepsis and that in-vitro simvastatin therapy would cause a 
further rise in NET production.  
 
NET production results in the controlled release of chromatin and histones from 
neutrophils. NET release can occur through oxidant-dependent mechanisms that are 
closely linked with ROS production and eventual cell death (NETosis). However, 
oxidant-independent mechanisms of NET release have been demonstrated that do 
not result in cell death and allow the neutrophils to continue with their other anti-
microbial functions. The assay used in these experiments to quantify NET production 
is dependent upon NADPH ROS production resulting in the eventual death of the cell 
via NETosis. Therefore any changes seen in NETs in healthy controls and sepsis 
patients must be due to either a reduction in the number of alive cells, alterations in 
ROS and/or changes in mechanisms regulating cell death via NETosis. Therefore 
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ROS generation and apoptosis in neutrophils was investigated to identify potential 
mechanisms involved in the changes seen in NETs (47, 59, 211, 365). 
 
It is proposed that the increased NET production observed in the elderly controls may 
lead to exaggerated endothelial damage, precipitate organ dysfunction and partially 
explain the increased severity of sepsis observed in the elderly. Current evidence 
links ageing with a progressive increase in ROS, with excessive ROS being linked to 
many age-related diseases, such as neurodegenerative diseases, cardiomyopathy 
and cancers. Although these experiments did not assess ROS production in young 
controls, it would suggest that the increase in NETs with ageing might be associated 
with increased ROS generation (366, 367). 
 
These results and those from previous studies of ROS production in the elderly are in 
contrast to Hazeldine et al who observed decreases in both NETs and ROS with age 
to CXCL-8 and LPS following neutrophil priming with TNF-α. They proposed the 
opposite, suggesting reduced ROS in the elderly leads to reduced NETosis and thus 
may account for poorer bacterial clearance and the increased rates of infection in the 
elderly. The differences could be related to the small sample size in Hazeldine et al’s 
study (18 in total) compared with 37 participants used in these experiments. 
Additionally, the use of TNF-α to prime neutrophils may have had significant 
influences on NET production as it activates PAD4 citrullination, a key step in the 
eventual release of NETs. The age-related differences were observed in response to 
PMA stimulation in these experiments, an effect not observed in Hazeldine’s study. 
The fluorometric methods used in these experiments and by Hazeldine et al for NET 
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generation have been validated using primarily PMA, with CXCL-8 and LPS derived 
NETs requiring microscopic techniques to detect the low levels of NETs generated 
(67, 75, 76, 362). 
 
The ability of neutrophils to generate NETs at the sites of infection attenuates the 
spread of infection by containing and elimination of bacteria, fungi and viruses. 
Murine models of infection using caecal ligation have demonstrated that mice 
treatment with recombinant DNAse to deplete NETs have an increased mortality and 
increased the severity of sepsis. However widespread systemic NET release may 
trap bacteria in the microvasculature but at the expense of endothelial injury. The role 
of NETosis in sepsis remains poorly characterised with this study being the first show 
a persistent reduction in NETosis with sepsis (16, 210, 214, 215, 368). 
 
A study in trauma patients revealed conflicting results to those described here, with 
inflammation induced by trauma causing an increased levels of NETs compared to 
healthy controls as opposed to the suppression seen in these experiments. They also 
showed NET production was increased in trauma patients who subsequently develop 
sepsis. Although trauma induces an inflammatory response similar to sepsis, it is 
difficult to translate results in trauma to sepsis, as the populations affected are 
significantly different, with trauma patients being younger and healthier. In addition 
the timing of the insult is much clearer compared with infections, which have a more 
insidious onset (212, 369).  
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The proposed mechanism based on the mechanistic studies of ROS, apoptosis and 
cell surface marking suggest that the reduction in NETosis is multifactorial with 
altered apoptosis, increased neutrophil activation (increased CD45, CD14 and 
CD63), ROS and immature neutrophils all contributing to the effects seen. The 
apoptosis experiments demonstrated reduced viability of freshly isolated neutrophils 
in patients with sepsis with a greater proportion of cells in the early stages of 
apoptosis. Sequential analysis of apoptosis following isolation showed prolonged 
neutrophil survival ex-vivo perhaps due the presence of pro-survival signals and the 
immaturity of the isolated neutrophils. The reduced expression of CD16 seen in 
neutrophils from sepsis may provide evidence to support the immature pool of 
neutrophils as this marker is reduced in these cells (175, 192, 365, 370, 371). 
 
Neutrophils from sepsis patients showed greater ROS production with cell surface 
markers indicating increased activation. It would have been expected that an 
increase in NETosis would be observed as the two processes are interlinked. 
However, a negative correlation was observed between NET release and ROS 
production in the healthy elderly controls and in sepsis patients suggesting that 
circulating neutrophils generating high levels of ROS in response to PMA produce 
fewer NETs. This may suggest that activated neutrophils, such as those isolated in 
sepsis, maintain their ability to phagocytose bacteria and generate ROS but resist 
NETosis and apoptosis, which ultimately results in their death.  
 
There is emerging evidence that not all circulating neutrophils have the capability to 
produce NETs with some authors suggesting that only 25% of the circulating 
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neutrophil pool are programmed to be NET producers, termed suicidal neutrophils. 
The remaining neutrophils are primarily programmed to carry out the traditional 
neutrophil functions but may produce NETs via an oxidant independent mechanism. 
This may also explain the reduction in NET formation observed in sepsis patients’ 
with the isolated pool programmed to live longer and generate NETs independent of 
NADPH oxidase. The suicidal neutrophils may well have already delivered their 
antimicrobial load and died by the time patients have presented to hospital with 
sepsis (370). 
 
The treatment of neutrophils from sepsis patients with 1μM simvastatin attenuated 
NET production further with this effect persisting to day 7 in response to PMA. The 
reduction seen in NETs was coupled with a reduction observed in ROS production 
with simvastatin treatment. Simvastatin reduces oxidative stress and inhibits NADPH 
oxidase thereby reducing ROS. This provides a mechanism for the reduced NETosis 
observed with simvastatin and is supported by the literature that suggests inhibition 
of ROS and NADPH oxidase leads to a reduction in NET formation. (363). 
 
The incubation of unstimulated neutrophils with 1μM simvastatin raised basal NET 
production. This may support theories of oxidant independent NET release, as cells 
in the basal state did not produce large amount of ROS, yet NET release was 
increased. Statins have been shown to increase NETosis via an oxidant independent 
mechanism. These mechanisms were not investigated here and thus the potential of 
statins to actually increase NETosis to other stimuli cannot be commented upon 
(364). 
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This is in contrary to the results of Chow et al who demonstrated that 10μM 
simvastatin induced greater NET formation in in-vitro, ex-vivo and in-vivo models of 
sepsis. They suggested that statins were able to induce NET generation in an 
NADPH-independent manner and that enhanced NET production by statins was 
associated with reduced inflammation at sites of sepsis and improved bacterial 
clearance (364).  
 
However several key differences arise between the two studies. Firstly, the 
populations were markedly differently as our study used patients with established 
sepsis and age-matched controls making the sample representative. Secondly, the 
dose of simvastatin used was therapeutically relevant in this study with the 1μM dose 
corresponding to 40-80mg simvastatin, the upper dosage limit of the drug. This dose 
has been shown in clinical trial of sepsis to be most efficacious and was the dose 
used in the HARP-2 trial (285).  
 
Thirdly, the methods used by Chow to generate NETs involved culturing neutrophils 
overnight in the presence of statin and PMA. No apoptosis experiments were 
reported and therefore changes in NETosis could not be excluded due to cellular 
necrosis or dysregulated apoptosis. 
 
Finally, the murine of model of sepsis, pre-treated mice with a diet of statin prior to 
inducing pneumonia with S.Aureus. This reflects previous research that 
demonstrates that pre-treatment with statins modulate the inflammatory response 
and leads to better outcomes, but does not reflect the situation of whether statins can 
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be used acutely to treat patients with established sepsis. The S.Aureus model of 
pneumonia is also not reflective of the common pathogens that cause pneumonia in 
humans and S.Aureus is known to induce rapid NETs through an oxidant 
independent manner (364). 
 
Taking this study and Chow’s study together it can be postulated that the early rapid 
release of NETs promoted by statins may be beneficial in containing infections at 
their source and preventing their dissemination. However as infection progresses to 
sepsis and MODS a reduction in systemic NET production would be beneficial to 
prevent further organ damage. Thus statins may act by more than one mechanism to 
modulate NET release in sepsis and thereby reduce the morbidity and mortality 
associated with it. 
 
A key limitation in the methods used to assess NETosis was the use of a fluorometric 
technique. This assay allows the measurement of “cell-free” DNA, which is thought to 
relate directly to NETs, as the cells used are freshly isolated and have a high purity. 
Therefore the presumption is that any “cell-free” DNA should arise only from its 
release by neutrophils. This assay has been validated in conjunction with microscopy 
to confirm that DNA release is related to NET formation. However future experiments 
should incorporate both methods to add validity to any findings (16, 303, 372, 373)  
 
In conclusion this study shows that immunosenescence is associated with increased 
NET formation compared to healthy young people and may be exacerbate organ 
dysfunction in sepsis and contribute to the increased incidence of sepsis in the 
Page | 239 
 
elderly. Sepsis reduces NET production with resolution of sepsis not associated with 
recovery of NET formation. The suppression of NETosis in sepsis is perhaps related 
to a pro-inflammatory phenotype adopted by neutrophils, with enhanced ROS 
production, prolonged survival and a mobilisation of neutrophils from the bone 
marrow resulting in an immature circulating pool.  
 
Statins increase basal NET production possible via an oxidant independent 
mechanism. However, they further attenuate NET production to PMA in sepsis via 
inhibition of NADPH oxidase and consequently ROS and by doing so may prevent 
micro-vascular damage. 
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Chapter 7. General Discussion and Thesis 
Conclusions 
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Sepsis is an important global health issue and is one of the leading of cause of 
death. The incidence of sepsis continues to increase with an ageing population being 
partially attributed to the rise. Age is considered an independent risk factor for the 
development of sepsis and outcomes with inflama-ageing, immunosenescence and 
the reduced functional status of the elderly being implicated (70, 80, 91, 97, 104, 
374).  
 
Infection triggers a host response designed to contain and eliminate pathogens whilst 
minimising host damage. In sepsis an exaggerated SIRS and CARS responses 
occurs leading to the development of organ dysfunction and the eventual death of the 
host. Targeting the immune dysfunction in sepsis remains a focus for medical 
research with no successful immune-modulatory treatments currently available (91, 
96, 109, 111, 128).  
 
At the time this thesis was developed there was interest in statins as immune 
modulators in sepsis, with studies suggesting that statin therapy prior to the 
development of sepsis improves outcomes. The precise mechanism underpinning 
these beneficial effects are still unknown, however statins exert potent anti-
inflammatory actions in addition to their anti-cholesterol effects. Statins are thought to 
attenuate neutrophil responses, by reducing migration into inflamed tissues, 
decreasing the production of pro-inflammatory cytokines and reducing neutrophil 
activation and ROS production (152, 237, 241, 245). 
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Research from within our group has demonstrated an age-related decline in 
neutrophil migration that could be improved with in-vitro simvastatin exposure. In 
addition the ASEPSIS trial (atorvastatin for the prevention of sepsis progression) 
showed that treatment with 40mg atorvastatin to statin-naïve patients with sepsis (no 
organ dysfunction) reduced the development of organ failure. This trial however 
failed to demonstrate any significant improvements in markers of inflammation (CRP, 
IL-6, TNF-α) with statin therapy, suggesting perhaps other mechanism were involved. 
It was on the back of these finding that the experiments within this thesis were 
designed to investigate the in-vivo and in-vitro effects of simvastatin of neutrophil 
function in healthy ageing and in sepsis (86, 375). 
7.1. Neutrophil dysfunction in sepsis 
Neutrophils are key mediators of sepsis intimately involved in containing and 
eliminating pathogens as well as resolving inflammation. However a balanced 
response is required with poor migration and ineffective anti-microbial actions 
causing dissemination of the bacteria, whilst excessive neutrophil recruitment to sites 
of infection may exacerbate host damage(1, 3).  
 
Neutrophil functions are thought to decline with increasing age, with poor migration, 
reduced phagocytosis, increased degranulation and ROS production and decreased 
NET release documented. It was hypothesised that sepsis would exaggerate age-
related innate immune dysfunctions of neutrophils. To assess this, the neutrophil 
functions of a cohort of healthy elderly subjects were compared with patients with 
sepsis, thus the control group, represented an “at risk” cohort allowing improved 
comparisons with the sepsis patients (78, 82, 86, 87, 307). 
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In summary, sepsis exaggerated immunosenescence by creating a state of 
neutrophil paralysis with reduced neutrophil migration. In contrast to the original 
hypothesis, neutrophils from sepsis patients generated greater ROS, demonstrated 
enhanced phagocytosis of E.Coli (no changes in S.Aureus) and released fewer NETs 
in response to PMA stimulation compared to healthy controls. Apoptosis experiments 
suggested that neutrophils in sepsis patients have delayed late apoptosis.  
 
Potential explanations to these findings are detailed below: 
 
Systemic inflammation is associated with prolonged neutrophil survival mediated by 
high concentrations of circulating G-CSF, GM-CSF, TNF-α and LPS. The potential 
delayed apoptosis results in a pool of “older” activated neutrophils circulating for 2-5 
days (192, 198, 199). Ideally these neutrophils should have migrated to the sites of 
infection, however the prolonged exposure to cytokines and bacterial products is 
thought to cause neutrophil “paralysis” and migratory failure via an increased TLR-4 
and -2 expression and the internalisation of key chemokine receptors (CXCR-1 and 
CXCR-2) (165, 166). Although these cells are unable to migrate they are activated, 
with migration experiments demonstrating increased neutrophil adhesion perhaps via 
an up-regulation of CD18 (Mac-1), whilst expression of activation markers was also 
significantly raised in sepsis (CD63, CD14 and CD45). In these experiments the 
increased expression in sepsis of CD63 in systemic circulating neutrophils is of 
particular significance as it suggests that degranulation of neutrophils is occurring in 
the systemic circulation without further stimulation. The overall consequences of this 
may be that activated neutrophils with prolonged life spans (delayed apoptosis) are 
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“trapped” within the systemic circulation and aggregate in the small blood vessels. 
These neutrophils continue to release MPO and NE (de-granulation), extracellular 
ROS and NETS in an uncontrolled manner resulting in collateral tissue damage and 
distal tissue hypoxia with resultant organ dysfunction that is the hallmark of sepsis (3, 
156, 165, 166, 206, 214, 376). 
 
Another potential explanation is a pool of immature band cells. An infectious insult 
results in rapid migration of neutrophils out of the systemic circulation into the 
infected sites. In response, the bone marrow releases large numbers of neutrophils 
into the systemic circulation, many of which have not fully matured. These immature 
bands cells are a well-recognised phenotype in sepsis and inflammation and can 
account for up to 50% of circulating neutrophils during sepsis (175, 360).  
 
Although band forms were not directly measured in these experiments the reduced 
expression of CD16 (a surrogate marker for neutrophil age) suggested the presence 
of an immature phenotype. Although reduced expression may also be an indication 
of neutrophil activation with lower expression related to receptor shedding. Immature 
neutrophils demonstrate reduced efficacy for chemotaxis and phagocytosis 
compared to mature neutrophils. The data in these experiments suggest maintained, 
if not up-regulated phagocytosis (to E.Coli) in the context of impaired migration. The 
preserved phagocytosis may be related to heightened activation of neutrophils (as 
described above) that may overcome the effects of maturity on neutrophil phagocytic 
function (175, 377-379).  
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There is emerging evidence that neutrophils in infection and inflammation are 
capable of migrating from infected/inflamed tissues back into the systemic circulation 
in a process known as reverse transmigration.  Although the potential role for a 
reverse transmigrated phenotype as a driver of neutrophil dysfunction in sepsis was 
not investigated in these experiments, the phenomenon may partially explain the 
increased activation (ROS and phagocytosis) observed in neutrophils from sepsis 
patients, as neutrophils that reverse transmigrate have prolonged life spans and are 
pro-inflammatory. They have been suggested as drivers of distal organ damage in 
sepsis as they circulate releasing ROS, de-granulating and phagocytosing foreign 
particles, whilst disseminating inflammation. This may further exacerbate the problem 
of “paralysed” and activated neutrophils in the systemic circulation (37, 227).  
 
The phagocytosis experiments performed generated interesting results, which were 
bacterial species specific. Similar to the results demonstrated in the sepsis cohort, 
phagocytic function in neutrophils following traumatic SIRS has been shown to be 
affect by bacterial species, with enhanced phagocytosis of E.Coli and maintained 
S.Aureus previously shown. Sepsis neutrophils express greater CD14 and are 
thought to be “primed” by the inflammatory process and may account for the 
increased phagocytosis of gram-negative bacteria in infections (169, 171, 173, 344, 
350, 354, 380). 
 
Experiments involving phagocytosis have demonstrated both increased and 
decreased bacterial ingestion in sepsis (169, 344, 381). Phagocytic ability may be 
increased due to neutrophil activation via the up-regulation of phagocytic receptor 
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expression. However what is less clear in these previous studies is the efficacy of 
bacterial killing following ingestion. These experiments suggest that intra-cellular 
mechanisms of bacterial killing are preserved in sepsis, as the bacteria used in the 
pHrodo (Invitrogen) assay only fluorescence once acidification of the phagolysosome 
occurs. This is a key process in the intracellular mechanisms leading to pathogen 
elimination (169, 344). 
 
In contrast to the original hypothesis neutrophils from the healthy elderly showed 
greater NETs compared to young controls in response to PMA. In sepsis, NET 
release to PMA was attenuated with the severity of sepsis corresponding to greater 
suppression.  The process of NETosis has been closely linked with ROS production 
in some studies, however the experiments here suggested that despite increased 
ROS a decrease in NETs was observed. NETosis is a terminal event for the 
neutrophil and perhaps the reduction in NETs could be explained by the activated 
pro-inflammatory phenotype (increased ROS and phagocytosis) that neutrophils 
adopt with a prolonged survival. However, the model for NETosis doesn’t reflect 
conditions in-vivo, with the biology of NET formation found to be complex with 
cytokines, platelets and bacteria all activating neutrophils to produce NETs. It seems 
probable that systemic NET release in the microvasculature occurs in response to 
various stimuli in an oxidant-dependent and independent manner. This may provide a 
mechanism of killing bacteria in the systemic circulation, however if these occur in 
areas where neutrophils have become “trapped” the NETs may contribute to the 
endothelial damage that results (8, 16, 59, 182, 192, 214, 215, 224, 363, 365, 368, 
382). 
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7.2. The use of simvastatin to modulate neutrophil function. 
The experiments detailed within the thesis suggested that in the healthy elderly 
aberrant migration could be improved by in-vivo 80mg simvastatin. Additionally, 
simvastatin did not have deleterious effects on other neutrophil functions and was 
well tolerated. These beneficial effects of simvastatin were not replicated in the in-
vitro experiments in established sepsis however, as neutrophil migration and 
phagocytosis was not modulated by simvastatin, whilst ROS production and NETosis 
was attenuated. 
 
The precise mechanism for the improved migration in the elderly was not 
investigated, however in-vitro work in the healthy elderly suggests that increased 
PI3K expression is associated with aberrant migration and the selective inhibition of 
P13Kγ and P13Kδ improved the accuracy of migration to levels similar to those 
observed in the young. This may be due to increased actin formation within the 
leading edge of the pseudopod and hence improve migratory accuracy. Simvastatin 
potentially inhibits PI3K activity and this may account for the improvements observed 
in neutrophil migration in the healthy elderly study (86, 383, 384).  
 
In sepsis, neutrophil migration may be unresponsive to modulation due to the 
desensitisation and internalisation of chemokine receptors from the cytokine storm. 
These experiments suggested that simvastatin reduced neutrophil adhesion (in-vivo 
and in-vitro), ROS production and NET formation (in-vitro only). These effects of 
simvastatin may well lead to decreased aggregation of neutrophils within vascular 
beds leading to improved tissue perfusion and reduced endothelial damage. 
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Additionally the beneficial effects of statins on other pathways in sepsis, such as TLR 
function, reduction in iNOS and cytokine release may stabilise the endothelium to 
reduce tissue hypoxia, thereby improving some of the key pathways associated with 
sepsis-related organ dysfunction (154, 156, 230, 273, 312, 385). 
 
Since the conception of the thesis, the use of simvastatin to improve outcomes in 
sepsis has been investigated in a number of clinical trials. All, with the exception of 
the ASEPSIS trial, have failed to show any benefit of acute statin therapy in the 
critically ill. Kruger et al used 20mg of atorvastatin to treat patients with severe sepsis 
admitted to ICU in a double-blinded randomised multi-centred Australian study. They 
found no benefit in the acute administration of atorvastatin in critically ill patients with 
sepsis. However pre-defined subgroup analysis of pre-existing statin users 
suggested that continuation of therapy during critical illness was associated with a 
reduced 28-day mortality, adding weight to evidence that statin administration prior to 
critical illness confers protection from death (286, 287, 292, 375, 386, 387).  
 
Papazian et al investigated the use of 60mg simvastatin in reducing mortality from 
ventilator-associated pneumonia (STATIN-VAP trial). The trial was terminated early 
due to a higher mortality in the simvastatin group, although this was not significant. 
Despite the slight increase in mortality, simvastatin was still well tolerated by patients, 
with no rise in transaminases or CK noted between placebo and simvastatin groups. 
The HARP-2 study and SAILS studies which investigate the use of 80mg simvastatin 
and 20mg rosuvastatin in ARDS respectively suggested that statin therapy did not 
improve outcomes. In fact SAILS reported an increase in the incidence of hepatic 
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and renal dysfunction amongst statin users, whilst HARP-2 reported no adverse side 
effects with high dose simvastatin (287, 386, 387). 
 
These large RCTs in patients with high disease severity suggest that in established 
severe sepsis statins are not beneficial. However the results from the healthy elderly 
trial reported here (Chapter 3) and the ASEPSIS trial suggest that perhaps early, or 
even pre-emptive therapy with simvastatin in high-risk groups, such as the elderly, 
may be beneficial in improving outcomes from sepsis. The vital issue regarding 
timing of statin therapy in infections is further highlighted by in-vitro data from 
patients with pneumonia (without sepsis) that suggests simvastatin improves 
migratory accuracy of neutrophils in these patients (personal communication with Dr 
Elizabeth Sapey), whilst in patients with established sepsis simvastatin had no effect 
(286, 287, 375, 386, 387). 
 
An emerging theory in the treatment of sepsis is the notion of individualised immune 
modulating therapy based on the phase of inflammation patients’ are experiencing.  
Classically sepsis can lead to exaggerated SIRS responses characterised by high 
levels of pro-inflammatory cytokines that lead to vasodilatory shock, MOF and death. 
The resolution of inflammation is dependent on a subsequent CARS occurring to re-
establish immune homeostasis. However, there is now increasing evidence that 
patients hospitalised with sepsis suffer from hypo-immune response (exaggerated 
CARS) and it is often significant immunosuppression that leads to eventual death 
from sepsis. The exact mechanisms that determine individual responses in uncertain 
with potential genetic influences being implicated (91, 108, 128, 144, 388, 389). 
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As sepsis encompasses a heterogeneous population, the immune response is likely 
to be significantly different. This may account for some of the failures in recent ICU 
based trials targeting immune modulation. Patients who could be identified as 
suffering from exaggerated SIRS responses may benefit from immune-suppressive 
therapies, such as statins, whilst those with exaggerated CARS response may 
benefit from immune-stimulatory therapies (e.g. G-CSF) (109, 388, 390-393). 
 
7.3. Limitations 
The functional neutrophil assays and the experimental designs included within this 
thesis had several limitations, which are described below and may limit the 
generalisability of the findings. 
 
The definitions of sepsis and severe sepsis remain non-specific (estimated at 58-
61%), resulting in many hospitalised patients being classified as suffering from 
sepsis, as many will have a degree of inflammation. This in combination with poor 
biomarkers for sepsis and low yields from microbiological cultures may have resulted 
in some of the recruited patients not suffering from a primary infectious insult (100, 
394, 395). 
 
The non-specific nature of the definitions was reflected in the high incidence of 
severe sepsis in the recruited (68.9%) patients. Despite this high incidence, rates of 
admission to ICU were low (31.1%) with few patients requiring organ support 
(median SOFA score 4) and subsequently, mortality was low at 24.4%. Patients were 
classified into sepsis severity on the basis of their worst physiological and 
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biochemical parameters within 48hours of their admission, resulting in many being 
classified into the severe sepsis category based on individual parameters (e.g. INR 
>1.5, lactate >2mmol/L, systolic blood pressure <90). These parameters rapidly 
resolved with appropriate treatment but also did not generate a SOFA score. This 
may accounts for the high incidence of severe sepsis with a low mortality in these 
experiments. Future studies should try and define severe sepsis more precisely and 
perhaps, the use of a persistent or worsening organ dysfunction (measured by the 
delta SOFA) could be employed (396, 397). 
 
Patients with sepsis reflected the heterogeneous population that is hospitalised with 
acute infections. The patients with sepsis were well matched for age and gender 
compared to the controls, however had a greater number of pre-existing health 
conditions and subsequently were taking a greater number of concomitant 
medications. The commonest conditions were diabetes mellitus and hypertension, 
with patients receiving a variety of oral hypogylcaemics, insulin and anti-hypertensive 
agents to manage their conditions. What is unclear is whether these patients were 
predisposed to sepsis due to constitutive neutrophil defects, or whether their sepsis 
caused the effects observed. Additionally many drugs used to treat diabetes, such as 
Metformin and the PPAR-γ inhibitors, and those used to treat hypertension (e.g. 
aspirin) may also neutrophil functions and may modulate pathophysiology of sepsis. 
Future neutrophil functional studies in patients with sepsis should be designed to 
analyse patients’ neutrophil function following complete recovery from their illness. 
This would overcome the potential confounding effects of co-morbid conditions and 
medications, allowing patients to act as their own controls. 
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Finally the neutrophil function assays performed on the sepsis cohort were all 
performed un-blinded. This has the potential to introduce both experimenter and 
observer bias to the results obtained. Due to the nature of these assays, it would be 
difficult to completely eliminate these. However, future studies should try and blind 
the investigators performing the assays as much as possible to avoid these biases 
potentially affecting the results generated. 
7.4. Future Work 
This thesis characterised many of the features of neutrophil function in sepsis and 
explored the role of statins in modulating them. However many further studies are 
required to investigate underlying mechanism for the changes observed in sepsis 
and to further assess the potential of statins in sepsis. 
1. Mechanism that up-regulate phagocytosis in sepsis should be explored by 
investigating the role of intra-cellular signalling mechanisms. Potential 
mechanistic pathways would be the potential role of PI3K signalling in 
phagocytosis in both health and in sepsis. Other bacterial species that are 
common sources of both community (Streptococcus pneumonia, H. Influenzae) 
and nosocomial (Klebsiella pneumonia) infections should be investigated to 
assess whether bacterial species contribute to alterations in neutrophil 
phagocytosis.   
2. The reduction in NETosis in sepsis requires further work to determine underlying 
mechanisms and their potential implication in bacterial clearance and tissue 
damage. The differentiation between oxidant-dependent and independent 
mechanisms of NET release in sepsis should be identified. The potential of time-
lapse video microscopy in directly visualising rapid NET production to live bacteria 
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and other inflammatory stimuli should be explored to determine oxidant-
independent NETosis. The use of DPI and other NADPH-oxidase inhibitors 
should be investigated to determine their role in oxidant dependent NETosis. 
Additionally the activity of PAD4 in sepsis should be investigated and correlated 
with NET release, as this is a key mechanistic step in citrullation and subsequent 
NET release. NETosis should be quantified using both a fluorometric technique 
and light microscopy to visualise NETs. The stimulants used should include 
physiologically relevant stimuli, such as TNF-α, CXCL-6 and -8, and live gram-
positive and gram-negative bacteria. 
3. Patients with pneumonia should have functional neutrophil assays performed 
from neutrophils from blood and BAL to characterise the function of transmigrated 
neutrophils in comparison to circulating neutrophils.  
4.  The function of healthy neutrophils from old and young donors should be 
assessed following incubation in plasma from sepsis patients. These experiments 
may help determine the influence of the inflammatory environment on neutrophil 
functions. 
5. The use of 80mg simvastatin should be investigated in the context of infections in 
the elderly. A study recruiting elderly patients admitted to hospital with an 
infection without significant organ dysfunction should help answer whether statins 
have a role in treating sepsis. 
6. A future sepsis study should be designed to determine whether it is possible to 
determine which phase of sepsis patients are in, i.e.: SIRS or CARS. Initially 
experiments should commence with cytokine profiling to assess whether 
classification of patients into immune response sub-types is possible. These 
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studies may eventually lead to the development of individualised sepsis 
treatments in the future. 
7.4. Conclusion 
The experiments here suggest that neutrophils in sepsis display a specific 
phenotype, with a failure of migration observed in combination with a retained 
phagocytic capacity and a propensity to de-granulate and generate high ROS, whilst 
NETosis and apoptosis are both suppressed. This suggests that neutrophils 
contribute to the pathogenesis of organ dysfunction in sepsis by being “stranded” in 
the systemic circulation unable to reach sites the sites of infection, thereby allowing 
potential pathogen dissemination, whilst simultaneously increased systemic 
activation leads to collateral tissue damage.  
 
For the first time, the age-related decline in neutrophil migration was corrected by in-
vivo treatment with simvastatin in the healthy elderly. Applying this theory in-vitro, to 
neutrophils from sepsis patients showed no improvement in migration, but did 
demonstrate that simvastatin was able to attenuate both ROS production and NET 
release in response to PMA. The precise nature of the immune responses that alter 
neutrophil functions and their implications in sepsis remains uncertain with further 
research to investigate these indicated. Although high profile trials regarding statin 
therapy in critical illness have failed to prove any benefit, it is proposed, based on the 
positive findings of simvastatin treatment in the healthy elderly and suggestions that 
earlier statin therapy may be beneficial in sepsis, that treatment with simvastatin in 
elderly patients with early on-set sepsis be investigated. 
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